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Abstract 
The endocannabinoid system (ECS) comprises the endocannabinoids (ECs), 
including anandamide (AEA) and 2-arachidonoyl glycerol (2AG), which 
interact with the G protein-coupled type-1 and type-2 cannabinoid receptors 
(CB1 and CB2 respectively). The ECS is thought to have a role in a number 
of central processes including neuroinflammation, neurogenesis, 
neuroprotection, learning and memory. Due to its influence on a diverse 
number of processes, it has been suggested that modifying the ECS may be 
therapeutically beneficial in Alzheimer's disease (AD). AD is an age-related 
neurodegenerative disorder characterised by the presence of extracellular 
amyloid ~ (A~) plaques and intracellular neurofibrillary tangles (NFTs) 
resulting in impairments in learning in memory. 
The aim of this thesis was to determine the status of the brain ECS in the 
APPswe/PS18E9 mouse model of AD and wild type littermates at 4, 6 and 8 
months of age and the performance of these animals in a behavioural test 
battery. The results of this study indicated that APPswe/PS18E9 animals 
were hyperactive compared to their wildtype counterparts at all ages and that 
they also displayed deficits in behavioural flexibility. EC levels increased 
with age in both wild type and APPswe/PS18E9 mice. Cannabinoid receptor 
coupling was increased in the frontal cortex and striatum of APPswe/PS18E9 
mice relative to wildtype. This study concluded that the status of the brain 
ECS is altered in AD. 
Modifications to the performance of the ECS were made in the form of 
chronic administration of a CB1 receptor antagonist (SR141716A1rimonabant) 
and a CB2 receptor agonist (JWH133). Chronic administration of 
SR141716A was able to reverse some learning impairments in 
APPswe/PS1~E9 animals. In contrast, chronic administration of JWH133 
resulted in impaired memory extinction in both wildtype and 
APPswe/PS1~E9 mice. The results support the potential benefit of 
modulating the endocannabinoid system in the treatment of memory 
impairment in AD. 
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1. 1 THE ENDOCANNABINOID SYSTEM 
1.1.1 What are Endocannabinoids? 
The psychoactive mind altering effects and medical attributes of cannabis 
sativa have been known for centuries, with some attributing its use as far 
back as the second millennium (Campbell, 1949). However, it was only in 
1964 that Yechiel Gaoni and Raphael Mechoulam (Gaoni et al. 1964) were 
able to isolate the compound responsible for the mind altering effects of 
cannabis sativa: ~9-tetrahydrocannabinol (~9-THC). This was followed 24 
years later by the discovery of a G protein coupled cannabinoid receptor in 
the brain, the existence of which suggested the presence of endogenous 
cannabinoids (endocannabinoids) which interact with it (Devane et al. 1988; 
Matsuda et al. 1990). This was confirmed in 1992 with the discovery of 
anandamide (Devane et al. 1992) and the endocannabinoid system was born. 
Endocannabinoids (EC) are neuromodulators and immunomodulators 
(Marchalanta et al. 2008) derived from arachidonic acid (AA), 
phosphatidylethanolamine and diacylglycerol (Maccarrone et al. 2007). The 
principal ECs known to date are anandamide (AEA) and 2-
arachidonoylglycerol (2-AG) with 2-AG being the most abundant form. AEA 
was first isolated from porcine brain in 1992 and 2AG in 1995 from canine 
intestines (Devane et al. 1992; Mechoulam et al. 1995). Both AEA and 2AG 
are members of the larger classes of lipid signalling molecules N-
acylethanolamines (NAEs) and monoacylglycerols (MAGs). In addition to 
the ECs, these classes comprise a number of endocannabinoid-like ligands 
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(ECl) which include N-oleoylethanolamide (OEA), N-palmitoylethanolamide 
(PEA) and N-arachidonoylglycine (AraGly) (figure 1.1) amongst others 
(Devane et al. 1994; Alexander et al. 2007). ECls are thought to facilitate 
the activity of AEA and 2-AG, as well as possessing important biological 
functions of their own (Ben-Shabat et al. 1998; De Petrocellis et al. 2001; Di 
Marzo et al. 2007). 
1.1.2 Mechanism of EC synthesis 
ECs are synthesised post-synaptically on demand in response to a range of 
stimuli including elevations in intracellular calcium (Ca2+). Although AEA and 
2AG are both derived from arachidonic acid-containing phospholipids 
(Okamoto et al. 2004; Bisogno et al. 2003; Wang et al. 2009) their formation 
utilises different synthetic routes. 
The main synthetic pathway for AEA involves an N-acyltransferase 
converting phospholipids to N-arachidonoylphoshatidylamines (NAPE) which 
are subsequently acted on by N-acylphosphatidylethanolamine 
phospholipase D (NAPE-PlD) to form AEA (Okamoto et al. 2004; Ahn et al. 
2008). In addition to this, 3 other synthetic pathways are proposed to exist 
(Wang et al. 2009; luchicchi et al. 2012) involving phospholipase C (PlC), 
Iyso phospholipase D and a~ hydrolase 4 (ABHD4). These pathways are 
depicted in figure 1.1 (taken from luchicchi et al. 2012). 
Similarly, 2AG synthesis also involves multiple synthetic routes. The primary 
route (Bisogno et al. 2003) involves the formation of diacylglycerols (DAGs) 
by PlC which are then acted on by diacylglycerol lipase a (DAGla) or ~ 
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(DAGL/3) to form 2AG (figure 1.1). A lesser known pathway utilizing 
phospholipase A1 (PLA1) and a Iysophosphatidyl inositol-specific PLC has 
also been proposed (Ueda et al. 1993). 
1.1.3 Endocannabinoid Metabolism 
EC actions are terminated by cellular uptake, although the precise 
mechanism by which this occurs is disputed, and rapid catabolism. The 
existence of an EC transporter has been hypothesised but solid evidence 
remains elusive to date (Moore et al. 2005). An alternative hypothesis is 
centred on the enzyme responsible for the degradation of AEA, fatty acid 
amide hydrolase (FAAH). FAAH is thought to maintain an inwardly directed 
concentration gradient enabling facilitated diffusion of AEA through the 
plasma membrane (Maccarrone et al. 2007). This concept has received 
support from the discovery in 2011 of a catalytically silent form of FAAH 
termed FAAH-like anandamide transporter (FLAT). FLAT has been shown to 
facilitate AEA transport into cells and is blocked by known AEA transport 
inhibitors such as AM404 (Fu et al. 2011). 
AEA metabolism, like its synthesis, can occur through multiple catabolic 
pathways (figure 1.1). The main route of degradation involves hydrolysis by 
FAAH but alternative mechanisms include hydrolysis by N-acylethanolamine 
hydrolysing acid amidase (NAAA) (Ueda et al. 2010) and oxidation by 
lipoxygenase (LOX), cyclooxygenase 2 (COX2) and cytochrome P450 (Ueda 
et al. 1995; Yu et al. 1997; Bornheim et al. 1993). 
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2AG is hydrolysed (figure 1.1) primarily through the action of 
monoacylglycerol lipase (MAGL) although the enzymes al3 hydrolase 6 
(ABHD6) and al3 hydrolase 12 (ABHD12) also contribute to some extent 
(Marrs et al. 2010; Savineinen et al. 2012). 
biosynihelic pathways 
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PL~...... ,-....,,-...,..JI.:-...... ........ mna 
. 
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Figu re 1.1: Routes of synthesis and breakdown for AEA and 2AG (taken from 
Luchicchi et al. 2012). NAPE = N-arachidonoylphosphatidylethanolamine; PLC = 
phospholipase c; pAEA = phosphoAEA; PTPN22 = protein tyrosine phosphatase N22; 
NAPE-PLD = NAPE-hydrolysing phospholipase D; PLA1 , PLA2 = phospholipase A1 ,A2; 
GP-AEA = glycerophospho AEA; GDE1 = glycerophosphodiesterase1 ; DAG-La-p = 
diacylglycerol lipase a-p; FAAH = fatty acid amide hydrolase; AA =arachidonic acid; NAAA 
= N-acylethanolamine hydrolysing acid amidase; LOX = lipoxygenase; COX-2 = 
cyclooxygenase 2; P450 = cytochrome P450; MAG-L = monoacylglycerol lipase; ABHD4, 
6, 12 = as hydrolase 4. 6. 12. 
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AEA and 2-AG bind to 7 transmembrane G protein-coupled type-1 (Matsuda 
et al. 1990) and type-2 (Munro et al. 1993) cannabinoid receptors (CB1 and 
CB2 respectively). CB1 and CB2 exhibit high sequence homology of 44% 
and are thought to originate from a common ancestor (Katona et al. 2012; 
Pertwee et al. 2010). Both CB1 and CB2 belong to the a group of rhodopsin-
like G protein-coupled receptors (GPCRs) which comprise one class within 
the GPCR superfamily (Fredriksson et al. 2003). CB1 is distributed 
extensively throughout the central nervous system (CNS) particularly in the 
hippocampus and basal ganglia (Mechoulam et al. 2012) and is considered 
the most prevalent GPCR in the brain (Maccarrone et al. 2011). In contrast, 
CB2 expression has traditionally only been associated with cells of the 
immune system, although in recent years, evidence has emerged for its 
presence on neurons (den Boon et al. 2012; Viscomi et al. 2009). 
CB 1 has been shown to form both homomers and heteromers 
(Mukhopadhyay et al. 2000). Little is known about homomers but CB1 is 
known to form heteromers with dopaminergic D2 (Marcellino et al. 2008), 
adenosine A2A (Carriba et al. 2007), IJ opioid (Rios et al. 2006) and orexin 1 
receptors (Ellis et al. 2006). Little is known about CB2 homomers or 
heteromers although a recent study demonstrated the formation of functional 
CB1/CB2 heteromers in transfected neuronal cells and in brain tissue (Callen 
et al. 2012). Of particular interest was their observation of bidirectional 
cross-antagonism in the heteromers with CB 1 antagonists able to block the 
effects of CB2 agonists and vice versa. 
15 
CB1 receptors are located both pre- and post-synaptically, whereas CB2 
receptors are thought to display a preferentially post-synaptic distribution 
(Callen et al. 2012; Brusco et al. 2008). CB1 but not CB2 receptor 
distribution is also affected by membrane cholesterol content, with lower 
cholesterol levels resulting in increased CB 1 signalling (Maccarone et al. 
2011; Bari et al. 2005). 
CB1 and CB2 both signal through the Gilo class of heterotrimeric G proteins 
(Stella et al. 1997; Bosier et al. 2010). AEA acts as a partial agonist at CB1 
and CB2, whereas 2AG is able to interact as a full agonist at both receptors 
(Stella et al. 1997). Both AEA and 2AG are considered to possess slightly 
greater affinity for CB1 than CB2 receptors (Pertwee et al. 2010). 
Activation of CB1 or CB2 through binding of ECs or synthetic agonists such 
as HU210, JWH133, WIN-55-212, results in dissociation of the Ga subunit 
from the Gl3v and the consequent initiation of a number of intracellular 
signalling cascades. Both CB1 and CB2 activation result in inhibition of 
adenlyl cyclase and the associated inactivation of protein kinase A through 
the Ga subunit, and activation of elements of the mitogen-activated protein 
kinase (MAPK) signalling mediated by Gl3v (Howlett. 2005). In addition, CB1 
stimulation also mediates activation of inwardly rectifying and type A 
potassium channels (Kir and KA respectively) inhibition of L, N, P/Q type 
voltage gated calcium channels (VGCCs) and can cause a rise in 
intracellular calcium by means of its actions on phopholipase C (PLC). 
These processes are clearly depicted in figure 1.2 taken from Bosier et al. 
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2010. In addition to the GI/o class of G proteins, CB1 is also known to signal 
through Gs (Glass et al. 1997) and Gq (Lauckner et al. 2005) subunits to 
promote a rise in intracellular Ca2+ . 
K" K' ea; ' Regulation of cell excitability 
and neurotransmiMer release 
PIP2 
I ~ Cal. • G1 
PKC 
1. T.... 
1 
. _-..r 
MAPKK 
Rat ~KK®~ 
1 1 1 
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Gene expression 
Figure 1.2: Signalling pathways activated by CB1/CB2 activation (figure taken from 
Bosier et al. 2010). Binding of endocannabinoids to CB/CB2 results in the dissocation 
of Go from the G~V subunit. Go goes on to inactivate adenylate cyclase (AC) whilst Gl3v 
activates the MAPK signalling cascades. In addition, Gl3v units from CB1 activation are 
able to inhibit A-type potassium channels (KA ) and L, N, P, Q type calcium channels 
(L,N, P, Q Ca2+) and activate inwardly rectifying potassium (Kir) channels. 
1.1.5 Transient Receptor Potential Vanilloid 1 Receptors 
AEA, but not 2AG, in addition to PEA (De Petrocellis et al. 2001) and OEA 
(Ahern, 2003) are able to bind to and activate transient receptor potential 
vanilloid type 1 (TRPV1) channels (De Petrocellis et al. 2010; Smart et al. 
2000). TRPV1 is a poorly selective cation channel, although changes in 
permeability upon activation result in it exhibiting a 10 fold . preference for 
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Ca2+ ions over monovalent cations (Ho et al. 2012), primarily expressed in 
nociceptive sensory neurons and is activated by high temperatures and 
noxious stimuli (Battista et al. 2012; De Petrocellis et al. 2010). In addition to 
sensory neurons, TRPV1 expression has also been reported in the striatum 
(Maccarrone et al. 2008) and hippocampus (Cristino et al. 2006). However, 
these observations have recently been contested using a TRPV1 reporter 
mouse which found no evidence for TRPV1 expression in the striatum and 
limited expression in the hippocampus (Cavanaugh et al. 2011 ). 
The ability of AEA to bind to TRPV1 in addition to cannabinoid receptors 
(CBRs), is thought to be due to it possessing conformational flexibility (De 
Petrocellis et al. 2010). CB and TRPV1 receptors are frequently co-localised 
in the same brain regions and, indeed, the same cells (De Petrocellis et al. 
2010) and, depending on its origins, AEA will interact with them sequentially. 
When AEA is synthesised outside the cell it is thought to interact with CBRs 
first followed by TRPV1; however, when it is synthesised within the cell it 
interacts with TRPV1 prior to CBRs. When CB1 is located pre-synaptically 
and TRPV1 post-synaptically, AEA is able to down regulate 2AG production 
and its subsequent retrograde signalling at presynaptic CB 1, by activating 
TRPV1 (Maccarrone et al. 2008; De Petrocellis et al. 2010). 
Other consequences of TRPV1 activation by ECs and ECls include a rise in 
intracellular Ca2+, increased expression of caspases and pro-apoptotic 
kinases, mitochondrial uncoupling and release of cytochrome c (Battista et al. 
2012). 
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1.1.6 Peroxisome Proliferator Activated Receptors 
Peroxisome proliferator activated receptors (PPARs) are also activated by 
ECs and ECls (Kozak et al. 2002; Fu et al. 2003). PPARs are members of a 
nuclear receptor superfamily comprising a deoxyribonucleic acid (DNA) 
binding domain, which form dimers with retinoid X receptors (RXRs) and are 
subsequently able to interact with peroxisome proliferator response elements 
(PPREs) in a range of target genes to regulate their expression (Aspostoli et 
al. 2012). Three PPAR isoforms are known to date: a, f3/~ and y with varying 
expression patterns (Wahli et al. 2012). PPARa is predominantly expressed 
in tissues catabolising a high volume of fatty acids such as liver, heart and 
kidney (Auboeuf et al. 1997; Vidal-Puig et al. 1997). PPARf3/~ displays the 
broadest expression pattern with levels in certain tissues determined by cell 
proliferation and differentiation (Michalik et al. 2006). PPARI3/~ is found in 
the skin, gut, adipose tissue, brain, skeletal and heart muscle amongst 
others (Auboeuf et al. 1997). PPARy has two isoforms: y1 found in the brain, 
vascular, immune and inflammatory cells, and y2 expressed predominantly in 
adipose tissue (Vidal-Puig et al. 1997; Michalik et al. 2006). 
In addition to the ECs and ECls, PPARs are able to bind fatty acids, 
eicosanoids, and phospholipids as well as a number of synthetic compounds 
such as non-steroidal anti-inflammatory drugs (Kliewer et al. 1997; Lehmann 
et al. 1997; Pertwee et al. 2010). Both ECs and ECls are able to activate 
PPARa whilst only ECs can activate PPARy (Bouaboulg et al. 2005; 
O'SUllivan et al. 2010). 
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1.1.7 Functions of endocannabinoids 
1.1.7.1 Retrograde Signalling 
One of the most well established functions of ECs is their role as retrograde 
messengers (Wilson et al. 2001; Ohno-Shosaku et al. 2001; 2012). ECs 
released from the post-synaptic neurons traverse the synaptic cleft and bind 
to pre-synaptic CB1 receptors reducing Ca2+ and potassium (K+) 
conductance and ultimately decreasing release of neurotransmitter (Ohno-
Shosaku et al. 2012). Historically, both AEA and 2AG have been associated 
with retrograde signalling, however, recent evidence suggests this role may 
primarily be mediated by 2AG (Tanimura et al. 2010; Pan et al. 2011). 
As a consequence of their role as retrograde messengers, ECs are intimately 
associated with the phenomena of long-term potentiation (L TP) and 
depression (LTD), 2 alternative forms of synaptic plasticity underlying 
learning and memory (Iremonger et al. 2011). L TP is defined as a 
persistent strengthening of a synapse whilst LTD in contrast refers to the 
persistent weakening of a synapse. Both L TP and LTD are dependent on 
glutamate-mediated activation of the N-methyl-D-aspartate (NMOA) receptor. 
ECs activate presynaptic CB1 receptors located on V amino butyric acid 
(GABA) interneurons (Carlson et al. 2002), thus suppressing inhibitory post 
synaptic currents (IPSCs), a process termed depolarisation-induced 
suppression of inhibition (051). IPSCs maintain the magnesium (Mg2+) plug 
preventing the activation of NMOA receptors. By suppressing IPSCs, ECs 
permit a given excitatory input to cause a greater depolarisation, 
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subsequently activating the NMOA receptors resulting in a rise in intracellular 
Ca2+ levels pre-requisite for the generation of L TP (Pallas, 2009). The 
opposite process, L TO involves the same sequence of events except the 
process involves depolarisation-induced suppression of excitation (DSE) in 
which case the CB1 receptors are located on glutamatergic neurons. 
Support for the involvement of the ECS in L TP and L TO is provided by 
observations in CB1-null mice which show enhanced L TP and no L TO 
(Varvel et al. 2009). 
The role of ECs in learning and memory has also been demonstrated by a 
number of behavioural experiments assessing recent memory. Intra-
hippocampal administration of the CB1 antagonist SR141716A (rimonabant) 
facilitates learning when given during a watermaze task (Robinson et al. 
2008). Intrahippocampal administration of SR141716A has also been shown 
to negate the memory-disrupting effects of the main psychoactive constituent 
of marijuana ~9-THC and the cannabinoid receptor agonist CP-55,940 (Wise 
et al. 2009). Chronic intrahippocampal infusion of SR141716A or the agonist 
WIN 55.212-2 has been shown to improve or impair performance 
respectively in a delayed non-matching to sample task (Hampson et al. 
2011). In particular, ECs have been shown to be critical for the extinction of 
aversive memories (Marsciano et al. 2002; Niyuhire et al. 2007;Ruehle et al. 
2012) and are, therefore, thought to underlie aspects of behavioural set 
shifting (Pamplona et al. 2008). 
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Studies using knockout animals have indicated MAGl-1- mice show enhanced 
l TP accompanied by improved performance in the novel object recognition 
and water maze paradigms relative to wildtype mice (Pan et al. 2011). 
Similarly, FAAH-1- animals display enhanced acquisition of an aversively 
motivated Barnes maze task (Wise et al. 2009). In conclusion, experimental 
evidence shows that CB activation by ECs impairs or facilitates learning and 
memory depending on the route and timing of administration. 
1.1.7.2 Anti-Inflammatory Mediators 
Another function of ECs and ECls is as anti-inflammatory mediators by 
means of activation of CB2 and PPARs. Some studies have shown that CB2 
expression is up-regulated in activated microglia during neuroinflammation 
(Ramirez et al. 2012; Stella, 2009). CB2 agonists have been shown to 
attenuate blood brain barrier (BBB) dysfunction by attenuating BBB 
permeability; partly through an increase in tight junction proteins (Ramirez et 
al. 2012). AEA has been shown to prevent synthesis of biologically active 
pro-inflammatory cytokines interleukin (Il) 12 (ll-12) and Il-23 (Correa et al. 
2009). A number of studies have demonstrated that ECs and synthetic 
cannabinoids are able to prevent the release of pro-inflammatory cytokines 
such as tumour necrosis factor a (TN Fa) and Il-113 (Ortega-Gutierrez et al. 
2005), whilst simultaneously promoting the release of anti-inflammatory 
cytokines such as Il-4 (Hickman et al. 2008) and the Il-1 receptor antagonist 
(Molina-Holgado et al. 2003). Furthermore, CB2 activation by 2AG has been 
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shown to increase microglial proliferation in response to an inflammatory 
insult (Carrier et al. 2004). 
In addition to CB2 stimulation, non-selective synthetic CBR agonists such as 
WIN55,212-2 and HU210 have been shown to possess anti-inflammatory 
actions through prevention of microglial activation following neurotoxic insults 
(Chung et al. 2012). 
In addition to CB2, the anti-inflammatory effects of ECs and ECls can also 
be mediated through PPARa (O'Sullivan et al. 2010). Both OEA and PEA 
and have been shown to reduce inflammation through a PPARa-dependant 
mechanism (D'Agostino et al. 2007; Sun et al. 2007). 2AG has been shown 
to inhibit Il-2 expression through PPARy activation (Rockwell et al. 2006). 
Additionally, 2AG is able to suppress the expression of cyclooxygenase-2 
(COX2), an inflammatory marker enzyme, by means of CB1-dependant 
restoration of PPARy expression (Du et al. 2011). 
1.1.7.3 Anti-Oxidants 
Phenolic cannabinoids (.19-THC, cannabinol, cannabidiol, CP 55,940, HU 
210 and AM 404) have also been shown to display anti-oxidant properties in 
a CB1-independent manner (Marsicano et al. 2002). More recent studies 
have demonstrated the involvement of CB 1-mediated inhibition of PKA in 
counteracting oxidative stress following stimulation by WIN,55 212-2 and 
AEA (Kim et al. 2005). Further support for a role of cannabinoids in oxidative 
stress is provided by a recent study indicating that HU210 and WIN55,212-2 
are able to inhibit NADPH oxidase (Chung et al. 2012) and consequently, 
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the associated generation of reactive oxygen species (ROS). In addition to 
CB1, CB2 selective stimulation has also been shown to reduce oxidative 
stress in neurons by inducing the expression of Bcl2 (an anti-apoptotic 
protein) and Hsp 70 (which protects against stress) whilst concomitantly 
promoting neuroprotection by preventing glial activation (Oddi et al. 2012). 
1.1.7.4 Neuroprotection 
The neuroprotective effects of cannabinoids, ECs and ECls have been well 
documented (Viscomi et al. 2009; Garg et al. 2010; Kreutz et al. 2009; 
Scuderi et al. 2012; Galan-Rodriguez et al. 2009). Neuroprotection by 
synthetic and endogenous cannabinoids and their associated ligands occurs 
in two main forms: protection from excitotoxiclty and prevention of microglial 
activation in the absence of inflammation. AEA has been shown to confer 
CB1-dependant neuroprotection in a rat model of excitotoxicity (Hansen et al. 
2001; Veldhuis et al. 2003). CB2 activation by the synthetic CB2 selective 
agonist JWH-015 is able to prevent remote cell death through prevention of 
cyctochrome c release from mitochondria (an early indication of apoptosis) 
and involves a P13K1Akt signalling mechanism (Viscomi et al. 2009). 
Additionally, the neurons of CB1-null (CB1-1-) mutants are more susceptible 
to neurodegeneration induced by excitotxic cell death than those from 
wildtypes (Marsicano et al. 2003). 
In addition to AEA, OEA (Sun et al. 2007; Galan-Rodriguez et al. 2009) and 
PEA (Hansen, 2010; Scuderi et al. 2012) have also been shown to provide 
neuroprotection through a PPARa-dependant mechanism following neuronal 
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insult. OEA and PEA prevented glial activation (Scuderi et al. 2012; Sun et 
al. 2007) in addition to reducing neuronal apoptosis (Galan-Rodriguez et al. 
2009). 2AG, apparently through its actions on the abnormal cannabidiol-
sensitive receptor found on microglia, is able to protect neurons against 
excitotoxic cell death (Kreutz et al. 2009). 
As a consequence of the manifold roles described above, ECs beginning to 
be considered as viable treatment options for neurodegenerative diseases 
including Alzheimer's disease (AD) (Marchalant et al. 2012). As this project 
will investigate the role endocannabinoids may play AD pathology, the next 
section provides a brief description of the disease process. 
1.2 ALZHEIMER'S DISEASE 
1.2.1 Alzheimer's Disease General Background 
AD is a progressive age-related neurodegenerative disorder affecting 
approximately 33.9 million people worldwide with the incidence estimated to 
triple in the next 40 years (Barnes et al. 2011). In the UK in 2012, 800,000 
individuals, including 17,000 under the age of 65, are affected by a form of 
dementia of which AD is the most common, (Alzheimer's Society 2012). 
AD represents the most common cause of dementia worldwide (Alzheimer's 
Society 2012) characterised by impairments in learning and memory. 
Memory can be classified into 2 broad categories: procedural and declarative. 
Procedural memory refers to the memory of 'how to do things' and requires 
no conscious attention during its activation leading to the suggestion that it 
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lies below the level of consciousness. In contrast, declarative memory can 
be subdivided into semantic and episodic memory. Semantic memory refers 
to memory for facts and general knowledge about the world and forms of it 
can exist in animals other than humans whereas episodic memory can 
broadly be defined as the memory of past experiences (Tulving, 2002). 
In the pre-symptomatic phase of AD, disturbances in semantic memory are 
detectable at least a decade prior to clinical presentation (Amieve et al. 
2008). Disturbances in episodic memory are detected closer to AD 
diagnosis and are usually classified as mild cognitive impairments (MCI) 
which are defined by the inability of an individual to retain information over a 
period of delay (Albert, 2011). An example would be recalling a conversation 
or appointment or learning something new such as a shopping list. MCI 
individuals also display impairments in behavioural flexibility, language 
functions and visuo-spatial abilities leading to disorientation (Albert, 2011). 
Emotional and sleep disturbances accompanied by changes in personality 
are also observed. The decline in performance continues until patients are 
no longer able to function independently. 
1.2.2 Genetics of Alzheimer'S disease 
Until 2009, the only known genetic associations for AD were for the genes 
encoding amyloid precursor protein (APP), preselinin (PS) 1 (PS1), PS2 and 
the £4 allelle of apolipoprotein 4 (APOE4) (Tanzi et al. 2012; Bertram et al. 
2010). Of these, only APOE4 was associated with the most common, late 
onset form of AD whilst the others were linked to the rare early presenting 
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«60 years) familial form which only represents 5% of AD cases (Tanzi et al. 
2012). To date, more than 40 point mutations have been discovered for APP 
resulting in the over-production of amyloid J3 (AJ3) , approximately 80 in PS1 
and 10 in PS2 (Ashe et al. 2010). For an up to date list of familial AD-related 
mutations the reader is referred to: http://www.alzforum.org/res/com/mutlasp. 
Twin studies have indicated that as much as 60% of the susceptibility to late 
onset AD (LOAD) may be accounted for by genetics (Lambert et al. 2009). 
The LOAD genes first identified by Harold et al. (2009) are APOE, clusterin 
(CLU) also known as APOJ, PICALM, complement component (3b/4b) 
receptor 1 (CR1), bridging integrator 1 (BIN1) and disabled homolog 1 
(DAB1). APOE, CLU and CR1 were also replicated in an independent study 
by Lambert et al. (2009). 
Since publication of the above, another 5 genes conferring genetic 
susceptibility for LOAD have been identified. These are ATP-binding 
cassette, sub-family A, member 7 (ABCA7), membrane spanning 4A gene 
cluster (MS4A), CD2 associated protein (CD2AP), CD33 and ephrin type-A 
receptor 1 (EPHA 1) (Hollingworth et al. 2011; Naj et al. 2011). For up to 
date information on LOAD associated genes the reader is referred to: 
http://www.alzgene.org/TopResults.asp. 
These genes can be broadly subdivided into 3 main classes according to 
their functions. CLU, CR1, ABCA7, CD33 and EPHA1 can all be linked to 
the immune system, PICALM, BIN1, CD33, CD2AP are associated with 
processes at the cell membrane and APOE, CLU and ABCA7 are thought to 
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play roles in lipid processing (Hollingworth et al. 2011). APOE and CLU are 
thought to be the most abundantly expressed lipoproteins in the brain and 
have both been detected in A~ plaques and are able to bind to A~ and, 
hypothetically, clear it (Lambert et al. 2009). APOE alone, of the 10 genes 
listed, is thought to account for up to 50% of the genetic susceptibility for 
LOAD, and as its main role in the brain is as a cholesterol-carrier protein, its 
influence in AD is thought to be related to impaired cholesterol transport 
(Lambert et al. 2009; Gamba et al. 2012). 
1.2.3 Risk Factors for Alzheimer's Disease 
Age is the biggest risk factor for AD followed by possession of the genes, 
APOE4 in particular, indicated above. However, there are a number of other 
potentially modifiable risk factors which increase susceptibility (Barnes et al. 
2011 ). These are stress, diabetes, hypertension, obesity, depression, 
physical inactivity, smoking and cognitive activity/low educational attainment 
(Pardon et al. 2008; Barnes et al. 2011 ). 
1.2.4 Neuropathology of Alzheimer's Disease 
AD is characterised by the presence of extracellular amyloid beta (A~) 
plaques and intracellular neurofibrillary tangles (NFTs) caused by 
hyperphosphorylation of the microtubule-associated protein tau (Liebscher et 
al. 2012). 
A~ is derived by proteolytic cleavage of APP. APP cleavage can follow 2 
main pathways of which one is pathogenic and the other is not (figure 1.3). 
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Figure 1.3: Amyloid precursor protein (APP) processing pathways (taken from 
Citron, 2004)_ APP is processed either along the a-secretase or l3-secretase pathway. In 
the non-pathogenic o-secretase pathway, a-secretase cleaves in the middle of the 13-
amyloid region (orange) to release soluble APP, a-APPs (blue), and the C83 peptide 
which is metabolised to p3 by y-secretase. In the l3-secretase pathway, l3-secretase 
cleaves APP to generate I3-APPs (blue) and Cgg peptide. C99 is then cleaved by y-
secretase at several positions to generate A1340 and the aggregation prone A1342. 
The non-pathogenic pathway involves cleavage of APP by a secretase to 
generate soluble APP and C83 peptide. In the pathogenic pathway, however, 
APP undergoes sequential cleavage by ~ and y secretase to produce A~40 
and A~42 (Liebscher et al. 2012; Citron et al. 2004). Of the two forms, A~42 is 
the more aggregation-prone species (Liebscher et al. 2012; Jankowsky et al. 
2004). Once generated, A~ monomers aggregate in a number of ways 
ultimately leading to the formation of A~ plaques. The intermediate steps 
result in the formation of a number of dimeric, trimeric species as well as A~-
derived diffusible ligands (ADDLs) , oligomers (15-20 monomeric units) and 
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multiples of oligomers termed protofibrils (Deshpande et al. 2009). These 
low molecular weight species are thought to play a significant role in 
triggering the neurodegeneration and memory decline associated with AD 
(Brouillette et al. 2012; Wilcox et al. 2011). The normal physiological role(s) 
of AJ3 are unclear, although recent evidence indicates that AJ3 may playa role 
in learning and memory when present in low picomolar quantities (Puzzo et 
al. 2008; Morley et al. 2010; Garcia-Osta et al. 2009) as well as influencing 
neuronal viability (Plant et al. 2003). 
Under non-pathological conditions, tau is a soluble microtubule-associated 
protein which binds to microtubules to stabilise and orientate them 
(Shahpasand et al. 2012; Iqbal et al. 2009). Tau is referred to as a 
phosphoprotein which means that its biological activity is regulated by its 
degree of phosphorylation (Shahpasand et al. 2012; Iqbal et al. 2009). 
Under normal circumstances tau is moderately phosphorylated, but becomes 
hyperphosphorylated in AD, resulting in the loss of its ability to bind to 
microtubules. As a consequence, the microtubule network becomes 
destabilised, resulting in impaired axonal transport. Hyperphosphorylated 
tau subsequently becomes insoluble and forms paired helical filaments and 
eventually NFTs. 
1.2.5 Amyloid Cascade Hypothesis 
Two main theories exist to explain AD pathology. The most prominent and 
widely accepted is the amyloid cascade hypothesis (AmCH) first heralded in 
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1992, which states that the major cause of neuronal dysfunction and death in 
AD is due to the production and aggregation of A~ (Wirths et al. 2004; Reitz 
et al. 2012). The hypothesis has undergone modification since its inception 
to include the impact of soluble A~ oligomers and figure 1.4 illustrates the 
most up to date version of the hypothesis for both familial and late onset AD. 
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Figure 1.4: Modified Version of the Amyloid Cascade Hypothesis taken from 
http://www.alzforum.org/res/adh/cur/knowntheamyloidcascade.asp. 
A number of factors strongly support the AmCH including the observations 
that administration of A~ in vitro and in vivo leads to neurodegeneration, and 
mutations in the genes involved in the rarer genetic form of AD (see below), 
APP, PS 1, PS2 over-expression results in overproduction and accumulation 
of A~ (Reitz et al. 2012). Additionally, mice expressing a mutation in the tau 
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gene alone show fewer NFTs than mice co-expressing the P301 L tau and 
APPs35 Swedish mutations. This observation suggests a role for AI3 in NFT 
formation, possibly by increasing the levels of enzymes such as glycogen 
synthase kinase 313 (GSK-3I3) responsible for the hyper-phosphorylation of 
tau seen in AD (Zhang et al. 2011). Indeed, GSK-313 inhibitors have been 
shown to reduce neuronal death and cognitive decline in a mouse model 
recapitulating some aspects of AD (Engel et al. 2006). 
However, in recent years the AmCH has become increasingly contentious 
with the continuing failure of multiple clinical trials targeting AI3 (Castellani et 
al. 2011) in addition to the continued absence of a correlation between AI3 
plaque load and cognitive decline (Giannakopoulos et al. 2003). Further 
objections to the AmCH come in the form of the suggestion that AI3 plaques 
and NFTs are a consequence of neurodegeneration rather than cause (Reitz, 
2012; Armstrong, 2011). 
The second hypothesis is centred on tau hyper-phosphorylation and 
suggests that NFTs are the root cause of the disease (Verdile et al. 2004). 
This second theory has fewer proponents but does receive support from the 
correlation between NFT density and AD severity (Bierer et al. 1995; 
Giannakopoulos et al. 2003). Additionally, NFTs have been found in the 
brains of patients expressing symptoms of dementia in the absence of AI3 
(de Paula et al. 2009). However, despite these caveats, the AmCH 
continues to predominate as the primary explanation for AD. 
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1.2.5 How does Af3 Contribute to Alzheimer's Disease? 
Exactly how Aj3 causes the deficits observed in AD remains controversial. 
This is not helped by the finding that deficits in learning and memory occur 
prior to the appearance of Aj3 plaques and NFTs. In relation to this, a 
relatively recent study suggested that neurons which degenerate in AD re-
enter the cell cycle prior to visible Aj3 deposition (Varvel et al. 2008). 
Neurons in AD patients displaying Mel also show cell cycle re-entry (Varvel 
et al. 2008). Hence, neuronal cell cycle re-entry can be regarded as a pre-
plaque indicator of neuronal distress (Varvel et al. 2008) and may be partially 
responsible for the occurrence of memory impairments prior to visible Aj3 
deposition. 
The physiological effects of Aj3 include excessive inflammation, oxidative 
stress, excitotoxicity and reduced forebrain cholinergic transmission. 
1.2.5.1 Inflammation in AD 
A key feature of the AD brain is neuroinflammation. Neuroinflammation is 
caused by activated microglia releasing a host of compounds which go on to 
activate astrocytes and cause effects such as excitotoxicty and the 
generation of reactive oxygen species (ROS) amongst others. 
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Microglia 
Microglia are the phagocytic immune cells of the brain. Studies have shown 
that microglia are activated early in the process of AD (Crehan et al. 2012) 
during which they take on anti-inflammatory roles (alternative activation; 
Jimenez et al. 2008) including the clearance of Af3 by macropinocytosis 
(Mandrekar et al. 2009). Additionally, infiltrating T cells in the CNS promote 
the release of the anti-inflammatory cytokine IL-4 from astrocytes. IL-4 
causes microglia to adopt an alternative activation phenotype in AD which 
promotes the release of anti-inflammatory agents and neurotrophic factors 
(Jimenez et al. 2008). 
However, with disease progression and the continued rise in Af3 load, it is 
thought that the capacity of microglia to clear Af3 is overwhelmed and they 
switch to a classical activation phenotype (Jimenez et al. 2008). Classical 
activation supports the release of a number of pro-inflammatory cytokines 
and chemokines including TNFa and IL-1f3 (Couturier et al. 2012). 
Additionally, microglia also release complement factors, chemokines, ROS, 
neurotoxic secretory products and nitric oxide (Couturier et al. 2012; Jimenez 
et al. 2008). Microglia mediate their actions through a number of signalling 
pathways including that of NFKB which is stimulated by Af3 (RubiO-Perez et al. 
2012). Prevention of NFKB activation has been shown to reduce the release 
of pro-inflammatory cytokines in addition to limiting apoptosis (Coutirier et al. 
2012; Delgado et al. 2008). Furthermore, as stated above, genetic variations 
in the CR1 gene encoding complement receptor 1 have been associated with 
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AD and CR1 levels are raised in AD (Crehan et al. 2012). CR1 is involved in 
regulating complement activation including that of complement C3, 
deficiency of which is associated with enhanced Aj3 deposition, apoptosis 
and a non-phagocytic phenotype in microglia (Crehan et al. 2012). Through 
their release of chemokines microglia encourage the homing of other glial 
cells to their location, thereby exacerbating the inflammatory process (Westin 
et al. 2012). C-C motif ligand 2 (CCL2) is one such chemokine, the levels of 
which are raised in the cerebrospinal fluid of AD patients and are associated 
with an accelerated rate of cognitive decline (Westin et al. 2012). 
Additionally, CCL2 signalling has previously been associated with increased 
Aj3 deposition in an AD animal model (Yamamoto et al. 2005). 
In contrast to the above, Hickman et al. (2008) showed that alternatively 
activated microglia are still present in the immediate region of Aj3 plaques, 
whilst the classically activated microglia are found almost everywhere else in 
the CNS, including regions devoid of Aj3. Their results suggest that soluble 
forms of Aj3 (ADDLs) may be responsible for the initiation of the classical 
response involving TNF-a release as it coincides with a large increase in 
ADDLs. 
In summary, microglia appear to playa dual role in AD. In the early stages 
of AD they provide a supportive function by clearing Aj3 and releasing 
neurotrophic and anti-inflammatory agents. However, with disease 
progression, the microglial phenotype switches such that it is now 
detrimental and exacerbates pathology. 
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Astrocytes 
Astrocytes are thought to playa number of roles in AD including clearance 
and degradation of Aj3, providing trophic support to neurons in addition to 
serving as barriers between Aj3 and neurons (Rubio-Perez et al. 2012). 
However, despite their beneficial role, in stressful conditions, they can 
prolong neuroinflammation by expressing inducible nitric oxide synthase 
(iNOS) which generates nitric oxide (NO) excessive levels of which are 
neurotoxic. Additionally, exposure of astrocytes to Aj3 results in increased 
levels of TNFo, IL-1j3 and IL-6 (Wyss-Coray et al. 2012). 
One of the most important functions of astrocytes is the regulation of 
glutamate levels in the CNS. Glutamate released into the extracellular space 
is transported into astrocytes where it is degraded by glutamine synthetase 
into glutamine. Glutamine is subsequently shipped to neuronal presynaptic 
terminals where it is used to synthesise glutamate for neurotransmission. 
However, Aj3 disrupts this process through an adenosine A2A receptor-
dependant mechanism (Matos et al. 2012). 
A number of other functions have also been ascribed to astrocytes in recent 
years including roles in L TP mediated by the release of D-serine in a 
calcium-dependant manner (Hennerberger et al. 2010). Astrocytes are also 
capable of providing neuroprotection through the release of neurotrophins 
(Barres 2008). 
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1.2.5.2 Excitotoxic Insult: 
Neuroinflammation, in addition to direct effects of AI3, causes the release of 
glutamate from neurons and glia. Glutamate activates NMDA receptors on 
neurons resulting in influx of Ca2+, thereby increasing intracellular Ca2+ 
concentration [Ca2+Ji. Additionally, A~ is capable of forming pores in the lipid 
bilayer which are permeable to Ca2+ thereby further enhancing [Ca2+]i. 
Excessively raised [Ca2+]j leads to cellular depolarisation, mitochondrial 
dysfunction, production of ROS and activation of DNAases, proteases and 
lipases amongst others. 
Memantine, a non-competitive NMDA receptor antagonist is used, albeit with 
limited efficacy, in the treatment of moderate to severe AD, thereby providing 
further corroboration for excitotoxic cell death being an important factor in AD 
pathology. Memantine acts by inhibiting pathological but not physiological 
actions of the NMDA receptor by reducing the neuronal signal to noise ratio 
during excessive glutamate release (Marchalant 2008). Additionally, it 
promotes the release of the brain-derived neurotrophic factor (BDNF). BDNF 
is thought to be pre-requisite for L TP and memory consolidation 
(Bekinschtein et al. 2008; Lu et al. 2008) and has been shown to have a 
number of beneficial effects in animal models of AD (Nagahara et al. 2009). 
Mice injected with lentiviral vectors constitutively expressing BDNF showed 
significant improvements in behavioural paradigms designed to test spatial 
and contextual memory (Nagahara et al. 2009). Additionally, BDNF was 
37 
shown to attenuate dysregulation of hippocampal and entorhinal gene 
expression and to reverse synaptic degeneration (Nagahara et al. 2009). 
Unfortunately, memantine provides only minor clinical improvements when 
given to moderate to severe AD cases, and benefits are virtually 
undetectable when given to patients with mild to moderate AD (McShane et 
al. 2006). 
1.2.5.3 Oxidative Stress in Alzheimer's Disease 
Oxidative stress is thought to occur early in the course of AD and manifests 
in the form of raised levels of oxidation of proteins, lipids, DNA and the 
formation of toxic compounds such as peroxides (Feng et al. 2012). Lipid 
peroxidation results in the generation of a number of toxic species including 
the highly reactive 4-hydroxy 2,3-nonenal (4HNE), levels of which are raised 
in AD (Feng et al. 2012; Lovell et al. 2012). 4HNE has a number of 
detrimental effects including impairing the uptake of glutamate by astrocytes 
(Lovell et al. 2012) in addition to depleting membrane phospholipids, 
inhibition of neuronal glutamate and glucose transporters, sodium/potassium 
ATPases and dysregulation of Ca2+ homeostasis amongst others (Feng et al. 
2012; Massaad, 2011). These processes are likely to cause the generation 
of further ROS and neuronal apoptosis leading to a self-perpetuating process 
(Feng et al. 2012). In addition, it has recently been demonstrated that 
neuronal apoptosis following oxidative stress is associated with an increase 
in lysosomal AJ3 accumulation mediated by macroautophagic mechanisms 
(Zheng et al. 2011; 2009). 
38 
Further detrimental effects occur as a consequence of ROS resulting in 
excessive influx of glutamate leading to excitotoxicty, damage to DNA in the 
region of AJ3 and NFTs (Feng et al. 2012), and generation of the hydroxyl 
(OHo) radical following AJ3 mediated reduction of copper (Cu2+) ions from 
Cu2+ to Cu+ (Massaad, 2011). 
1.2.5.4 Cholinergic Transmission in Alzheimer's Disease 
Acetylcholine (ACh) is one of the primary neurotransmitters in the brain and 
has roles in a number of processes including memory and executive 
functions (Bernier et al. 2009). ACh activates two classes of receptors: 
muscarinic and nicotinic. In AD, the expression of the presynaptic nicotinic 
ion channel receptors (nAChRs) is reduced (Schliebs et al. 2011). Deficits in 
levels of the enzyme required to manufacture ACh, choline acetyl transferase 
(ChAT), are observed in the course of AD and in animal models of AD, due 
to degeneration of ChAT -positive neurons in the basal forebrain (Schliebs et 
al. 2011). The death of these neurons results in degeneration of the cortical 
neurons to which they project. It has been suggested that AJ3 is able to bind 
directly to nAChRs, in particular the a7 subtype, with high affinity, prompting 
the suggestion that, in certain cases, deficits in cholinergic transmission may 
be due to inactivation of nAChRs as a consequence of AJ3 binding, rather 
than cell death (Parri et al. 2011; Schliebs et al. 2011). In addition, 
a7nAChRs have been shown to co-localise with AJ342 in AJ3 plaques in post-
mortem human AD brains and the addition of AJ342 results in the death of 
human neuroblastoma cells over-expressing a7nAChRs whilst the addition of 
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an a7nAChRs agonist protects them (Dziewczapolski et al. 2009). 
Furthermore, deletion of a7nAChRs in the PDAPP mouse model of AD 
resulted in the rescue of cognitive deficits, the preservation of synaptic 
markers and reduced gliosis (Dziewczapolski et al. 2009). It has also been 
proposed that a7nAChRs are present on microglia where their activation is 
associated with reduced release of TNFa. In AD, microglial a7nAChRs are 
thought to be chronically inactivated by Af3 binding, thereby contributing to 
the inflammatory process (Parri et al. 2011). 
Agonists of nAChRs have been shown to improve cognitive performance 
whilst antagonists worsen it (Schliebs et al. 2011). In addition, the 
muscarinic acetylcholine receptor antagonist scopolamine has long been 
associated with amnesic effects. As a result, the cholinesterase inhibitors 
such as galantamine and donepezil are used as current therapies for AD with 
the aim of prolonging the amount of time for which ACh is active. However, 
whilst their use modestly alleviates the symptoms of AD it does not halt or 
reverse the disease process. Additionally, both of these compounds have 
extensive side effect profiles limiting their use to some extent (Sozio et al. 
2012). Due to the effects discussed above, the a7nAChRs has recently 
become a prime target for pharmacological intervention and the search is 
underway for suitable agonists (Pohanka, 2011). 
In summary, the pathological consequences of AD arise as a result of 
perturbations in multiple CNS pathways. Currently available therapies are 
only able to act on one or two of these systems and, therefore, can only 
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attenuate symptoms whilst providing no cure. Moreover, current therapies 
(NMDAR antagonists/AChEI) treat the symptoms of AD but offer no disease 
modifying benefits. Thus, there is a need for therapies which modify disease 
progression and also offer a means of halting or reversing 
neurodegeneration. The most successful clinical trials to date have centred 
on AI3 immunotherapy, although trials had to be halted due to 6% of 
participants developing meningoencephalitis (Lemere et al. 2010; Menendez-
Gonzalez et al. 2011). However, despite this setback, AI3 pathology was 
reduced to some extent and modest improvements in cognition were 
observed. Given that impairments in cognition are observed prior to the 
visible plaque pathology, by tackling the problem only when AI3 plaques are 
observed, immunotherapy is unlikely to provide the permanent solution 
needed to reverse AD. Hence, there is an urgent requirement to find a 
therapeutic approach which is able to act on the multiple systems involved in 
AD and potentially reverse pathological changes. The development of animal 
models of AD has enabled significant advances in exploring the therapeutic 
potential of various compounds and some of these models are described in 
the following section. 
1.2.5.5 Animal Models of Alzheimer'S Disease 
Studying AD in humans is limited by the fact that tissue is only available 
post-mortem and this will have undergone a number of unpredictable 
changes as a consequence. Furthermore, variations in the manner in which 
the tissue was processed, the age of the subject, the stage of AD they had 
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reached, the variations in treatment regimens and the presence of co-
morbidities further complicate research. As a result of these limitations, 
animal models have become increasingly popular for studying diseases such 
as AD. Advantages of animal models include the ability to control and 
manipulate their environment, a high throughput rate and the ability to apply 
experimental intervention strategies. 
There are a number of animal models of AD that have been developed. 
These models are mainly based on replicating the mutations in the APP and 
PS genes associated with familial AD. As stated earlier, APP is cleaved by ~ 
and V secretases to form pathogenic A~. PS1 and 2 are both essential 
components of the core V secretase complex in addition to 3 other molecules. 
It has been suggested that the active site of the V secretase complex may be 
formed by 2 aspartate residues located on the presenelins (Tanzi et al. 2005). 
Additionally, presenelins playa number of other important physiological roles 
including the maintenance of neuronal function and survival, modulation of 
calcium entry and protein trafficking and turnover. The presence of APP and 
PS genes results in the formation and deposition of A~ but these animals fail 
to develop NFT pathology (Ashe et al. 2010; Kokjohn et al. 2009). This 
precipitated the use of the frontotemporal dementia (FTD) associated 
mutation P301 L in tau protein being used alongside either APP or APP/PS to 
generate animals which express NFT pathology in (Kokjohn et al. 2009). For 
comprehensive reviews, the reader is referred to Duyckaerts et al. 2008; Hall, 
2012 and Ashe et al. 2010. 
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APP transgenics 
The genetic manipulations employed include abolishing the expression of a 
protein coded for by a gene (knock-outs, KOs), introducing mutations into a 
gene so that the protein it expresses is altered (knock-ins, Kls) and 
introducing foreign genes into the mouse genome (transgenics) (Mineur et al. 
2005). The transgenic approach for the study of AD was the first that was 
successful (Games et al. 1995). It involved the insertion of a mutant form of 
the human APP (hAPP) gene into the mouse genome resulting in APP over-
expression and subsequently enhanced levels of AJ3 with some of the 
associated cognitive defects. 
To date, there are 8 APP transgenics (Duyckaerts et al. 2008) which have 
been developed and characterised, all of which show defects across a range 
of behavioural tests conducted in a variety of laboratories. 
Presenelin transgenics 
Another strategy has been to focus on PS1 and 2 and a number of 
transgenic and KO models have been generated. In general PS1 KO are not 
viable unless a conditional KO is used, which means that the gene is 
inactivated post-natally (Mineur et al. 2005). Wildtype and mutant PS1 KI, on 
the other hand, are viable but show no obvious behavioural abnormalities or 
AJ3 plaques (Dineley et al. 2002). 
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APP Presenelin double transgenics 
Expression of mutant PS1 in the presence of the hAPP transgene results in 
an accelerated Af3 deposition rate (Borchelt et al. 1997). These APP/PS1 
double transgenic mice show A(3 as early as 2-3 months of age whilst none is 
seen in the APP single transgenics at this stage (Borchelt et al. 1997). 
Furthermore, by 9 months of age, the plaque load in the cortex and 
hippocampus of APPswe/PS1 resembles those seen in 18 month old 
APPswe alone (Borchelt et al. 1997). These observations led Borchelt et al. 
to suggest that APP and PS1 mutations show a synergistic interaction 
resulting in enhanced A(3 deposition, as well as promoting production of the 
more aggregation-prone A(342 isoform. Berezovska et al. (2005) suggested 
that the enhanced production of the Af342 isoform may be due to PS1 
mutations resulting in an alteration in the distance between the Nand C 
termini of PS1. This results in a change in the alignment between PS1 and 
APP and its presentation to the V secretase active site leading to A(342 being 
produced instead of A(340. 
APP PS1 double transgenic mice show impaired cognition 
APP/PS1 mutants display a number of cognitive abnormalities which support 
their validity as models for AD. These include deficits in spatial reference 
memory as measured by performance in the radial arm (Gordon et al. 2001; 
Volianskis et al. 2008) and Morris water mazes (Jankowsky et al. 2005). 
Additionally, deficits are also observed in attention and recognition memory 
in a novel object paradigm (Howlett et al. 2004; Scullion et al. 2009) and 
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impaired contextual fear memory (Dineley et al. 2002; Pardon et al. 2009; 
Rattray et al. 2009). 
APP Tau double transgenic mice 
Double mutants for APP and tau have also been generated (Lewis et al. 
2001). These mice show AI3 plaques similar in number and distribution to 
single APP mutants and NFTs morphologically resembling those observed in 
tau mutants (Lewis et al. 2001). However, large numbers of both AJ3 plaques 
and NFTs are only seen at advanced ages in these animals (Lewis et al. 
2001). Additionally, they also show non-AD-related motor deficits and 
generally tend to breed poorly and have a short life-expectancy (Laferla et al. 
2005). Hence, they are not deemed to be very suitable for age-related AD 
research. 
APP PS1 Tau triple transgenic mice: 
In addition to APP/PS1 double mutant mice, triple transgenic mice (3xTg) 
harbouring mutations in APP, PS1 and tau protein genes have also been 
generated. These mice develop AJ3 plaques at approximately 6 months of 
age and NFTs by 10-12 months (Laferla and Oddo, 2005). Impaired 
cognition is first seen in these mice at 4 months and manifests as retention 
deficits observed in the contextual fear memory paradigm (Billings et al. 
2005). 
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APPswedish/Presenelin 1 Deleted Exon 9 
For the purposes of the studies described in this thesis, a double transgenic 
mouse model comprising the human APPS95 Swedish transgene 
encompassing the FAD-related mutations K595N/M596L (APPswe), and the 
deleted exon PS1 (PS1t1E9) variant transgene (APPswe/PS1t1E9) were 
used (Borchelt et al. 1997; Jankowsky, 2001). This model was chosen for a 
number of reasons, including the fact that it is amongst the best 
characterised. Additionally, the APPswe/PS1t1E9 model shows an 
accelerated rate of Af3 deposition compared to other APPswe/PS1 models 
such as the APPswe/A246E PS1 (Jankowsky et al. 2004). Af3 is present 
before 3 months of age (Volianskis et al. 2008) and Af3 plaques are present 
in APPswe/PS 1 t1E9 mice by 4 months of age and progressively increase 
with age, particularly between 6 and 8 months (Garcia-Alloza et al. 2006). 
The APPswe/PS1t1E9 model demonstrates a higher deposition rate for the 
more aggregation prone Af342 such that the ratio of Af340:Af342 is 0.75:1 
(Jankowsky et al. 2004), which may partially explain the aggressive course of 
the disease in this model, as Af342 is considered to be more toxic than Af340 
(Berezovska et al. 2005). Importantly, it is the only AD model to date in 
which there is some neurodegeneration (Richner et al. 2009; Liu et aI.2008), 
the absence of which has provoked debate ~bout the validity of other AD 
models. At 4 months of age APPswe/PS 1 t1E9 mice exhibit forebrain 
monoaminergic axon density similar to wildtype animals but by 12 and 18 
months, these axons have progressively degenerated with a concomitant 
increase in Af3 plaque pathology (Liu et al. 2008). Tyrosine hydroxylase 
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positive (TH+) axons appear to be more prone to degeneration than 5-
hydroxytryptamine (5-HT)-containing neurons (Liu et al. 2008). All 
monoaminergic neurons which project axons to the cortex and hippocampus 
appear to be susceptible to neurodegeneration, with neuronal atrophy visible 
at 12 months followed by neuronal death by 18 months (Liu et al. 2008). In 
contrast to monaminergic axons and neurons, no loss is seen in cholinergic 
neurons (Perez et al. 2007). However, in common with human AD, these 
mice show defects in cholinergic transmission which may be due to 
impairments in vesicular transport and muscarinic receptor-effector coupling 
(Perez et al. 2007; Machova et al. 2008). Neuronal loss is also observed in 
the striatum of 12 month old APPswe/PS1 dE9 animals, whilst 6 month 
APPswe/PS1dE9 exhibit levels similar to wildtype (Richner et al. 2009). The 
latter authors suggested a causal relationship between neuronal loss and the 
progressive increase in AJ3 levels. 
AD is associated with altered neurogenesis. In common with human AD 
patients, APPswe/PS1dE9 animals also show evidence of impaired 
neurogenesis. with 7 month old APPswe/PS1dE9 animals showing a 
dramatic reduction in the survival rates of newly generated neurons 
compared to wildtypes (Verret et al. 2007). 
The APPswedE9PS1 model also displays evidence of progressive cognitive 
decline in a number of behavioural tests assessing episodic and reference 
memory. Savonenko et al. (2005) demonstrated impaired episodic memory 
but intact reference memory in 18 month old APPswe/PS1dE9 animals using 
47 
the radial water maze. However, 6 month old APPswe/PS1 ~E9 animals 
displayed no deficits in either. Jankowsky et al. (2005) found evidence of 
impairments in spatial memory in 8 month old female APPswe/PS1~E9 in 
the water maze paradigm. Reiserer et al. (2007) detected impairments in 
spatial memory in 7 month old APPswe/PS 1 ~E9 in the Barnes maze and 
Zhang et al. (2011) detected impairments in long-term contextual memory 
using the step-down passive avoidance test. Additionally, 
APPswe/PS1~E9 animals display multiple inflammatory responses 
associated with an early pre-plaque age corresponding to the formation of 
soluble Af3 species (Zhang et al. 2012). 
A further benefit of the APPswe/PS1~E9 model is that unlike the TASTPM 
(APPswe/PS1 M146V) mouse model of AD, it was not developed by the 
pharmaceutical industry, and hence is not subject to any intellectual property 
issues. 
A double transgenic model was chosen for study in preference to a 3xTg 
model for a number of reasons. Af3 pathology in the 3xTg precedes that of 
tau hyperphosphorylation which does not usually appear in the hippocampus 
until 12 months of age, thereby mimicking the situation in aging humans 
(Oddo et al. 2003; Pietropaolo et al. 2008). In human AD, cognitive decline 
correlates best with NFT formation (Verdile et al. 2004) but deficits in LTP 
and cognition in 3xTg mice were shown to proceed from intra-neuronal Af3 
and not tau (Oddo et al. 2003; Laferla et al. 2005). Additionally, at 6 months 
3xTg did not show deficits in the conditioned fear (CF) paradigm designed to 
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test for associative learning which is impaired early in the course of human 
AD (Pietropaulo et al. 2008). Furthermore, P301 L is a susceptibility gene for 
fronto-temporal dementia and not genetically linked to AD (Laferla et al. 2005; 
Garcia-Alloza et al. 2006) making the 3xTg an artificial model which does not 
mimic the genetic basis of AD. 
In summary, animal models enable recapitulation of some of the features of 
AD in a laboratory setting. It is important to emphasise that there are no 
animal models which display the full range or neuropsychiatric and 
neuropathological features of human AD (Hall et al. 2012). The ideal model 
would be one which displayed behavioural and cognitive deficits 
accompanied by A~ plaques, NFTs, gliosis, loss of synapses, axonopathy 
and substantial neurodegeneration (Hall et al. 2012). Until such a model is 
generated, however, research is limited to the ones currently available, most 
of which do display impairments in cognition and A~ pathology. By 
manipulating the processes underlying these features, for example by 
activating or inhibiting certain hippocampal memory circuits through the 
application of various drugs, it may be possible to gain a better 
understanding of the disease process. Once a better understanding is 
gained, it will be possible to search effectively for compounds which 
effectively halt or reverse the pathology. One approach which might be 
beneficial in AD is manipulation of the endocannabinoid signalling system in 
the brain. 
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1.3 ENDOCANNABINOIDS AND ALZHEIMER'S DISEASE 
1.3.1 Endocannabinoid Actions 
ECs have been shown to have anti-inflammatory and antioxidant actions as 
well as protecting against excitotoxicity and enhancing neurogenesis. The 
main mechanisms involved in AD have been defined earlier. As ECs are 
able to impact upon all of these systems to various extents, they may 
potentially have beneficial effects in AD (Marchalant et al. 2012; Benito et al. 
2007). 
1.3.2 Evidence supporting a role for the endocannabinoid system in AD 
Support for the involvement of the ECS in AD pathology is provided by a 
number of human studies which show upregulation and nitrosylation of CB1 
and CB2 receptors on microglia in the post-mortem AD brain (Ramirez et al. 
2005). CB1 expression was reduced whilst CB2 expression was enhanced 
in post-mortem AD brains (Ramirez et al. 2005; Solas et al. 2012). Solas et 
al. also found that cortical CB2 expression was correlated to AJ342 levels and 
senile plaque score. In contrast to Ramirez et al. (2005) and Solas et al. 
(2012), Lee et al. (2010) found no differences in CB1 levels in post-mortem 
AD brain, but they did observe a correlation between frontal cortical CB1 
levels and cognitive test scores assessed in the year prior to death. 
Additionally, Lee et al. (2010) demonstrated that CB1 receptors in these 
patients were functionally intact and may have played a role in the 
preservation of cognitive function. 
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Additionally, levels of AEA and its lipid precursor 1-stearoyl, 2-
docosahexaenoyl-sn-glycerophosphoethanolamine-N-arachidonoyl (NArPE) 
were reduced in the mid-frontal and temporal cortices of AD patients post-
mortem (Jung et al. 2012). Furthermore, AEA levels in these patients were 
found to be inversely correlated to A1342 but not A1340, and positively 
correlated with measures of speed of information processing and language 
abilities (Jung et al. 2012). In contrast, Jung et al. observed no differences in 
2AG levels. 
Raised levels of FMH are also found in brain areas containing plaque 
pathology (Benito et al. 2003). In normal brains, FMH immunoreactivity is 
primarily detected in neuronal elements whereas, in AD brains, 
hypertrophied astrocytes show the most intense staining (Benito et al. 2003). 
Astrocytic FMH is hypothesised to degrade AEA, thereby releasing M and 
resultant pro-inflammatory eicosanoids into the surrounding area leading to 
an exacerbation of inflammation (Maccarrone et al. 2007). These changes 
are more pronounced in the vicinity of the plaques and are observed less 
frequently, or not at all, at more distant sites. Furthermore, FMH gene 
expression and protein levels are raised in the peripheral blood mononuclear 
cells of AD sufferers (D'Addario et al. 2012). FAAH inhibition has, therefore, 
been suggested as a logical therapeutic strategy for reducing AD-related 
neuroinflammation (Benito et al 2003). However, when testing this 
hypothesis by incubating astrocytes derived from wildtype and FMH 
knockout (FAAH"-) animals with AI3, Benito et al (2012) surprisingly observed 
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an increase in the expression of pro-inflammatory cytokines by FAAH-1-
astrocytes. This effect, however, was not reproduced using pharmacological 
blockade of FAAH (Benito et al. 2012), thereby supporting the underlying 
proposal of potential beneficial effects of FAAH inhibition. In support of this 
proposal, Murphy et al. (2012) observed that pharmacological blockade of 
FAAH resulted in attenuation of the age-related increase in inflammatory 
markers and partial restoration of a deficit in L TP. 
In contrast to FAAH deletion, genetic deletion of the main enzyme 
responsible for 2AG degradation, MAGL, has also been proposed to have 
beneficial effects in AD (Piro et al. 2012). Piro et al (2012) based this on 
their observation that MAGL controls the release of arachidonic acid which is 
used to synthesise eicosanoids such as prostaglandins. Genetic deletion of 
MAGL in an APP/PS1 double transgenic mouse model of AD resulted in 
reduced eicosanoid levels, attenuated glial activation and associated 
neuroinflammation and reduced amyloid plaque burden (Piro et al. 2012). 
Conversely, Mulder et al. (2011) observed impaired recruitment of MAGL to 
biological membranes of post-mortem AD patients leading them to suggest 
that 2AG signalling is terminated more slowly in these patients. This 
observation lead them to suggest that this impairment in 2AG signalling may 
cause prolonged DSI, resulting in synapse silencing as was observed by 
them in experiments involving the superfusion of mouse hippocampi with A~ 
(Mulder et al. 2011). This suggests that the use of MAGL inhibitors should 
be approached with caution when assessing their potential for therapy in AD. 
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Primary cell culture experiments using cortical neurons incubated with Aj3 in 
the presence of AEA, 2AG, or the FAAH inhibitor URB597, displayed 
reduced apoptosis and lysosomal destabilisation (Noonan et al. 2010). The 
application of exogenous 2AG or MAGL inhibitors to primary hippocampal 
neurons incubated with Aj3 also resulted in reduced apoptosis and 
neurodegeneration in a CB1-dependant manner (Chen et al. 2011). 
Aj3-induced hippocampal degeneration and cognitive deficits are 
accompanied by increased synthesis of 2AG, leading to the proposal that 
neuronal damage up-regulates EC synthesis (van der Stelt et al. 2006). This 
has prompted the suggestion that the production of ECs and the resultant 
CBR activation may be an attempt by the CNS to protect against damage 
(Campbell et al. 2007). Further support for this theory is provided by the 
observation that intraperitoneal administration of the EC transport inhibitor 
VDM-11 to rodents previously injected with Aj3 peptide in the frontal cortex, 
alleviated memory impairments and attenuated the resultant neurotoxicity 
(van der Stelt et al. 2006). However, the exact timing of VDM-11 
administration was critical. For VDM-11 to have any beneficial effects it had 
to be administered early in the disease process. Given later in the course of 
AD it actually impaired memory retention, possibly as a result of reducing 
hippocampal ACh levels (Campbell et al. 2007). 
CB1-null mutants show enhanced release of ACh, prompting the suggestion 
by Davies et al (2002) that a degree of tonic inhibition of ACh release 
mediated by the ECS must exist in the normal CNS. In contrast to this, a 
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different study showed that the intravenous administration of a small amount 
of CBR agonist such as WIN-55,212-2, can also increase the release of ACh 
in vivo, which could be diminished by the CB1 antagonist SR141716A 
(Acquas et al. 2000). In this instance, upregulation of the ECS may be 
beneficial in AD, particularly in light of the fact that one of the main 
treatments for AD involves the use of acetylcholinesterase inhibitors. 
CB2 levels are raised in microglia in AD brains by neuroinflammation (Benito 
et al. 2007). The synthetic cannabinoid receptor agonists HU210, 
WIN55,212-2 and JWH 133 were able to return activated microglia to their 
resting state morphology in vitro whereby they were no longer secreting pro-
inflammatory cytokines (Ramirez et al. 2005). Additional effects attributed to 
CB2 include down-regulation of the CD40 ligand which may be involved in 
Aj3 deposition and inhibition of NO production (Maccarrone et al. 2007). Oral 
administration of the CB2 selective agonist JWH133 for 4 months rescued 
recognition memory impairments in 11 month old APP mice in addition to 
normalizing cerebral glucose metabolism as measured by FOG-PET and 
counteracting microglial activation (Martin-Moreno et al. 2012). Similarly, in 
6 month old APP/PS1 animals, 5 weeks of intraperitoneal JWH133 
administration resulted in reduced levels of microglial reactivity and release 
of prO-inflammatory cytokines as well as alleviation of memory impairments 
(Aso et al. 2012). 
Inhibition of NO generation by inhibiting iNOS reduces lipid peroxidation and 
is thought to be part of the mechanism by which cannabinoids function as 
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anti-oxidants. Furthermore, Law et al. (2001) suggested that NO may be 
involved in the development of plaques and NFTs, and that its inhibition 
would influence multiple pathological parameters. 
Another feature of AD that can be modified by cannabinoids is excitotoxicity. 
A number of studies have shown that activation of CB1 receptors reduces 
excitotoxic cell death of hippocampal neurons by a number of mechanisms 
(Skaper et aI., 1996; Shen et al. 1998). Under normal circumstances, one of 
the primary roles of the ECS is the regulation of neuronal ion channels 
(Alexander et al. 2007). Hence, cannabinoids acting through CB1 located in 
the vicinity of the NMDA channel are able to attenuate its activation. Thus, 
they are able to inhibit the release of Ca2+ from intracellular calcium stores, 
thereby preventing a further toxic rise in [Ca2+k Additionally, elevations in 
Ca2+ levels would be predicted to increase generation of ECs which 
feedback negatively to reduce transmitter release. In support of these 
concepts, CB1 agonists have previously been shown to reduce glutamate 
release by attenuating presynaptic Ca2+ entry (Shen et al. 1998; Twitchell et 
al. 1997). The synthetic cannabinoid analogue HU-211 is also able to 
prevent excitotoxicity probably by direct inhibition of NMDA receptors. 
Furthermore, cannabinoids are able act on microglial CB2 receptors to inhibit 
their activation and, hence, prevent excess glutamate release, thereby 
reducing excitotoxic cell death in AD (Ramirez et al. 2005). 
Other mechanisms by which cannabinoids are potentially able to attenuate 
AD pathology include the inhibition of GSK-3~ and subsequent 
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hyperphosphorylation of tau (Esposito et al. 2006), the release of 
neurotrophic factors such as BDNF (Khaspekov et al. 2004) and stimulation 
of anti-apoptotic pathways (Tyler et al. 2002; Maccarrone et al. 2007). 
Finally, cannabinoids are also involved in adult neurogenesis in the 
subventricular zone and dentate gyrus of the hippocampus. Neurogenesis is 
defective in animal models of AD, although post-mortem examination of 
human AD brains suggests increased neurogenesis (Jin et al. 2004). A 
study by Beatriz Gonclaves et al. (2008) suggested that it is the activity of the 
CB2 receptor in partnership with that of DAGL which is of primary importance 
in neurogenesis. This was based on the observation that the DAGL inhibitor 
RHC-80267 and CB2-selective antagonist JTE-907 reduced neural 
progenitor cell proliferation while the CB2-selective agonist JWH-133 
enhanced it. Hence, it may be possible to manipulate the ECS to enhance 
adult neurogenesis in a bid to replace the neurons lost in AD, and potentially 
attenuate the rate of cognitive decline. 
1.3.3 Cannabinoids and AD 
In addition to ECs, a number of external cannabinoids such as the 
constituents of cannabis sativa have also been shown to have beneficial 
effects in AD. These include the phytocannabinoid cannabidiol (Esposito et 
al. 2007; 2011), the active component of cannabis sativa ~9 
tetrahydrocannabinol (~9 THC) (Eubanks et al. 2006) and a constituent of ~9 
THC, dronabinol (Volicer et al. 1997). 
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In vitro cannabidiol has been shown to protect PC12, N13 and rat primary 
microglial cells from AJ3 induced neurotoxicity through a combination of anti-
apoptotic, anti-oxidative and reduced intracellular calcium influx (Iuvone et al. 
2004; Martin-Moreno et al. 2011). These effects were shown to be mediated 
by the inhibition of the phosphorylated form of p38 MAPK and the 
transcription factor NFKB (Esposito et al. 2006). In vivo studies examining 
the effects of cannabidiol treatment prior to intrahippocampal injections of AJ3 
into 3-5 month old mice supported in vitro studies by demonstrating 
attenuated measures of inflammation and oxidative stress (Esposito et al. 
2007). The same group subsequently showed the neuroprotective effects of 
cannabidiol to be mediated by PPARy activation (Esposito et al. 2011) 
although other groups have suggested a role for the cannabinoid and 
adenosine A2A receptors (Martin-Moreno et al. 2011). 
In addition to cannabidiol, studies have also demonstrated potential 
beneficial effects of ~9THC in AD. As stated previously, one of the main 
mechanisms for treating AD currently is through the use of AChE inhibitors . 
.69THC has been shown to competitively inhibit AChE through its peripheral 
anionic site whereby it serves a dual function in preventing ACh metabolism 
and also diminishing AJ3 aggregation (Eubanks et al. 2006). Furthermore, 
.69THC is a much more effective inhibitor of AChE induced AJ3 aggregation 
than either Tacrine or Donepezil as it is able to prevent aggregation to a 
greater extent at a lower concentration (Eubanks et al. 2006). 
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In addition to its role in AChE inhibition, a primary constituent of il9THC, 
dronabinol has been shown to be effective in stimulating appetite and 
alleviating disturbed behaviour in patients with a clinical diagnosis of 
probable AD who were refusing food (Volicer et al. 1997). 
1.3.4 Summary 
In summary, ECs may act as a double-edged sword in the pathophysiology 
of AD. Activation of CB 1 has been shown to exacerbate memory 
impairments unless it occurs within a narrow spatial and temporal window 
(Van der Stelt, 2006). In contrast, the neurogenesis and anti-inflammatory 
actions associated with CB2 activation may be of benefit. Hence, blockade 
of CB1 receptors concomitantly with enhanced CB2 activation could provide 
a feasible treatment option for attenuation and possibly reversal of AD 
pathology. Additonally, as cannabis smoking is linked to memory 
impairments (Solowij et al. 2008), it is possible that CB1 antagonism may 
provide some short-term benefits even in the absence of the ECS having a 
role in AD. 
1.4 Experimental Hypothesis 
It is hypothesised that activation of the ECS produces multiple, possibly 
opposing, effects in AD. It can potentially attenuate neuroinflammation and 
AD progression through CB2 activation but will disrupt memory and cognition 
through CB1 stimulation. 
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1.5 Aim and Objectives 
The main aim of this project is to determine the role of EGs in AD. This will 
be achieved by characterising the state of the brain EGS in the 
APPswe/PS1~E9 mouse model of AD by correlating changes in EG levels, 
catabolic enzyme activity and receptor/effector coupling with age-related 
deposition of A~, cognitive impairments and inflammatory markers. Initial 
studies will course the age-related changes in the EGS and behavioural 
performance of wildtype and APPswe/PS1~E9 mice at 4, 6 and 8 months. 
Following this, GB1 antagonist and GB2 agonist administration 
preceding/following behavioural tests assessing short-term memory will be 
used to determine the feasibility of targeting the EGS in AD. 
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Chapter 2 
Behavioural Analysis 
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2.1 Introduction 
One of the earliest presenting features of human AD are impairments in 
episodic memory (Backman et al. 2001). The subject of whether animals 
possess episodic memory is contentious although it is generally accepted 
that they exhibit 'episodic-like' memory (Morris, 2001). This can be assessed 
in rodents using the novel objecVlocation tests (Ennaceur et a1.1988; 1992), 
spontaneous alternation in the T -maze (Gerlai, 1998) and contextual fear 
conditioning (Maren, 2001). These tasks have also been used extensively in 
laboratories all over the world for many years and as such are well 
established validated protocols for testing learning and memory in rodents. 
Additionally, all these tasks are hippocampal-dependant to some extent 
(Gerlai, 1998; Tronson et al. 2009), as a result of which they are particularly 
useful in studying Alzheimer'S related memory decline which is partially 
attributed to hippocampal neurodegeneration. One of the advantages of 
these tests is that, in contrast to others such as the Morris water maze, there 
is no requirement for rule learning. Hence, the behaviour being measured is 
based on the natural behaviour of the rodent to complex environmental 
stimuli. 
Novel object and novel location recognition tests are based on the natural 
tendency of rodents to explore novel objects or environments more than 
familiar ones (Ennaceur et al. 1988; 1992). Novel object or location 
recognition paradigms comprise 2 phases: 1) the habituation phase and 2) 
the testing phase. For novel object recognition, the habituation phase 
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involves the placement of an animal into an arena containing 2 identical 
objects which it is permitted to explore freely for a given amount of time, with 
the intention of it becoming 'habituated' to the objects. The animal is 
subsequently removed from the arena for x amount of time (termed the inter-
trial-interval) following which it is placed back in the arena for the testing 
phase. In the testing phase, one of the previous objects has been replaced 
with a novel object. The amount of time the animals spends exploring the 
familiar and novel object is recorded. The novel location test is based upon 
a similar principle, with the exception that the location of one of the objects 
from the habituation phase is changed in the testing phase and no novel 
object is introduced. Both these tasks are referred to as one trial tests due to 
there being no requirement for rule learning as a result of which the tasks 
can be administered in one testing session. Ennaceur et al. 1992 cite the 
lack of rule learning as being a distinct advantage of these tests based on 
the observation that memories of a unique event are more vulnerable to 
damage than more robust memories of repetitive events. Furthermore, they 
argue that the lack of reinforcement learning means that the motivational and 
arousal states of the animal more closely replicate the conditions under 
which human memories are measured (Ennaceur et al. 1992). 
The T -maze spontaneous alternation task is also based upon the principle of 
animals preferring to explore a novel environment over a familiar one 
(Lalonde, 2002). Animals are expected to become familiar with the goal arm 
they enter first so that they select the opposite goal arm to explore next time 
as it will be novel to them, and hence alternate between them. Performance 
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in the task appears to depend on the presence of extra-maze cues to a 
certain extent (Gerlai, 1998). Mice naturally tend to show alternation at 
levels significantly above chance (Lalonde, 2002) although differences in 
performance have been reported between inbred and out bredstrains (Gerlai, 
1998). 
Contextual fear conditioning (CFC) is a form of Pavolvian associative 
learning whereby an animal forms an association between a conditioned 
stimulus (CS) and an unconditioned stimulus (US) (Kim et al. 2006). In the 
case of CFC the CS is the context, and the US a mild foolshock (Rudy et al. 
2004). The animal learns to fear the context even in the absence of the US 
which manifests as freezing behaviour when the animal is in the context. 
CFC measures 2 main components: learning and memory. The animal is 
initially required to 'learn' the association between CS and US and later 
remember the connection when it is placed back into the context. 
Furthermore, the test is able to measure new learning in the extinction phase 
whereby the CS-US pairings become disassociated to the extent that a new 
memory is formed where CS and US are not linked (Kim et al. 2004). This 
process is referred to as 'cognitive flexibility' by some and is frequently 
impaired in AD patients (Albert, 1996). 
As CFC uses immobility as an indicator of contextual fear (CF), baseline 
activity levels of animals are recorded prior to administration of the CFC 
paradigm to ensure there are no underlying differences in activity to 
confound the CFC outcome measures. Baseline activity levels are 
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measured either immediately preceding the administration of the first 
footshock, or in a separate open field task whereby the animal is placed in an 
arena or permitted to explore for a given length of time. 
This study utilised all of the above methods for characterising the behaviour 
of wildtype and transgenic APPswe/PS1~E9 mice at a range of ages. The 
study is presented in two parts, an initial characterisation followed by a more 
in-depth behavioural examination. 
2.2 Aims and study design; part 1 
The first part of this chapter details an initial study which aimed to ascertain 
the behaviour of the APPswe/PS1~E9 mice at 4 and 5.5 months of age in 
the contextual fear conditioning (CFC) paradigm and the locomotor activity 
(LMA) task. This study was conducted due to this being the first instance 
that the APPswe/PS 1 ~E9 mouse model of AD had been used at the 
University of Nottingham, and to confirm that it showed similar deficits to 
those displayed by the TASTPM model used previously. The TASTPM 
mouse model displayed deficits in cognitive flexibility and episodic memory 
which are also affected early in the course of human AD (Pardon et al. 2009; 
Rattray et al. 2009). Both these parameters can be tested using the CFC 
paradigm. Additionally, this study aimed to confirm 4 months as being a 
suitable baseline from which to initiate future studies. 
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2.3 Materials and Methods 
2.3.1 Animals 
Double transgenic mice backcrossed on a C57 background, over-expressing 
the human APP695 Swedish gene encompassing the familial AD-related 
mutations K595N/M596L (APPswe), and the deleted exon PS1 (PS1~E9) 
variant gene (Borchelt et al. 1997; Jankowsky et al. 2001) were generated in-
house following purchase of the initial breeding stock from Jackson 
Laboratories (Bar Harbor, ME). The APPswe/PS1~E9 double transgenic 
animals were subsequently mated with wildtype C57 mice to produce 
heterozygote double mutants (APPswe/PS1~E9) or wildtype littermates. 
Due to possible sexual dimorphisms in pathology, only male mice were used 
for the study. All animals were housed in the same room on a 12h lightdark 
cycle with room temperature, humidity and air exchange all being 
automatically regulated. Animals were initially group-housed in cages 
supplied with nesting material and a play tube, with ad-libitum access to food 
and water until 3 months of age. At 3 months, animals were isolated due to 
age-related increases in aggression commonly observed in male mice. 
Animals were randomly allocated to 2 independent groups which were tested 
at either 4 (n=13-14) or 5.5 (n=10-11) months. 
All animal procedures were carried out in accordance with the UK Animal 
Scientific Procedures Act under project license 40/3238. 
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2.3.2 Experimental design 
Animals underwent a LMA task on day 1 followed by the C~C paradigm 3 
days later comprising 3 phases which were conducted over 3 days: 
acquisition (day 4), retention (day 5) and extinction (day 6). Following the 
extinction trial , animals were placed back in their home cage for 48 hours to 
allow physiological parameters to return to baseline. Animals were 
subsequently killed (Schedule 1) and the frontal cortices and hippocampi 
were removed, snap frozen in liquid nitrogen, and stored at -80°C to 
determine endocannabinoid levels and cannabinoid receptor-effector 
coupling (figure 2.1). 
3 M 
Isolat e t----
Figure 2.1 : Timeline of behavioural experiments ; LMA = Locomotor Activity. 
Acq = CF acquisition . Ret = CF retention. Ext = CF extinction . 
2.3.3 Locomotor activity 
LMA was conducted to ensure that any potential differences observed 
between the groups in the CFC paradigm were not due to differences in 
activity levels, as immobility levels are used to indicate CF . . Animals were 
placed in Perspex activity boxes (30cm x 35 cm x 25 cm) for 30 minutes 
during which their behaviour was recorded and subsequently analysed using 
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Ethovision software (Noldus, Wagenigen, Netherlands). The total distance 
moved in 30 minutes was recorded and used for statistical analysis. 
2.3.4 Contextual Fear Conditioning 
CFC is a form of Pavlovian conditioning which analyses the pairing of a 
conditioned stimulus (context) with a noxious electric foot shock 
(unconditioned stimulus). It has previously been established that the 
hippocampus is crucial for the acquisition and retrieval of CFC which can be 
regarded as a test for episodic memory (Matus-Amat et al. 2004). As 
impairments in episodic memory are amongst the earliest traits observed in 
human AD patients, CFC was considered an appropriate tool for assessing 
this parameter. 
The protocol adopted for this study was based on that employed by Pardon 
et al. (2009) and Rattray et al. (2009). The acquisition, retention and 
extinction (re-Iearning that the context is no longer aversive) phases of the 
task were all conducted in the same chamber (25cm x 25cm x 38cm) 
conSisting of 3 grey stainless steel walls and a transparent Perspex wall, with 
stainless steel rods placed 1 cm apart forming the floor. The steel rods on 
the floor of the chamber were connected to a shock generator (Campden 
Instruments, Loughborough, UK) and formed the means by which the shock 
was administered to the animals. A camera placed above the chamber was 
used to monitor and record the behaviour of the animals. The recordings 
were subsequently used to determine the amount of time the animal spent 
immobile in each trial. Immobility levels were manually scored twice per trial. 
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If the difference between measurements was greater than 5 seconds, the 
trial was re-scored a third time and the two closest values used for data 
analysis. The average values obtained were used for statistical analysis. 
Acquisition (Trial 1): Animals were placed in the chamber (conditioning 
context) for 1 minute prior to receiving their first foot shock (1 sec, O.4mA). 
Following this, a further 9 foot shocks were administered at 1 minute 
intervals for 9 minutes, giving a total of 10 foot shocks. The animals were 
then removed from the chamber and placed back in their home cage. 
Increasing immobility (e.g. lack of displacement, body movement, head turn 
and grooming (Pardon et al. 2009; Rattray et al. 2009) in response to 
repeated administration of foot shocks was used as an indicator of 
acquisition (learning) of fear conditioning. 
Retention (Trial 2): 24 hours after the acquisition trial, animals were placed 
back in the chamber for 3 minutes to test their recent CF memory. No foot 
shocks were applied and their behaviour was recorded as before. The 
amount of time the animal spent immobile was used as an indication of fear 
memory i.e. how well the animal remembered the aversive experience 
received 24 hours earlier. 
Extinction (Trial 3): A further 24 hours later (48 hours after acquisition) the 
animal was placed back in the chamber for 3 minutes and its behaviour 
recorded. As before the total amount of time spent immobile was determined. 
It was expected that the animal would show less immobility in this trial due to 
relearning that the context was no longer aversive in trial 2. An extinction 
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index value was calculated by subtracting the time spent immobile in the 
retention trial from that in the extinction trial. The more negative the 
extinction index value, the better the extinction. 
It has previously been shown that the increasing immobility observed in all 3 
trials is due to the aversive experience. Animals that did not receive foot 
shocks were active at least 80% of the time in all 3 trials compared to 
animals that did receive foot shocks and displayed increasing immobility with 
time in trial 1 (Rattray et al. 2009). 
2.3.6 Statistical Analysis: 
LMA: Total distance travelled was analysed using a two-way ANOVA with 
age and genotype as between group factors. 
CFC: Immobility during the acquisition trial was assessed by means of a two-
way repeated measures ANOVA with age and genotype as the between-
subjects factors and time (1 shock per minute, 10 modalities) as the within-
subjects factor. Intra-group differences in retention and extinction were also 
analysed using a two-way repeated measures ANOVA with age and 
genotype as between-subjects factors and trial (2 modalities) as the within-
subjects factor. A one-sample t-test was used to determine whether the 
extinction index is significantly different from 0 which would indicate no 
extinction has taken place. 
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Post-hoc testing: 
Planned comparisons were conducted post hoc when appropriate using the 
least significant difference (LSD) test. The main focus of this study was to 
identify differences between wildtype and APPswe/PS1LlE9 animals at each 
age group. Hence, planned comparisons identified to be of interest prior to 
the start of the experiment were those between wildtype and 
APPswe/PS1LlE9 at 4 months, and 5.5 months. 
Rationale for statistical tests: 
One sample t-tests were conducted to establish whether an animal has 
performed the requirements of the task, in the case of CFC this would be 
indicated by an extinction index significantly different from o. Repeated 
measures and two way ANOVAs were conducted in order to determine 
differences within and between groups as a factor of age and genotype 
irrespective of whether an animal has performed the requirements of the task. 
2.5 Results 
2.5.1 Locomotor Activity 
The results of the LMA test indicated that APPswe/PS1LlE9 mice were 
significantly hyperactive compared to their wildtype littermates [F(1,45) = 25.96; 
p<0.001]. APPswe/PS1LlE9 animals consistently travelled a greater distance 
during the 30 minute test than wildtype animals at both ages (figure 2.2a). 
Post-hoc analysis applied to the main effect of genotype indicated significant 
differences between 4 month old wildtype and APPswe/PS1LlE9 and 5.5 
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month old wildtype and APPswe/PS1L\E9 mice (p<0.001 in both cases). No 
significant effect of age or genotype x age interaction was observed. 
2.5.2 Contextual Fear Conditioning 
Acquisition of contextual fear conditioning 
Shock-induced immobility was measured during the acquisition of contextual 
fear as an indicator of how well the animal learned the task. All groups 
showed a significant increase in immobility with time [F(9.396) = 121.45; p< 
0.001] indicating that they were all able to associate the context with the 
aversive stimulus (figures 2.2b-c). No significant effects of age or genotype 
were observed. 
Retention and extinction of contextual fear conditioning 
APPswe/PS1L\E9 showed significantly higher immobility levels compared to 
wildtype animals during the retention [F(1.45) = 4.19; p=0.046] and extinction 
[F(1.45) = 8.22; p=0.006] trials (figures 2.2d-e). No significant effects of age 
or an age x genotype interaction were observed in the retention or extinction 
trial. Post-hoc tests revealed a significantly higher levels of immobility in 
APPswe/PS1L\E9 compared to wild type animals at 5.5 months of age 
[pairwise comparison: p=O.004] and a non significant increase in immobility 
during the retention trial at 5.5 months [pairwise comparison: p=O.069]. 
Statistical analysis of immobility levels during retention compared to 
extinction revealed significant main effects of trial [F(1. 45) = 8.51; p=O.006] 
and genotype [F(1. 45) = 7.26; p=O.010]. Post hoc analysis applied to the main 
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effects of genotype and trial indicated that 4 month old wildtype animals 
showed significantly lower levels of immobility in the extinction trial compared 
to the retention [pairwise comparison: p=O.039]. Similarly, 4 month old 
APPswe/PS 1 ~E9 showed significantly lower immobility levels during the 
extinction trial compared to the retention [pairwise comparison: p=O.030]. In 
contrast no significant differences were observed in immobility levels during 
retention compared to extinction for 5.5 month old wildtype or 
APPswe/PS 1 ~E9 animals. 
To determine whether an animal had successfully extinguished contextual 
fear, an extinction index value was calculated by subtracting immobility 
during the retention trial from that in the extinction trial. For successful 
extinction to have taken place the value of the extinction index needs to be 
negative and significantly different from 0 (figure 2.2f). Wildtype animals at 4 
months (one sample t-test: p=O.016) and 5.5 months of age (one sample t-
test: p=O.009) demonstrated successful extinction in contrast to 
APPswe/PS1~E9 which did not. In the case of 4 month WT and 
APPswe/PS 1 ~E9 animals, the mean extinction index values were very 
similar. However, the standard deviation for the APPswe/PS1~E9 group was 
almost double that of the wildtype group, hence why the wildtype value is 
significantly different from 0 whilst that for the APPswe/PS1~E9 is not. 
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Figure 2.2 (data presented as mean ± SEM): (a) Locomotor activity. Total distance travelled in 30 minutes by wildtype (WT) and APPswe/PS16E9 
(APP) mice aged 4 (n=13-14) and S.S (n=11) months. Pairwise comparisons: *p=0.002. Contextual fear conditioning b-f; (b-c) All animals were able to 
learn the task at 4 (n=13-14) and S.S (n=10-11) months demonstrated by immobility increasing significantly with time (p<O.001); (d) APP animals display 
significantly high~r levels of immobility compared to wildtype animals independent of age during the retention trial (p=O.046); (e) APP animals show 
significantly greater levels of immobility compared to wildtype animals at S.S months (pairwise comparison *p=O.004); (f) only wildtype animals showed 
successful extinction of contextual fear. One-sample t-test *p=O.016 (4 months) and *p=O.009(S.5 months) compared to 0 (no extinction). 
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2.6 Discussion 
The aim of this experiment was to determine whether the APPswe/PS 1 ~E9 
mouse model of AD exhibited deficits in the CFC paradigm as displayed 
previously by the TASTPM model, and whether 4 months of age was a 
suitable starting point for further studies. 
This study demonstrated that APPswe/PS1~E9 mice are significantly 
hyperactive compared to their wildtype littermates, independent of age. This 
observation was supported by Bonardi et al. 2011 which also found evidence 
of hyperactivity in 4 month old female APPswe/PS1~E9 mice. This is in 
contrast to other studies which have not found evidence of hyperactivity in 
these animals (Lalonde et al. 2004; Park et al. 2010). This may be due to 
methodological differences. For this study, LMA was recorded for 30 
minutes, whereas the aforementioned studies only recorded for 5 and 10 
minutes respectively. Hence, it is possible that for the first 10 minutes of the 
task the novel environment may result in increased exploration by both 
wildtype and APPswe/PS1~E9 mice which may mask any genotype related 
differences in LMA. However, with time, the animals would be expected to 
become habituated to the arena and reduce their exploratory behaviour. 
This would mean that LMA levels of wildtype animals would decrease but as 
the APPswe/PS1~E9 are hyperactive their levels would remain high. This 
assertion receives some support from the unpublished observations made in 
this study which show that APPswe/PS 1 ~E9 exhibit higher activity levels 
than wildtype animals throughout the whole 30 minute testing period, even 
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when broken down and examined in 5 minute time bins. Furthermore, both 
wildtype and APPswe/PS1LlE9 animals show highest activity levels in the 
first 5 minutes of the task followed by relatively steady levels for the 
remainder of the 30 minutes testing session. This would indicate that 
animals become habituated to the arena after 5 minutes. Hence, when 
animals are only tested for 5 minutes the activity levels will be reflective of 
the fact that the animal is in a novel environment and thus more likely to 
exhibit exploratory behaviour rather than being an indication of steady state 
activity levels. However, by testing for 30 minutes this caveat is overcome 
and a genuine estimate of steady state activity levels is obtained. 
The increased activity levels may be due to APPswe/PS 1 LlE9 mice 
possessing a greater exploratory drive, or reflect evidence for behavioural 
disinhibition as suggested by Lalonde et al. (2005), although their data were 
from 12-month-old APPswe/PS1LlE9 mice of both genders. Alternatively, it 
may be related to an alternative mechanism hitherto undiscovered such as 
increased excitability of striatal neurons although this hypothesis would need 
to be tested through the use of electrophysiology or microdialysis. 
APPswe/PS1LlE9 animals were able to learn CF at the same rate as their 
wildtype counterparts at both 4 and 5.5 months thereby demonstrating that 
learning is not impaired in these animals. Hence, any differences observed 
during the retention trial must be due to impaired recall and not learning 
defects. Both wildtype and APPswe/PS1LlE9 displayed high levels of 
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immobility in the retention trial, thus confirming recall of the aversive 
experience from the previous day and therefore no memory impairments. 
However, contrary to expectations APPswe/PS1LlE9 exhibited no 
impairments in recent contextual fear memory at 4 or 5.5 months. This was 
demonstrated by APPswe/PS1LlE9 mice showing greater levels of immobility 
compared to their wild type littermates, and not lower, as would be expected if 
there were impairments in retention of contextual fear. This outcome 
receives support from 2 recent studies conducted using the same mouse 
model, which also found no differences in the freezing behaviour of both 
male and female APPswe/PS 1 LlE9 over 8 months and 4 month old females 
24 hours after acquisition of CF (Park et al. 2010; Bonardi et al. 2011). In 
contrast, another study conducted using a different APP/PS1 model 
(TASTPM) did show impairments in contextual fear memory at 5.5 months 
(Pardon et al. 2009; Rattray et al. 2009). However, studies conducted in the 
APPswe/PS1LlE9 using different tests of hippocampal memory such as the 
Morris water maze or radial arm water maze also do not show short-term 
episodic memory deficits in animals at 6 (Savonenko et al. 2005) and 7 
months (Reiserer et al. 2007; Volianskis et al. 2010). Additionally, 
suggestions that hyperactivity may mask impairments in CF memory can be 
refuted by the observation that despite their hyperactive nature 
APPswe/PS1LlE9 display higher levels of immobility compared to non-
hyperactive wildtype mice. In light of these factors, it is possible that recent 
memory is not impaired in the APPswe/PS1LlE9 model until a later age. 
Alternatively, it is possible that memory deficits are rescued in this model of 
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AD due to their hyperactive nature. It has been shown that exercise reduces 
the levels of AI3 in a mouse model of AD (Adlard et al. 2005) as well as 
inducing synaptogenesis in hippocampal CA 1 and dentate gyrus (Dietrich et 
al. 2008). Thus, it is theoretically possible that the increased activity of 
APPswe/PS 1 ~E9 result in beneficial effects which counteract the synaptic 
dysfunction. 
As mentioned earlier, contrary to expectations, APPswe/PS1~E9 mice 
displayed higher levels of immobility in both the retention and extinction trials 
relative to wild type mice at both 4 and 5.5 months. Furthermore, 5.5 month 
APPswe/PS1~E9 animals actually display higher immobility levels in the 
extinction trial than the retention. 
Under normal circumstances, animals would be expected to re-Iearn during 
the retention trial that the context is no longer aversive and, therefore, show 
increased mobility during the extinction trial. This was seen for the wildtype 
but not APPswe/PS1~E9 animals, indicating the presence of a deficit in 
extinction. This suggests that APPswe/PS1~E9 mice, in common with the 
TASTPM model, are unable to inhibit previously learned associations that 
are no longer relevant (Pardon et al. 2009). This is supported by Bonardi et 
al. 2011 which also found impairments in CF extinction in 4 month old female 
APPswe/PS1~E9 mice. Additional support is provided by the demonstration 
by Savonenko et al. (2005) that during the radial arm watermaze procedure 
18 month old APPswe/PS1~E9 mice showed a strong tendency to visit the 
previous day's platform location. Savonenko et al. (2005) suggested this 
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may be due to APPswe/PS1~E9 being unable to quickly learn information 
related to the new episode of training and also postulated this defect may be 
accompanied by old memory traces being continuously activated. These 
observations correlate well with changes seen early in human AD where 
defects in cognitive flexibility are also apparent early in the course of the 
disease. Tests for cognitive flexibility are amongst the most reliable 
indicators for distinguishing between controls and MCI individuals and MCI 
and mild dementia patients (Gualtieri et al. 2005; Albert, 1996). 
2.7 Aims and study design: part 2 
The second part of this chapter describes a longitudinal study examining the 
behaviour of APPswe/PS1~E9 animals at 4, 6 or 8 months of age (n=18-20 
determined by power analysiS of data from part 1 using an a error probability 
of 0.05, effect size of 0.25 and power of 0.96). Animals were subjected to a 
battery of behavioural tests over a 12 day testing period (figure 2.3a). 
Animals underwent LMA testing on day 1, followed by a novel location/novel 
object recognition test (Nov) on day 2 and spontaneous alternation in the T-
maze on day 4. After a recovery period of 3 days, animals were subjected to 
the acquisition (day 8), retention (day 9) and extinction (day 10) trials of the 
CF task. Following the extinction trial, animals were placed back in their 
home cage for 48 hours to allow physiological parameters to return to 
baseline. Animals were subsequently killed (Schedule 1) and the frontal 
cortex, striatum and hippocampi were removed, snap frozen in liquid nitrogen, 
and stored at -80·C for further analysis (see Chapter 3). 
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Figure 2.3a: Timeline for 12 day behavioural testing protocol. 
2.8 Materials and Methods 
2.8.1 Locomotor Activity 
The LMA task was performed as detailed in 2.3.3 
2.8.2 Novel Location and Novel Object Recognition 
This test had two components, novel location, which measures spatial 
memory, and novel object recognition which measures recognition memory. 
The test is based on the tendency of animals to spend more time exploring 
novel situations more than familiar ones. The tests were carried out in the 
same arena as described previously for LMA. Two sets of objects were used; 
these were circular or triangular wooden blocks. It has previously been 
shown that animals display no preference for one shape over another 
(Scullion et al. 2009). Animals were subjected to 3 trials each; acquisition, 
novel location and novel object recognition. During the acquisition trials, 
animals were placed in an arena containing 2 identical objects and permitted 
to explore freely for 10 minutes following which they were placed back in 
their home cage. The novel location trial took place 1 hour and 20 minutes 
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later. Animals were placed back in the arena where the location of one of 
the objects had been changed, and allowed to explore freely for 10 minutes 
before being returned to their home cage. A further 1 hour and 30 minutes 
later, animals were placed back into the arena which now contained a novel 
object in addition to the familiar one, and were allowed to explore for 10 
minutes (figure 2.3b). The position of the objects was counterbalanced 
throughout the procedure and all objects and the arena were' cleaned using 
20% ethanol between each trial to eliminate odour cues. All of the trials were 
recorded by a camera positioned directly above the arena and later used to 
determine the amount of time spent exploring each object. Exploration was 
defined as the amount of time spent by an animal with its nose pointing 
towards the object at a distance of ~ 0.5 cm. The distance moved, total 
exploration time and exploration time for each object were recorded for each 
trial. To determine an animals' preference for the novel object, the amount of 
time spent exploring the novel object was divided by the total exploration 
time and multiplied by 100% to obtain a preference index value. 
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Figure 2.3b: Novel Location and Novel Object Recognition Protocol. 
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2.8.3 Spontaneous Alternation in the T-maze 
Spontaneous alternation in the T -maze is a test of working memory 
performance measuring the exploratory behaviour of mice. The procedure 
used was adapted from Spowert-Manning et al. (2004). The T -maze 
comprised three grey Perspex arms each measuring 41.5 cm in length and 6 
cm in width surrounded by 15 cm high transparent Perspex walls. The start 
box 6 cm x 7.5 cm was located in the lower central arm of the maze. The 
entrance to the start box and the arms of the maze could be closed using 
vertical sliding doors. 
Animals were placed into the start box and permitted to explore freely for 1 
minute after which they were guided back to the start box and the door 
lowered. For trial 1, the door was lifted and the animal was given a free 
choice to enter either the left or right arm of the maze. Once an animal had 
entered one arm the entrance to the other arm was closed off using the 
vertical doors. The animal was allowed to explore down the length of the 
arm and then guided back to the start box by sectioning off the area behind it. 
The process was then repeated for trial 2. A total of 5 consecutive trials 
were conducted enabling a maximum of 4 alternations. The number of 
alternations made was recorded and used to calculate percentage 
alternation. Each animal was allocated 10 minutes in which to complete the 
task.· Any animal failing to complete the task in 10 minutes was 
subsequently excluded. Animals were not handled during the task to 
minimise stress. 
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2.8.4 Contextual Fear Conditioning 
The CFC paradigm was identical to that detailed in 2.3.4 
2.8.5 Statistical Analysis 
LMA: Total distance travelled was analysed using a two-way ANOVA with 
age and genotype as between group factors. 
CFC: Immobility during the acquisition trial was assessed by means of a two-
way repeated measures ANOVA with age and genotype as the between-
subjects factors and time (1 shock per minute, 10 modalities) as the within-
subjects factor. Intra-group differences in retention and extinction were also 
analysed using a two-way repeated measures ANOVA with age and 
genotype as between-subjects factors and trial (2 modalities) as the within-
subjects factor. A one-sample t-test was used to determine whether the 
extinction index is significantly different from 0 which would indicate no 
extinction has taken place. 
T -maze: Percentage alternation was analysed using a two-way ANOVA with 
age and genotype as between-subject factors. A one sample t-test was used 
to determine whether percentage alternation, within each group, was 
significantly different from 50% which represents chance levels. 
Novel location and novel object recognition: A two-way repeated measures 
ANOVA was used to determine differences in total exploration times between 
the 3 trials with age and genotype as between-subjects factors and trial (3 
modalities) as within-subjects. A two-way ANOVA was used to examine 
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differences in preference indices for the novel location task with age and 
genotype as between-subjects factors. The same test was also conducted to 
analyse preference indices for the novel object task. Novel location and 
novel object discrimination were assessed individually by means of a two-
way repeated measures ANOVA for exploration times with age and genotype 
as between-subjects factors and object familiarity (2 modalities) as within-
subjects factors. One sample t-tests were conducted to determine if 
preference indices were above the level of chance (50%). 
Post-hoc testing: 
Planned comparisons were conducted post hoc when appropriate using the 
least significant difference (LSD) test. As previously, the performance of 
wildtype and APPswe/PS1~E9 animals at 4,6 and 8 months was compared. 
2.8 Results 
2.8.1 Locomotor Activity: 
APPswe/PS1~E9 animals were significantly hyperactive compared to their 
wildtype counterparts [F(1.106) = 93.34; p<0.001] at 4, 6 and 8 months (figure 
2.4a). Activity declined significantly with age [F(2.106) = 4.45; p=0.014], but at 
all ages, APPswe/PS1~E9 were hyperactive compared to their age-matched 
wildtype littermates (p<0.001 at 4 and 6 months and p=0.001 at 8 months). 
As APPswe/PS1~E9 animals were found to be hyperactive in the first part of 
this study, it was determined that the possibility of these animals exhibiting 
anxiety-like traits which may influence behavioural testing should be 
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excluded. This was assessed by comparing the ratio of activity in the centre 
of the arena to that in the periphery. No significant differences in this ratio 
were observed between wildtype and APPswe/PS1~E9 mice as a function of 
age or genotype (figure 2.4b). 
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Figure 2.4 (data presented as mean ± SEM): (a) Locomotor Activity). Total distance 
travelled in 30 minute testing session of 4 (n=20), 6 (n=20) and 8 (n=18) wildtype (WT) and 
APPswe/PS16E9 (APP) mice. APP mice display significant hyperactivity compared to their WT 
counterparts which decreased with age. (p<O.001 and p=0.014 respectively). Pairwise 
comparisons:*p~O .001. (b) Ratio of activity in the centre of the arena:time:activity in the 
periphery. No significant differences were observed as a function of age or genotype. 
2.8.2 LMA and Exploration Times During Acquisition, Novel Location 
and Novel Object Recognition Trials 
Locomotor activity during the acquisition, novel location and novel object 
recognition trials was also analysed. In line with the LMA data above, 
APPswe/PS1~E9 animals were significantly hyperactive [F(1 .106) = 54.50; 
p<0.001] compared to their wildtype counterparts (Table 2.1) but activity 
declined significantly with age [F(1 .106) = 11.76; p<0.001]. A significant effect 
of trial [F(2.212) = 323; p<0.001] and a trial x genotype interaction [F(2.212) = 
5.55; p=0.005] were also observed indicating activity decreased with 
increasing trial number. Post hoc pairwise comparisons indicated that 
APPswe/PS1~E9 exhibited higher activity than wildtype animals during the 
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acquisition trial at 4, 6 and 8 months (p<O.001), the novel location trial at 4, 6 
(p<O.001) and 8 months (p=O.016) and the novel object recognition trial at 4 
(p=O.001), 6 (p=0.008) and 8 (p=0.036) months (Table 2.1). 
blstance Moved (m) 4MWT I 4MAPP 6MWT I 6M~PP BMWT 1 BM-APP 
Acquisition 35.13101.13 -' 42.43101.42 31.46:tl 12 J 38.86101.47 31 23:tO.86 J 37.99101.32 
Pairwise comparisons P<O.OOI P<O.OOI peOOOl 
Novel Location 25.59101.05 J 34.22101 35 23.74101.18 J 31.08±173 23 .48:tO .85 J 27 .9S± 1 .32 
Pairwise comparisons peOOOl peO.OOl P=O 016 
Novel Object 25.59±1.03 I 3110±1.30 22.54±1.05 I 27.0111.22 20.22±O72 T 24.1111.10 
Pairwise comoarisons P=O.OOI p=o.ooa P=O.036 
Table 2.1 (data presented as mean i SEM): Locomotor activity in the acquisition, novel 
object location and novel object recognition trials for 4 (n=20). 6 (n=20) and 8 (n=18) 
month old wildtype (WT) and APPswe/PS1~E9 (APP) animals. Distance moved over 10 
minutes Der trial. 
There was a significant overall reduction in total exploration time as a 
function of age [F(2,110) = 11.03; p<0.001]. genotype [F(1,110) = 14.50; p<0.001] 
and trial [F(2,110) = 169.80; p<0.001]. APPswe/PS1~E9 displayed greater 
total exploration times at all ages and for all 3 trials compared to their 
wildtype counterparts (Figure 2.5a) as indicated by significant age x trial 
[F(4,220) = 2.83; p=0.025] and genotype x trial [F(2,220) = 3.65; p=0.028] 
interactions. Post hoc analysis demonstrated that APPswe/PS1~E9 aged 4 
(p<0.001). 6 (p=0.036) and 8 (p=0.032) months displayed significantly higher 
total exploratory activity in the acquisition trial compared to their age 
matched wildtype counterparts. 
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Figure 2.5 a-c (data 
presented as mean ± 
SEM): Total and Object 
Exploration Times 
during the acquisition, 
.Acquisition novel location and novel 
o Novel Location object recognition trials 
o Novel Object for 4 (n=20), 6 (n=20) and 
8 (n=18) month old 
wildtype (WT) and 
APPswe/PS1~E9 (APP) 
animals. 
_Novel 
o Familiar 
_Novel 
a Familiar 
(a) Total exploration time 
over each 10 minute trial. 
Exploration time 
decreased significantly 
with age and trial 
(p<O.001). APP displayed 
significantly higher 
exploration times 
compared to WT animals 
at all ages (P=O.025) and 
in all trials (p=O.028). 
Pairwise comparisons: 
p<O.001 (4 months) 
p=O.036 (6 months). 
p=O.038 (8 months). 
(b) Animals spent 
significantly more time 
exploring the object in the 
novel location (p<O.001) 
than the familiar with 4 
month old animals 
displaying significantly 
higher exploration times 
than 6 and 8 month old 
(p<O.001) and APP more 
than wildtype (p=O.007). 
Pairwise comparisons: 
p=O.035 (4 and 6 months). 
(c) Animals spent significantly more time exploring the novel object 
than the familiar (p=O.022). Exploration times decreased significantly 
with age (p=O.005). APP displayed greater exploratory activity than 
wildtype mice (p=O.008). Pairwise comparisons: 4 month old WT 
(p<O.001) and APP (p=O.006) displayed significantly higher exploration 
times for the novel object that the familiar. 
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2.8.3 Novel Location Test 
The novel location task was used to determine whether there were any 
differences in spatial memory due to age or genotype. Animals had 
previously been habituated to the test arena during the LMA task 24 hours 
earlier. 
In the acquisition trial, there was no preference shown by the animals for the 
object which was to be displaced to a novel location compared to the object 
which was to remain in the same location. In the novel location trial (figure 
2.5b), there was a significant effect of object location [F(1.110) = 24.31; 
p<O.001] on exploration times with animals spending more time exploring the 
object in the novel location. A significant effect of age [F(2.110) = 12.83; 
p<O.001] was also observed with 4 month old animals displaying higher 
exploration times than 6 or 8 month old animals. Furthermore, a significant 
genotype x object interaction [F(1.110) = 7.47; p=O.007] indicated that 
APPswe/PS1.1E9 mice spent more time exploring the displaced object than 
wildtype animals at 4 and 6 months as determined by post hoc analysis 
(p=O.035). A significant effect of genotype [F(1.110) = 5.65; p=O.019] was 
observed for the preference index which post hoc analysis determined to be 
due to 6-monlh-old APPswe/PS1.1E9 displaying a significantly greater 
preference than wildlype animals for the displaced object (p=O.014). One 
sample t-testing demonstrated preference indices to be significantly above 
chance for all groups except 6 and 8 month old wildtype animals (figure 2.5d). 
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Figure 2.5 doe (data presented as mean ± SEM): Preference Index for the novel 
location and novel object recognition trials for 4 (n=20), 6 (n=20) and 8 (n=18) month 
old wildtype (WT) and APPswe/PS1~E9 (APP) animals. (d) Preference index is 
calculated as a percentage using the following formula: novel location exploration time/total 
exploration time x100%. APP display significantly greater preference indices than wildtype 
animals (p=0.019). ·Pairwise comparisons: 6 months p=O.014. A one sample t-test 
compared preference index for each test to those obtained by chance (50%) :tp<0.05 (e) 
Preference index is calculated as a percentage using the following formula: novel object 
exploration time/total exploration time x 100%. Preference index decreased significantly 
with age (p=0.009) and genotype (p=0.005). ·Pairwise comparisons: 6 months p=0.022. A 
one sample t-test compared preference index for each test to those obtained by chance 
(50%) ;f:p<O.05; :t:tp=O.OOO. 
2.8.4 Novel Object Recognition 
The novel object recognition task was used to determine whether there were 
any differences in recognition memory due to age or genotype. A significant 
main effect of object was observed [F(1 ,110) = 5.38; p=O.022] indicating that 
animals spent more time exploring the novel object than the familiar one 
(Figure 2.5c). Exploration times decreased significantly with age [F(2,110) = 
5.66; p=O.005] but APPswe/PS1.1E9 displayed significantly greater 
exploratory activity than wildtype mice [F(1 ,110) = 7.38; p=O.008]. 
Significant age x object [F(2,110) = 7.25; p=O.0051] and genotype x object 
[F(2,110) = 4.91; p=O.029] interactions were also observed indicating that the 
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difference in the time spent exploring the novel versus the familiar object 
decreased as a function of age and genotype with 6 and 8 month old animals 
spending more time exploring the familiar object over the novel. Post hoc 
analysis indicated that 4 month old wild type (p<0.001) and 4 month old 
APPswe/PS1 ~E9 (p=0.006) showed significantly greater exploration times 
for the novel object than the familiar. No significant differences in exploration 
times were observed for 6 or 8 month old animals. Significant main effects 
were observed for age [F(2.110) = 4.91; p=0.009] and genotype [F(1.110) = 8.09; 
p=0.005] on the preference index (figure 2.5e). Post hoc analysis indicated 
this was due to a significant difference in preference indices between 6 
month old wildtype and APPswe/PS1~E9 animals (p=O.022). Only 4 month 
old wildtype and APPswe/PS1~E9 animals displayed a preference index 
significantly above chance (p=O.OOO and 0.048 respectively) whilst all other 
animals displayed values close to 50%. 
2.8.5 T -Maze 
Animals were assessed for spatial memory using spontaneous alternation in 
the T-maze (figure 2.6). There was a significant genotype x age interaction 
[F(2.99) = 3.19; p<0.05] reflecting the observed decrease in alternation rates 
with age in wildtype animals and its increase in APPswe/PS1~E9 mice. No 
significant differences were observed in alternation rates between wildtype 
and APPswe/PS1~E9 animals at 4 (p=0.68), 6 (p=0.74) or 8 (p=0.48) 
months. No group showed alternation rates significantly different from 
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chance (50%) although the 8 month old wildtype group approached 
significance (p=0.059). 
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Figure 2.6 (data presented as mean ± SEM): Spontaneous 
alternation In the T -Maze. Percentage alternation displayed by 
wildtype (WT) and APPswe/PS1~E9 (APP) animals of 4 (n=20) , 6 
(n=20) and 8 (n=18) months. There are no significant differences 
in percentage alternation due to genotype or age. A significant 
genotype x age interaction (p<0.05) was observed. Alternation 
rates are not significantly different from chance (50%). 
2.8.6 Contextual Fear Conditioning (CFC) 
Acquisition of contextual fear 
Shock-induced immobility was measured during the acquisition task (figure 
2.7a) as an indicator of how well the animal has learned the task. All groups 
showed increasing immobility with time indicating that they were able to 
associate the context with the aversive stimulus [F(8,793) = 296.61 ; p<0.001]. 
A significant main effect of genotype was also observed [F(1.108) = 4.20; 
pSO.05] which post hoc analysis attributed to 4 month old APPswe/PS1LlE9 
mice displaying significantly lower immobility levels than wildtype mice at the 
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5th, 7'h, 8th and 9th minutes (psO.05). There were no other significant main 
effects indicating that age did not influence acquisition of contextual fear. 
Retention and extinction of contextual fear 
During the retention (figure 2.7b) and extinction (figure 2.7c) trials, the levels 
of immobility were used to indicate how well the animal remembered the 
aversive experience it previously underwent in that context. A significant 
main effect of genotype was observed in both the retention [F(1.11o) = 6.41; 
p=0.012] and the extinction [F(1.110) = 8.73; p=0.004] trials indicating that 
APPswe/PS1.1E9 mice displayed higher immobility levels in both trials 
compared to wildtype animals. A significant main effect of trial was also 
observed demonstrating that both APPswe/PS1.1E9 and wildtype mice 
displayed lower immobility levels in the extinction trial than the retention 
[F(1.110) = 6.20; p=0.014]. Post-hoc analysis indicated a significant difference 
between wildtype and APPswe/PS1.1E9 mice at 8 months of age in both the 
retention (p=0.014) and the extinction (p=0.004) trials. 
To determine whether an animal had successfully extinguished contextual 
fear, an extinction index value was calculated (as described in part 1) by 
subtracting immobility during the retention trial from that in the extinction trial. 
For successful extinction to have taken place, the value of the extinction 
index needs to be negative and significantly different from 0 (Figure 2.7d). 
There were no significant differences between wildtype and 
APPswe/PS1.1E9 mice as a function of age, genotype or age x genotype 
interactions for extinction index (figure 2.7d). One sample t-test analysis 
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demonstrated that only wildtype animals at 6 months of age were 
successfully able to extinguish contextual fear memory (p=O.016). 
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Figure 2.7 (data presented as mean ± SEM): Contextual Fear Memory. Immobility levels 
displayed by wildtype and APPswe/PS1 ~E9 animals of 4 (n=20), 6 (n=20) and 8 (n=18) 
months in the contextual fear memory task. (a) Both wildtype and APPswe/PS1~E9 
animals similarly acquired contextual fear. (b-c) APPswe/PS1 ~E9 displayed significantly 
higher immobility levels than wildtype mice in the CF retention and extinction trials. Post 
hoc *ps 0.01 . Both genotypes displayed significantly lower immobility levels in the 
extinction trial than the retention. (d) Only 6 months wildtype animals displayed successful 
extinction. One sample t-test *p=0.016 compared to a (no extinction). 
92 
2.9 Discussion 
Animals underwent a battery of behavioural tests at 4, 6 and 8 months of age 
to determine their performance in a range of different memory tests 
assessing episodic memory components of associative memory, spatial 
memory and recognition memory. In addition, exploratory activity and 
anxiogenic reactivity were also analysed to ensure that cognitive 
performance was not influenced by traits other than those being tested. 
As determined in the first part of this study, APPswe/PS1.1E9 animals were 
hyperactive compared to wildtype animals. However, in contrast to the 
earlier study, exploratory activity appeared to decline with age, although 
APPswe/PS1.1E9 levels consistently remained elevated above those of 
wildtype mice. A reduction in exploratory behaviour with age has previously 
been reported for other animal models of amyloidosis (Scullion et al. 2009). 
The reduction cannot be attributed to habituation as animals were only 
placed in the arena for one 30 minute trial in order to assess activity levels. 
Similarly, the observation that both wildtype and APPswe/PS1.1E9 animals 
displayed reduced activity levels across trials in the novel location and novel 
object paradigm argues against the suggestion that APPswe/PS1.1E9 mice 
may be failing to habituate. Alternative explanations suggested in section 
2.6 may also apply. 
As these animals were found to be hyperactive in the earlier study (2.5.1), 
their anxiogenic reactivity was measured to ensure that they did not exhibit 
anXiety-like traits which could influence their performance in other 
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behavioural tests. A comparison of the ratio of activity in the centre of the 
arena to that in the periphery demonstrated no differences due to genotype 
or age. This is in line with previous reports indicating that APPswe/PS 1 LlE9 
mice do not exhibit anxiety like behaviour in the plus maze at 7 or 12 months 
of age (Lalonde et al. 2004; 2005). Hence, any changes observed in the 
behavioural test parameters are unlikely to be due to the animals being 
anxious. 
Spatial memory performance was assessed using the novel location and 
spontaneous alternation tasks. No genotype-related differences were 
observed in novel location exploration times. Spatial memory performance in 
the novel location task diminishes with age as demonstrated by 6 and 8 
month old wildtype animals exhibiting exploratory activity at chance levels, 
whilst it remained greater than chance for APPswe/PS 1 LlE9 mice at all ages. 
In the case of the spontaneous alternation task, a significant interaction 
between age and genotype reflected an increase in alternation with age in 
APPswe/PS1LlE9 and decrease in wildtype animals. This may be due to 
spatial alternation requiring an optimal level of anxiety (Lalonde, 2002) based 
on which, the evidence for behavioural disinhibition in APPswe/PS1LlE9 
animals may explain why these animals perform well in this task. However, 
the results of this study do not support this concept as no differences in 
anxiety were observed between wildtype and APPswe/PS 1 LlE9 animal. 
These results are consistent with previous studies employing this model at 7 
and 12 months (Lalonde et al. 2004, 2005; Reiserer et al. 2007) which also 
did not find any differences in spatial alternation and, indeed, found 12 month 
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old APPswe/PS1~E9 to display alternation rates significantly above chance 
in contrast to age-matched wildtype animals (Lalonde et al. 2005). 
These findings would suggest that spatial memory performance remains 
intact in these animals between 4 and 8 months of age. Previous studies 
using alternative methods such as the Morris water maze or radial arm maze, 
for testing spatial memory awareness suggest that this may be the case as 
animals in those studies do not typically show impairments until later in life 
(Savonenko et al. 2005; Volianskis et al. 2008). 
Recognition memory using the novel object task indicated that all animals 
were able to distinguish between the novel and familiar objects. However, 
exploration times decreased significantly with age and genotype such that 6 
and 8 month-old APPswe/PS 1 ~E9 animals spent more time exploring the 
familiar object than the novel although the difference was not significant. 
This may indicate animals are beginning to find it more difficult to distinguish 
between the novel and familiar object. Preference index of 6 and 8 month-
old animals did not vary much within genotypes. Only 4 month old animals 
showed a preference index greater than chance, although in the case of 
APPswe/PS1~E9 this was only just significant, whilst all other groups did not. 
This could possibly be due to animals becoming confused between the 
objects after exposure to them for a total of 20 minutes during the acquisition 
and novel location trial. Although the novel object was a different shape to 
the familiar object, they were still exposed to 2 objects per trial and it is 
possible by the third trial that they would simply have lost interest in exploring 
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them, but as exploration times remain relatively high in the third trial this 
proposal is not supported by the data. A more straightforward novel object 
test uses one object in the acquisition trial and subsequently adds in another 
object in the test phase. Hence, it is a lot more apparent that there is a new 
object in the arena. As the animals seem to do comparatively better in the 
novel location test, it suggests that their spatial memory remains intact; 
hence, when they enter the arena in a novel object test which excluded a 
novel location trial previously, the fact that there is a second object in there 
now may register more strongly, than in an arena where there are still 2 
objects (except that the shape of one has changed). An alternative 
explanation may be related to the inter-trial interval of 1 hour 30 minutes 
being too short, as a consequence of which the animal becomes confused or 
loses interest as it has not 'dis-habituated' from the previous test trial (novel 
location). This hypothesis could be tested by repeating the protocol using 
different groups of animals with increasing inter-trial-intervals e.g. 1.5/3/6 
hours. The fact that only the 4 month old wildtype and APPswe/PS1.1E9 
animals· displayed a preference index greater than chance would suggest 
that any confusion which arises is age related and not genotype specific 
although the protocol itself may have an influence. It is also possible that 
these factors apply differently to each group. For instance, the failure of 6 
and 8 month old wildtype animals to display a preference index greater than 
chance may be due to a combination of habituation, and confusion or 
reduced motivation to explore. This suggestion receives support from the 
reduction in total exploration times observed in these animals with age in the 
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acquisition trial. In contrast, 6 and 8 month old APPswe/PS1~E9 mice may 
not exhibit a preference index greater than chance due to them being unable 
to discriminate between the novel and familiar object. This interpretation is 
supported by the observation that, at these ages, APPswe/PS 1 ~E9 mice 
spent more time exploring the familiar object than the novel, a trait which was 
not observed in wildtype animals. 
Furthermore, both the wildtype and APPswe/PS1~E9 animals exhibited a 
reduction in total exploration time and LMA with age and increasing trial 
number, with the decline being more apparent in wildtype animals than 
APPswe/PS1~E9. This indicates that animals become habituated to the 
arena and, thereby, display reduced motivation to explore, the more they are 
exposed to it. As the novel object trial was the last of three trials, at this point, 
an animals' motivation to explore would have been at its lowest level and, 
thus, may potentially have resulted in the observed decline in discrimination 
of the novel object from the familiar. In future experiments, it would be 
advisable to use an alternative test for spatial memory and use only one 
object in the acquisition trial and two in the test phase. Alternatively, 
switching the order of the trials so that the object recognition trial is second 
and the location trial last may be of benefit. Additionally, increasing the inter-
trial interval to 4 hours may prove beneficial in discerning behavioural 
differences between the different groups. 
The contextual fear memory paradigm, in line with earlier studies (2.5.2), 
demonstrated that both wildtype and APPswe/PS1~E9 mice were able to 
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learn an association between the foots hock and the chamber in which they 
received it at all ages. APPswe/PS1L\E9 animals of 4 months of age 
appeared to learn slower than their wild type counterparts at the 5, 7, 8 and 9 
minutes time-points. However, as they appear to demonstrate a similar rate 
of learning to wildtype animals at all other times, and at 6 and 8 months of 
age, this effect is most likely due to variation in individual data points 
comprising the group mean rather than a slower task acquisition rate. Hence, 
APPswe/PS1L\E9 animals did not exhibit learning impairments at 4, 6 or 8 
months of age. However, although both wildtype and APPswe/PS1L\E9 
animals were able to recall CF in the retention trial, APPswe/PS1L\E9 mice 
appeared to display better recall as demonstrated by higher immobility levels 
than wildtype animals. The difference in recall between the two genotypes 
was particularly pronounced at 8 months of age. A similar pattern was 
observed for the extinction trial in which animals would be expected to 
display lower immobility levels than in the retention trials as a practical 
illustration of them re-Iearning that the context is no longer aversive. Whilst 
animals did display lower immobility levels in most cases (4 month old 
APPswe/PS1L\E9 animals actually display slightly higher immobility levels), 
the reduction was not significant for any of them except 6-month-old wildtype 
animals. This is reflected in the extinction index data, whereby only 6 month 
old wildtype animals were able to successfully extinguish CF. Hence, in this 
study, contrary to expectations, 4 and 8 month-old wildtype and 
APPswe/PS1L\E9 mice at all ages were unable to extinguish CF. This is in 
contrast to the observations described in section 2.5 in which wildtype 
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animals aged 4 and 5.5 months were able to successfully extinguish CF. 
This difference may be accounted for by the presence of large individual 
variations in immobility levels in the groups examined in this study as 
illustrated by the presence of relatively large variance in the data. In the 
case of 4 and 5.5 month-old animals (section 2.5) and of 6 month old 
wildtype animals in this study, the variance was comparatively smaller, 
thereby suggesting lower levels of individual variation and, hence, successful 
extinction. The individual variation is particularly apparent in the 4 month old 
group. In the case of failure to extinguish in the 8 month old wildtype group, 
in addition to it being due to the variation in individual scores, it is possible 
that, at this age, the animals are naturally becoming cognitively impaired due 
to advancing age. In the case of APPswe/PS1.1E9 animals. based on the 
results described in the first half of this chapter and demonstrated by other 
studies (e.g. Bonardi et al. 2011), it was expected that they would 
demonstrate a failure to extinguish CF memory and thus show impairments 
in cognitive flexibility. However, despite increasing age and, therefore, 
advancing pathology, these animals still did not display evidence for recent 
memory impairments even at 8 months of age. 
In summary, the strongest outcomes from the battery of behavioural tests 
conducted in the course of this study indicate that APPswe/PS 1.1E9 mice are 
hyperactive and demonstrate impairments in cognitive flexibility. Both of 
these traits are apparent at 4 months and can still be detected at 8 months of 
age. Additionally, both of these tasks involve aspects of striatal circuitry 
(Clarke et al. 2008; Brooks et al. 1995). This is of particular interest as an 
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age-related decrease in the number of neurons in the striatum of 12, but not 
6 month old APPswe/PS1~E9 mice in response to increasing Aj3 load has 
previously been reported (Richner et al. 2009). It is, therefore, possible that 
the behavioural deficits detected during the course of this study represent a 
means by which damage to striatal neurons preceding degeneration could be 
assessed. 
Spatial memory appears to remain intact in APPswe/PS1~E9 animals up to 8 
months of age whilst recognition memory indices suggest the possibility of 
impairment in APPswe/PS1~E9 mice. This is interesting as lesion studies 
have previously demonstrated that a smaller lesion volume of the 
hippocampus is required to induce impairments in spatial memory (-50%) 
whilst a greater lesion (75-100%) is necessary to cause defects in 
recognition memory (Broadbent et al. 2004). However, the results of this 
study suggest that spatial memory remains intact whilst recognition memory 
may be impaired in APPswe/PS1~E9 animals. Alternatively, it is possible 
that the recognition memory impairments observed may not be related to an 
inability to distinguish between novel and familiar objects but may be due to 
habituation to the test arena as suggested for wildtype animals. 
2.10 Conclusion 
The results presented in both parts of this chapter suggest that the 
APPswe/PS 1 ~E9 mouse model of AD is an appropriate one for investigating 
behavioural impairments arising from the presence of the genetic insertion of 
the APPswe and PS1~E9 transgenes into the mouse genome. In particular, 
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the presence of impairments in cognitive flexibility present in these animals 
as early as 4 months of age allows its use for investigating the efficacy of any 
potential therapeutic interventions at an early stage of the disease process, 
prior to the manifestation of extensive neuronal damage and global cognitive 
decline. Furthermore, an impairment in cognitive flexibility is one of the 
earliest effects distinguishable in human AD, using this parameter to study 
drug effects may enable better translation from a preclinical to clinical stage. 
However, despite these benefits, the conclusions drawn above should be 
tempered by the wildtype animals not exhibiting the behavioural phenotype 
expected. 
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Chapter 3 
Endocannabinoid 
System and Lipidomics 
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3.1 Introduction 
Alterations in lipid metabolism are thought to play a role in Alzheimer's 
disease (AD). Two groups of lipids which have received particular attention 
are the plasmalogens (Rothhaar et al. 2012) and cholesterol (Hartmann et al. 
2007). Plasmalogens are glycerophospholipids which are the primary 
constituents of neuronal cell membranes as well as having roles in 
membrane fusion, ion transport and cholesterol efflux (Rothhaar et al. 2012). 
In relation to AD, plasmalogen levels are found to be decreased in the post-
mortem brains of human AD patients, particularly in areas displaying 
extensive neurodegeneration (Ginsberg et al. 1995). Further analysis by 
Han et al. (2001) demonstrated this deficiency to be more prevalent in white 
matter than grey matter. Rothhaar et al. (2012) recently demonstrated that 
reduced plasmalogen levels result in increased activity of y-secretase, 
thereby promoting enhanced production of amyloid beta (A(3). 
In addition to glycerophospholipids, cholesterol is also an essential 
component of neuronal membranes. Cholesterol metabolism is essential for 
efficient neurotransmission and repair (Bales, 2010). In the CNS, cholesterol 
is primarily supplied by glia after development as its synthesis is an 
energetically demanding process which is thought to confer too great a 
burden on neurons (Pfriegar, 2003). Instead, neurons rely on lipoproteins to 
provide them with cholesterol, in particular apolipoprotein E (APOE) (Gamba 
et al. 2012). The APOE type 4 al/elle (E4) was one of the earliest and most 
persistent risk factors discovered for sporadic AD (Strittmatter et al. 1993) 
103 
thus implicating perturbations in cholesterol transport. In addition, it has 
been suggested that high levels of cholesterol promote processing of APP 
along the amyloidgenic pathway and may associate with APOE to provide a 
seeding platform for AJ3 aggregation (Gamba et al. 2012). 
Other lipid entities associated with AD include 
alkylacylglycerophosphocholine second messengers which are thought to 
increase tau phosphorylation and initiate signalling cascades leading to 
neuronal cell death (Ryan et al. 2009) and endocannabinoid production 
(Pardon et al. 2009). 
The role of endocannabinoids in AD has been extensively covered in 
Chapter 1. As stated earlier, a sUbstantial body of research implicates 
beneficial roles of endocannabinoids in AD resulting from their multimodal 
functionality as anti-inflammatory (Murphy et al. 2012; Piro et al. 2012), anti-
oxidant (Oddi et al. 2012), neuroprotective (Sun et al. 2007; Chen et al. 2011) 
and pro-neurogenic agents (Soltys et al. 2010; Goncalves et al. 2008). 
Amongst the evidence suggesting that endocannabinoid levels have an 
influence in AD, is the observation by Pardon et al. (2009) of differences in 
regional endocannabinoid levels at 5.5 months between wildtype animals 
and the TASTPM mouse model of AD (Pardon et al. 2009). 
Aberrant lipid metabolism has also been implicated in a number of diseases 
other than AD (Han et al. 2001; 2002) resulting in an urgent need for 
developing sensitive MS techniques enabling detection, characterisation and 
quantification of components of the cellular lipidome (Oresic et aI.2008). 
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These requirements have been addressed in recent years by the emerging 
field of lipidomics. Lipidomics is a branch of metabolomics, which is the 
study of global metabolite changes in cells, tissues and biofluids (Oresic et al. 
2011). Hence, lipidomics can be defined as an attempt to analyse and 
characterise lipids and the molecules they interact with by unravelling 
individual pathways and combining them to generate a picture of how the 
system operates as a whole (Wenk et al. 2003). A major advantage of 
lipidomics is that it enables the application of an unbiased approach as no 
prior assumptions are programmed into the method. Hence, it provides a 
global output of all the elements of the lipidome as it has not been instructed 
to monitor only certain m/z values as with many other analytical approaches. 
This can result in the revelation of novel mediators previously not associated 
with the conditions being evaluated. 
Ultra performance liquid chromatography (UPLC) coupled to MS is a recent 
technique developed for application in research into lipidomics (Wenk et al. 
2005). UPLC involves the use of particles less than 2.5~m in size to line a 
column enabling greater efficiency, resolution and speed of separation 
(Scwartz, 2005). However, because of the diverse array of lipid structures 
and their complex interactions, analysing and interpreting the information 
gained from MS studies is currently still a work in progress, hindered by the 
lack of availability of reliable internal standards for several lipid classes, 
although rapid advances are being made (Oresic et al. 2008; Shevchenko et 
al. 2010). 
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The limitations associated with accurately measuring lipid levels are 
particularly exacerbated when applied to the small tissue quantities 
associated with regional mouse brain areas such as the frontal cortex, 
hippocampus and striatum. This is particularly problematic in the case of 
endocannabinoids and related compounds as their levels are relatively low in 
the brain compared to other lipid entities (Buczynski et al. 2010). It has 
previously been reported by Muccioli et al. (2008) that a minimum tissue 
weight of 30 mg is necessary for accurate detection of N-acylethanolamines 
using gas-chromatography coupled with mass spectrometry (GC-MS). 
However, regions such as the striatum can weigh as little as 6 mg when 
using samples from one hemisphere only (Maroof et al. unpublished 
observations). In addition to this, the absence of functional groups conferring 
electrical activity, fluorescence or permitting UV absorption increases the 
difficulty of isolating endocannabinoids from other lipid mediators (Buczynski 
et al. 2010; Zoerner et al. 2011). As a consequence, most quantitative 
analysis of endocannabinoids is conducted using mass spectrometry 
coupled to liquid chromatography (LC-MS). LC-MS enables separation of 
the various endocannabinoids and related molecules on the LC column 
followed by their fragmentation and detection of the fragmented component 
using MS (Le Blanc et a. 2003; Buczynski et al. 2010). The use of LC-MS 
enhances the signal to noise ratio of the sample, thereby reducing 
interference from other constituents of the biological matrix (Buczynski et al. 
2010). 
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Due to manipulations of the endocannabinoid system being increasingly 
endorsed as potential treatment strategies for neurodegenerative disorders, 
and much of this being based on pre-clinical work undertaken in rodent 
models, it is essential to determine regional levels of endocannabinoids in 
the absence of pharmacological manipulations. At present, much of the work 
assumes the changes observed are due to alterations in endocannabinoid 
tone but little is known regarding the innate state of the system prior to 
external manipulations, or as a function of age. This is particularly important 
as ageing is known to be affected by endocannabinoids based on the 
observation that CB receptor knockout mice display features of accelerated 
ageing (Bilkei-Gorzo et al. 2012). 
Many other techniques are used in conjunction with the above methods to 
obtain a comprehensive understanding of processes driving the cellular and 
systemic aberrations associated with pathology. Amongst these are assays 
enabling measurement of the functional consequences of receptor activation 
by the analytes measured using MS, such as the e5S] GTPyS binding assay 
(Harrison et al. 2003). The binding of a ligand to a G protein-coupled 
receptor (GPCR) results in the activation and subsequent dissociation of a 
Ga(GDP)Gj3v heterotrimer complex. Upon activation GDP dissociates from 
Ga and is replaced by GTP which results in the Ga subunit separating from 
the Gj3v and activating downstream signalling cascades (Figure 1.2; Harrison 
et al. 2003). The reformation of the GaGDP complex by the action of 
GTPase and its subsequent binding to Gj3v terminates the process. The [35S] 
GTPyS binding assay replaces normal GTP with a non hydrolysable 35S 
107 
labelled GTPyS. As it cannot be hydrolysed Ga [35S] GTPyS complexes 
accumulate in the sample and can be measured by quantifying the amount of 
radioactivity present. 
In addition to assessing G protein activation, the e5S] GTPyS binding assay 
can also be used to determine the efficacy and potency of ligands at a 
particular GPCR. As a result, the assay is a particularly useful tool for 
analysing the pharmacodynamics of new drug candidates which have usually 
been identified using MS-based approaches. Coupling these techniques to 
those used in metabolomics approaches enables a picture to be built of a 
given disease process as well as providing means for assessing potential 
treatments. 
3.2 Aims 
The aims of this chapter were to determine the levels of AEA. OEA. PEA and 
2AG in the mouse hippocampus (HC), frontal cortex (FCTX) and striatum 
(STR) using LC-MS/MS in order to determine whether alterations are 
observed in the ECS with advancing age. A lipidomic analysis was also 
conducted to determine whether there were any group differences in the lipid 
metabolome as a consequence of either age or genotype. Additionally, the 
efficiency of cannabinoid receptor-effector coupling in these regions was 
investigated using the [35S] GTPyS binding assay. 
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3.3 Materials and Methods 
3.3.1 Chemicals 
Acetonitrile (far UV grade). methanol. ethanol. ethyl acetate. hexane. 
ammonium acetate and formic acid were obtained from Fisher Scientific 
(Loughborough. UK). Sodium chloride was purchased from MP Biomedicals 
Inc (Ohio. USA). AEA. OEA. PEA. 2AG. AEA-d8 and 2AG-d8 were obtained 
from Cambridge Bioscience (Cambridge. UK). High pressure liquid 
chromatography (HPLC) grade water was used for all experiments (Elga. 
High Wycombe. UK). 
3.3.2 Standard preparation 
Stock solutions were prepared in ethanol to give a final concentration of 
14mM AEA, 2.8mM AEA-d8. 15mM OEA. and 17mM PEA. 13mM 2AG and 
259 ~M 2AG-d8 were prepared in acetonitrile. All stock solutions were 
stored at -80·C. Stock solutions were diluted in a solution of ethyl 
acetate:hexane (9:1 v/v). to prepare standard concentrations ranging from 
500nM to 100pM for extraction and analysis. 
3.3.3 Tissue acquisition 
As stated in Chapter 2.3.2. animals underwent Schedule 1 killing following 
which the brain was removed. the frontal cortex. hippocampus and striatum 
were dissected out. snap frozen in liquid nitrogen and stored at -80·C until 
use. 
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3.3.4 Sample extraction 
The analytical method used is based on that of Richardson et al. (2007) with 
further optimisation and developments introduced to enable quantification of 
endocannabinoids using the smaller tissue weights obtained from mouse 
brain regions. Since the sample size used was typically in the region of 10-
20 mg, the main changes involved a significant scaling down in volumes of 
solvents and solutions used compared with previous methodology intended 
for rat brain tissue. In addition, water as a sample diluent was replaced with 
0.9% NaGI to better mimic the physiological tissue environment, and 
homogenisation of tissue samples was performed directly in Eppendorf tubes 
without silanisation using a pestle pellet cordless motor. Furthermore, both 
standards and internal standards were prepared in ethyl acetate:hexane (9:1 
v/v). These changes to the sample preparation procedure significantly 
improved the sensitivity and reliability of the method to measure EGs and 
other lipids in the small samples sizes as can be observed in table 3.3. 
Tissue samples were weighed and homogenised in 400 IJI 0.9% sodium 
chloride (NaGI) using a handheld pellet pestle cordless motor with disposable 
pestles (Sigma Aldrich). Once homogenised, 750 j.l1 of ethyl acetate:hexane 
(9:1 v/v) and internal standards (S.4 pmol AEA-d8 and 1 nmol 2AG-dS) were 
added followed by vortexing and placement on the shaker for 30 minutes. 
Following this, samples were centrifuged at 13,000 RPM for 10 minutes and 
the ethyl acetate:hexane layer removed and placed in fresh tubes. The 
remaining pellet was resuspended in 9:1 ethyl acetate:hexane and the 
process repeated. The supernatants were pooled and subsequently 
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evaporated to dryness using a centrifugal evaporator (Jouan RC10.32). The 
same procedure was used for the extraction of EC standards and human 
plasma QC (quality control) samples. Human plasma was used for QC due 
to the difficulty associated with obtaining large quantities of standardised 
brain tissue for this purpose. However, as a substitute, human plasma 
contains all of the endocannabinoids and related molecules being 
investigated in addition to a range of other mammalian lipids. Plasma QC 
samples were included for each batch of study samples in accordance with 
bioanalytical QC guidelines and used to ensure analytical results were valid 
for each sample set. Following evaporation, samples were concentrated by 
re-constituting in 200 IJI acetonitrile and evaporated to dryness again, after 
which they were reconstituted in a final volume of 50 IJI acetonitrile and 10 IJI 
injected for analysis .. 
3.3.5 HPLC·MS/MS conditions for EC identification and quantification 
All samples were analysed using Applied Biosystem MDS SCIEX 4000 Q-
Trap hybrid triple-quadrupole-linear ion trap LC/MS/MS mass spectrometer 
model 1004229-F (Applied Biosystem, Foster City, CA, USA) in conjunction 
with a Shimadzu series 10AD VP LC system (Shimadzu,Columbia, MD, USA) 
comprising a cooled autosampling unit. A Thermo Scientific HyPurity 
Advance C8 column (100mm length, 2.1mm ID, 3IJm particle size) fitted with 
a guard column was used for LC separation. The column was maintained at 
a temperature of 40·C, a flow rate of 0.3mllminutes and maximum pressure 
set to 350 bar. Mobile phases comprising aqueous (water, 1 gIL ammonium 
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acetate, 0.1% formic acid, 10% acetonitrile) and organic (acetonitrile, 19/L 
ammonium acetate, 0.1 % formic acid, 10% water) solutions were passed 
through the column using a stepwise gradient (Table 3.1). Samples were 
maintained at 4'C in the auto sampler prior to analysis and an injection 
volume of 101-11 was used. 
Analytes and internal standards were quantified using tandem electrospray 
mass spectrometry in positive ion mode (ES+) using multiple reaction 
monitoring (MRM) to enable simultaneous detection of multiple analytes of 
interest. A source temperature of 550'C was used. Protonated [M+Ht and 
product ion mass to charge (m/z) values were used to identify 
endocannabinoids and deuterated forms of the internal standards. The 
declustering potential (DP), collision cell entrance (CE) and exit (CXP) 
potentials are listed in Table 3.2. 
3.3.5.1 Analyte Quantification 
Samples were quantified using Analyst 1.4.1 (Applied Biosystems, Foster 
City, CA, USA). Compounds were identified by their LC retention times 
combined with m/z values. Peaks for each individual compound were 
integrated and used to determine area under curve (AUC). Data obtained 
were subsequently imported into Microsoft Excel. A ratio of the AUC for the 
extracted standard to the AUC of the internal standard (y axis) was plotted 
against concentration (x axis) for each standard. Linear regression analysis 
was subsequently applied and used to generate an equation for each 
standard. The ratio of sample AUC to internal standard AUC was put into 
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Irlme (mlns) I[Pump A1 % Pump B1 % 
0.01 ~5 55 
2 __ 00 35 65 
6.50 G5 65 
8.00 30 70 
~.01 0 100 
9.00 P 100 
9.01 ~5 55 
15.00 Stop 
Table 3.1: Gradient conditions for LC/MS/MS. 
Retention 
~nalyte rrlme (mlns) Ql Mass 1a3 Mass EP (V) DP (V) CE (V) CXP (V) 
AEA 5.78 348.28 ~2.06 10 40 30 8.56 
OEA 7.55 326.30 ~2.06 10 40 32 8.19 
PEA 6.60 300.28 ~2.06 10 40 30 9.22 
~AG 6.97 379.28 287.22 10 88 22 4.90 
~EA-d8 5.70 356.33 63.03 10 80 45 15.00 
~AG-d8 6.89 1387.33 95.11 10 70 61 7.08 
Table 3.2 Retention times, m/z values for precursor (Q1), product (Q3) Ions and MS/MS 
conditions for AEA, OEA, PEA, 2AG, AEA-d8 and 2AG-d8. EP = Entrance potential, DP = 
Declustering potential, CE = Collision cell entrance potential, CXP = Collision cell exit potential. 
Lowest Standard 
Detected % CVAEA-d8 % CV2AG-d8 
Ext Ext 
Modification ~EA OEA PEA 2AG QC Stds Samples QC Stds Samples 
~ame procedure as Richardson 
at al. 2007 but with all 
components scaled down and 
using Q-Trap instead of Quattro 5 100 
Ultima. nM 2nM 5nM nM 3.46 16.74 71.2 8.4 22.8 61.48 
~s above but standards and 
nternal standards made up in 
ethyl acetate:hexane (9:1 v/v). 
Additionally, water has been 500 
replaced with 0.9% NaCI. pM 1 nM 2nM 10 nM 2.14 8.3 7.84 1.64 3.06 11.05 
~EA-d8 dilution altered from 100 100 
1:100 to 1:5000 pM pM 1 nM 5nM 3.58 5.11 8.77 0.6 4.08 9.81 
Figure 3.3: Effects of modifications made to protocol of Richardson et al. 2007. Modifications resulted 
in standards of lower concentration being detectable and improvements in coefficients of variation (% CV) for 
the internal standard content of plasma QCs, extracted standards and tissue samples. 
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the equation and used to determine the concentration of each analyte of 
interest present in the sample. AEA-d8 was used as the internal standard for 
AEA, OEA and PEA and 2AG-d8 for 2AG analysis. 
3.3.5.2 Statistical Analysis 
The concentration of each endocannabinoids was analysed using two way 
ANOVA with age and genotype as between subject factors. Planned 
comparisons were conducted post hoc when necessary using the least 
significant difference (LSD) test for multiple comparisons. 
3.3.6 Lipidomics Analysis 
The frontal cortical, hippocampal and striatal samples prepared for the above 
study were subsequently used to conduct a lipidomics analysis using UPLC 
linked to high resolution mass spectrometry (HRMS). This analytical work 
was conducted by Srinivasarao Ravipati using the protocol outlined below. 
3.3.6.1 Chemicals 
Acetonitrile (far UV grade), chloroform, methanol, ethanol, isopropanol and 
ammonium acetate were all purchased from Fisher Scientific (Loughborough, 
UK). AEA, OEA, PEA, 2AG, AEA-d8, 2AG-d8, 5,6-dihydroxyeicosatrienoic 
acid (5,6-DHET), 8,9-dihydroxyeicosatrienoic acid (8,9-DHET), 11,12-
dihydroxyeicosatrienoic acid (11, 12-DHET), 14,15-dihydroxyeicosatrienoic 
acid (14,15-DHET), 9-hydroxyeicosatetraenoic acid (9-HETE), 11-
hydroxyeicosatetraenoic acid (11-HETE), 12-hydroxyeicosatetraenoic acid 
(12-HETE), 15-hydroxyeicosatetraenoic 
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acid (15-HETE), 16-
hydroxyeicosatetraenoic acid (16-HETE), 19- hydroxyeicosatetraenoic acid 
(19-HETE), 20-hydroxyeicosatetraenoic acid (20-HETE), arachidonic acid 
(AA). 5,6-epoxyeicosatrienamide (5,6-EET -EA), 2-(14,15-
epoxyeicosatrienoyl)-glycerol (14, 15-EET-G), Prostaglandin O2 ethanolamide 
(PG02-EA), prostaglandin E1 ethanolamide (PGE1-EA), prostaglandin E2 
ethanolamide (PGE2-EA) and prostaglandin F2a ethanolamide (PGF2(J-EA) 
were obtained from Cambridge Bioscience (Cambridge, UK). 5-
hydroxyeicosatetraenoic acid (5-HETE), 8-hydroxyeicosatetraenoic acid (8-
HETE), 5,6-epoxyeicosatrienoic acid (5,6-EET), 8,9-epoxyeicosatrienoic acid 
(8,9-EET), 11, 12-epoxyeicosatrienoic acid (11, 12-EET), 14,15-
epoxyeicosatrienoic acid (14, 15-EET), 12-hydroperoxyeicosatetraenoic acid 
(12-HPETE) were all purchased from Biomol International (Exeter, UK). 
High pressure liquid chromatography (HPLC) grade water was used for all 
experiments (Elga, High Wycombe, UK). 
3.3.6.2 Standard and QC Preparation 
Standard preparations comprising the ECs, eicosanoids and prostaglandins 
listed in 3.3.9 were prepared and diluted to a final concentration of 1IJM in 
ethanol for use in quantitative determination 
Plasma lipids from QC samples were extracted using 500 IJL of ice-cold (-
20°C) chloroform/methanol (1:2 v/v) to 50 IJL of blood plasma, followed by 
vortexing and the addition of 500 IJL of water. Samples were placed on a 
shaker for 10 minutes followed by centrifugation at 13000 rpm for 10 minutes 
at 4°C. Lower lipophilic and upper hydrophilic phases were separated by a 
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central protein layer in this procedure. For the lipid metabolomics 
measurements, 100IJL of lower lipophilic phase was removed and mixed with 
an equal amount of 100% isopropanol prior to injection. 
3.3.6.3 UPLC·MS Conditions 
Lipidomic profiling was conducted using a Accela High speed UPLC-MS 
system comprising an Orbitrap Exactive Mass Analyser, Accela Exactive 
Pump, Accela Exactive Column Oven and Accela Exactive autosampler with 
Xcalibur v2.1 operating system (Thermo Fisher Scientific, USA). An ACE 2 
C18 column (150x2.1mm, 21Jm) 
UPLC separation was performed using an ACE Excel C18 reverse phase 
column (150mm length, 2.1mm 10, 2IJm particle size). The column was 
maintained at a temperature of 30 DC and flow rate of 300IJI per minute with 
maximum pressure set to 350 Bar. Mobile phases comprising aqueous 
(60:40 ACN/10mM ammonium acetate in 100% H20), and organic (90:10 
I PAl 1 OmM ammonium acetate in 100% ACN) solutions were passed through 
the column using a stepwise gradient to elute lipid species of variable polarity. 
An injection volume of 101J1 was used for all samples. 
Analytes were identified using tandem electrospray in both positive (ES+) or 
negative (ES-) ion mode. Capillary voltage was set to 25 V in ES+ mode and 
27 V in ES- ion mode. Tube lens and skimmer voltages in ES+ were 
115V/22V and 140V/28V in ES-. Flow rates of sheath gas, auxiliary gas and 
sweep gas for both ion modes were set to 30, 15 and 5 (arbitrary units) 
respectively and capillary and heater temperature were maintained at 300°C. 
116 
Data was collected in full scan ion mode using m/z values 100-1200. The 
maximum scan inject time was 100ms per micro scan. 
3.3.6.4 Data Analysis 
Data acquired by Xcalibur were imported and processed using Sieve 
(Thermo Scientific, USA). Sieve aligns and extracts the relative ion 
chromatograms (RICs) for every aligned ion. It gives specific differences 
between groups for all the extracted RICs. The data given by Sieve is 
exported to SIMCA-P (MKS Umetrics AB, Umea, Sweden) to produce 
principle component analysis of the sample sets. PCA provided a ratio for 
each rn/z value which was used to determine differences between wildtype 
and APPswe/PS 1 ~E9 mice. 
3.3.6.5 Principle Component Analysis 
Principal component analysis (PCA) is a mUltivariate statistical technique 
used to reduce large volumes of data comprising many variables into a 
smaller number of artificial variables (principal components) which enable the 
identification of similarities and differences in the data set. Each variable is 
assigned a weighting score which determines how much of the variance 
present in the data set is due to that variable. Hence, the variable (A) with 
the highest weighting score accounts for the greatest amount of variance in 
the data set. The variable (B) with the second highest weighting score 
accounts for second greatest amount of variance in the data set that is not 
accounted for by the first variable and so on. Importantly, A and B are not 
correlated. 
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3.3.6.6 Compound Identification 
The rnIz values corresponding to the top fifty PCA weighting scores for each 
group were selected for compound identification. Compounds were 
identified by entering the m/z value into either the human metabolome 
database (HMOB: http://www.hmdb.ca) or Lipid Maps 
(http://www.lipidmaps.org) 
3.3.7 [355] GTPy5 Binding Assay 
Cannbinoid receptor-effector coupling efficiency was determined using the 
esS] GTPyS binding assay following optimisations. 
3.3.7.1 Reagents 
Tris, hydrated magnesium chloride (MgCI2.6H20), bovine serum albumin 
(BSA) Guanosine diphosphate (GOP), theophyliine and Guanosine 5'-[y-
thio]triphosphate tetralithium (GTPy) salt were purchased from Sigma Aldrich 
(UK), Sodium chloride (NaC!) from Fisher Scientific, HU-210 from Tocris 
Bioscience (Bristol, UK) and [3sS]Guanosine 5'-[y-thio]triphosphate from 
Perkin Elmer (MA, USA). 
3.3.7.2 Brain Membrane Preparations 
Membrane fractions were prepared using tissue from the frontal cortex, 
striatum and hippocampus. Tissue was weighed and homogenised using a 
pestle pellet cordless motor in a 20x volume of 50mM Tris, pH 7.4 at 4°C. 
Following homogenisation, samples were centrifuged at 20,OOOg for 10 
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minutes and the supernatant was removed. Samples were re-suspended in 
a further 20x volume of 50mM Tris and the process repeated 4 times in total. 
Following the final centrifugation step, samples were re-suspended to give a 
final concentration of 1mg/ml and stored at -20·C until needed. 
3.3.7.3 e5S] GTPVS binding assay 
Membrane preparations were re-suspended in binding buffer (50mM Tris, 
100mM NaCI, 10mM MgCI2.6H20. 0.2mg/ml BSA in distilled water). 50~g of 
tissue was added to each tube as optimisation studies indicated that a lower 
tissue concentration provides the greatest increase in activity above basal 
(figure 3.1a) along with 40~M GOP (optimised value. figure 3.1b) and 2mM 
theophylline. Samples were vortexed and incubated at 30·C for 30 minutes. 
Following incubation samples were separated into one of three conditions: 
basal, non-specific binding and HU210 (Le. cannabinoid receptor activated). 
Each sample condition was conducted in triplicate for each animal. Drug 
buffer was added to basal samples. 1 ~M unlabelled GTPy to non-specific 
binding samples and 1 ~M HU-210 to HU-210 samples. All samples were 
subsequently incubated with 0.02nM [35S] GTPyS for 90 minutes at 30·C to 
attain steady state. Following incubation. the reaction was terminated by 
rapid filtration of membrane samples through a Brandel Tissue Harvester 
(Gaithersburg, MD, USA) onto Whatman GF/B glass-fiber filters (Clifton, NJ) 
and the filters were washed four times using distilled water at 4 ·C. Filter 
discs were subsequently transferred to scintillation vials and covered with 
Ultima Gold XR scintillant (Perkin Elmer, MA. USA) and the radioactive 
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decay measured using a Packard Tri-Carb 2100 TR scintillation counter 
(Isotech, Chesterfield, UK) with a count time of 3 minutes. 
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Figure 3.1: HU210 Induced [355] GTPy5 binding with Increasing 
tissue content (a) and GOP concentration (b) (mean 1: 5EM). 
Percentage binding above basal elicited by the cannabinoid 
receptor agonist HU210 to cannabinoid receptors in the cortex of 
5.5 month old wildtype mice. (a) Lower tissue quantities yielded 
greater binding. (b) Higher concentrations of GOP elicited greater 
binding. 
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3.3.7.4 Data Analysis 
[35S] GTPyS specific binding was determined by subtracting the non-specific 
binding from the basal and HU210 conditions. The specific binding in the 
HU210 condition was subsequently divided by that of the basal samples to 
enable percentage activity over basal to be calculated. 
3.3.7.5 Statistical Analysis 
The percentage activity over basal was analysed using two way ANOVA with 
age and genotype as between subject factors. Planned comparisons were 
conducted post hoc when necessary using the least significant difference 
(LSD) test for multiple comparisons. 
3.4 Results 
3.4.1 Endocannabinoid Concentrations 
Improvements to Assay Method 
Reducing the volume of solvents did not significantly increase sensitivity as 
indicated by the lower standard ranges not being detected (Table 3.3). 
However, by preparing the internal standards and standards in ethyl acetate: 
hexane (9:1 v/v), in addition to replacing water with 0.9% NaCI, dramatically 
increased the peak areas for both the extracted standards and internal 
standards (data not shown). Furthermore, these alterations enabled lower 
standard concentration ranges to be detected whilst simultaneously lowering 
the coefficient of variation (CV) for internal standards in plasma QCs, 
121 
extracted standards and tissue samples thus indicating reduced variation in 
their levels between different samples. Finally, the peak area determined by 
LC-MS/MS for AEA-d8 when diluted 1:100 in ethyl acetate:hexane (9:1 v/v) 
was in the region of 106 a very high value which could potentially lead to 
interference from minor contaminants in the AEA-d8 solution. To normalise 
this peak area to that routinely obtained in other protocols the dilution factor 
for AEA-d8 was changed to 1 :5000 which resulted in more reasonable peak 
areas in the expected region of 105. This step resulted in a further increase 
in sensitivity, possibly as a reduction in unwanted background intereference, 
as demonstrated by the limit of detection being lowered further so that more 
standards in the lower concentration ranges could be detected (Table 3.3). 
Endocannabinoid analysis 
Concentrations of the two principal endocannabinoids AEA and 2AG, and the 
endocannabinoid-related acylethanolamines OEA and PEA were determined 
in the hippocampus, frontal cortex and striatum (figure 3.3). There was a 
significant age-related increase in the concentrations of AEA [F(2,54) = 15.41; 
p<0.001], OEA [F(2,54) = 9.37; p<0.001] and PEA [F(2,54) = 22.22; p<0.001] in 
the hippocampus of both wildtype and APPswe/PS 1 AE9 animals. 
APPswe/PS1AE9 exhibited significantly higher hippocampal AEA 
concentrations than wildtype animals [F(1,54) = 4.70; p=0.03]. 
A similar significant age-related increase was also observed in the frontal 
cortex for AEA [F(2,53) = 17.54; p<0.001], OEA [F(2,53) = 13.62; p<0.001] and 
PEA [F(2,53) = 10.91; p<0.001]. No significant differences were observed for 
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Figure 3.2: Endocannabinoid Levels in Hippocampus, Frontal Cortex, and Striatum (mean ± SEM). Concentrations of AEA, OEA, 
2AG and PEA in the hippocampus, frontal cortex and striatum of wildtype and APPswe/PS1 ~E9 mice at 4, 6 and 8 (n=10) months. (a-h) 
AEA, OEA and PEA increase significantly with age in the hippocampus and frontal cortex of wildtype and APPswe/PS1~E9 (p<0.001); 123 
no Significant differences were observed for 2AG; (i-k) AEA and OEA increase Significantly with age in the striatum (p SO.001) of 
wildtype and APPswe/PSME9 mice; post hoc"p sO.01. (k) 2AG concentration is Significantly lower in APPswe/PS1~E9 (p=O.014); post 
hoc .... p=O.006. (I) Post hoc "p=O.03. 
the concentration of 2AG in the hippocampus or frontal cortex as a function 
of age or genotype. 
A significant age-related increase in AEA [F(2.52) = 9.82; p<O.001] and OEA 
[F(2.52) = 7.62; p=0.001] was also observed In the striatum of both wildtype 
and APPswe/PS1~E9 mice. Additionally, significant genotype x age 
interactions were also observed for AEA [F(2.52) = 4.63; p=O.01], OEA [F(2.52) = 
5.01; p=0.01] and PEA [F(2.53) = 4.63; p=0.01]. Post-hoc analysis indicated 
significant differences in concentrations between wild type and 
APPswe/PS1~E9 mice at 6 months of age for AEA (p=0.01), OEA (p=0.01) 
and PEA (p=O.025). Furthermore, APPswe/PS1~E9 mice displayed 
significantly lower levels of 2AG in the striatum compared to their wildtype 
littermates [F(2.52) = 6.53; p=O.01] which post hoc analysis indicated to be due 
to the 8 months age group (p=O.006). 
3.4.2 Lipidomics Analysis 
No clear differences were observed using PCA in the frontal cortex or 
hippocampus at 4, 6, or 8 months for wildtype or APPswe/PS1~E9 mice. A 
distinct separation was observed between PCA weighting scores for wildtype 
and APPswe/PS1~E9 animals at 6 (figure 3.3c) and 8 (figure 3.3b) months of 
age. Corresponding loading score plots representing each individual 
metabolite m/z value for which variation was observed, indicate that there 
are a greater number of metabolites in which variation is apparent between 
wildtype and APPswe/PS1~E9 animals at 8 months (figure 3.3d) than at 6 
(figure 3.3.c). The 50 metabolite m/z values showing the greatest amount of 
124 
variability for each group were selected for identification due to time 
constraints. These were further refined following identification to exclude 
those m/z values which displayed complex adducts which were unlikely to 
have formed. As compounds were analysed using an untargeted MS 
rmethod rather than a targeted MS/MS approach it was not possible to 
identify a given m/z value as corresponding to a specific metabolite. Thus, 
for the m/z values remaining after exclusions, a number of different possible 
metabolites were identified as shown in the appendix. However, in certain 
cases HMDB only identified one metabolite as corresponding to a given m/z 
value, such as for m/z 708.664 (figure 3.4) which corresponds to cholesteryl 
ester only (appendix). Table 3.4 lists some of the lipid metabolites showing 
the greatest variation in each of the four groups. Scatter plots for signal 
intensity were subsequently generated for the m/z values listed in table 3.4 
and t-tests conducted (figure 3.4) to further corroborate the results obtained 
by peA. A metabolite which is listed as high for one group e.g. 6 month 
wildtype will by default be considered to be lower in the corresponding 
APPswe/PS1~E9 animals. Variations in diglycerides levels were observed in 
all groups (p<0.01 6 and 8 month old APP; p<0.001 6 month wildtype; figure 
3.4a; m and n respectively) except 8 month old wildtype animals. 
Monoglyceride levels were only significantly high in 8 month old wildtype 
animals, and, thus, low in 8 month APPswe/PS1~E9 (p<0.01; figure 3.4r-s). 
Variations in N-acylethanolamines and related compounds were observed at 
6 (p<0.001; figure 3.4j; p<0.05 3.4k) and 8 months (p<0.01; figure 3.4t) with 
levels being significantly higher in wildtype animals than in APPswe/PS 1 ~E9 
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mice. Levels of fatty acids in general were higher in 6 month wildtype 
animals than APPswe/PS1~E9 (p<O.001; figures 3.4h-i). Compounds 
derived from cholesterol such as bile acids were raised in both wildtype 
(p<O.001) and APPswe/PS1.1E9 (p<O.05) mice at 6 months of age but the 
individual identities of the bile acids differ between groups (see appendix for 
m/z 394.3293 wildtype and 473.3185 APPswe/PS1~E9). Cholesteryl ester, 
the major transport and storage form of cholesterol was significantly higher in 
6 month old APPswe/PS1~E9 relative to their age matched wildtype 
counterparts (p<O.05; figure 3.4d). Components of the cholesterol (p<O.01; 
figure 3.4q) and steroid biosynthethic pathways (p<O.01; figure 3.4q) were 
also raised in 8 month wildtype animals relative to APPswe/PS1.1E9. 
Additonally, 6 month old APPswe/PS1~E9 exhbited significantly raised levels 
of corticosteroids (p<O.05; figure 3.4 e), antioxidant activity (p<O.05; figure 
3.4 b) and potential apoptotic inducers (p<O.01; figure 3.4g). 8 month old 
APPswe/PS1.1E9 displayed significantly higher levels of glutathione 
conjugates (p<O.001; figure 3.4p) and leukotriene 64 (p<O.05; figure 3.40). 
Levels of glycerol-3-phosphate were also raised in 6 month 
APPswe/PS1~E9 animals (p<O.05; figure 3At). 
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Figure 3.3: Principle component analysis weighting score plots for striatum samples for 6 (a) and 8 (b) month old wildtype 0NT) and 
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127 
mIz Possible Metabolite(sl High In Figure 3.4 
737.5466 DiQlycerides 6MAPP a 
407.3045 9'-Carboxy-alpha-chromanol (antioxidari) 6MAPP b 
Bile acids (derived from cholesterol metabolism; 
473.3185 implicated in regulating enzymes involved in 6MAPP c 
cholesterol homeostasis ) 
708.6664 Cholesteryl ester (major transport and storage form 6MAPP d 
of cholesterol) 
325.1833 Corticosteroid 6MAPP e 
Various possible metabolites including a 
190.0500 component of giycerolipid metabolism, gl~erol-3 6MAPP f 
phosphate and kvrurenic acid 
Various including 2-0x0-4-methyltnobutanoic acid, 
149.0234 a preclXSor of methional=potent inducer of 6MAPP g 
apoptosis. 
348.2864 Eicosatrienoic acid and/or docosapentaenoic acid 6MWT h 
322.2709 Various fatty acids including linoleic acid and 6MWT i 
arachidonic acid NAEs spnraolipids 
376.3191 N-acytethanolamine (NAE) and/or fatty acid 6MWT j 
Various possible metabolites including NAEs, N,N-
350.3053 Dimethylsphingosine (apoptotic inducer) orfatty 6MWT k 
acid. 
Bile acids (derived from cholesterol metabolism; 
394.3293 implicated in regulating enzymes involved in 6MWT I 
cholesterol homeostasis) 
698.665 Diglycerides 6MWT m 
737.5466 Diglycerides 8MAPP n 
427.2526 10 11-dihyejro-20-trihyejroxy-leukotriene B4 8MAPP 0 
661.3425 Glutathione coniuoates SMAPP p 
4a-formyt-5alpha-cholesta-8-en-3~-o1 (intermediate 
475.4153 in cholesterol syntheSiS) or (22a)-hydroxy-campest- SMWT q 
4-en-3-1 (involved in brasinsteroid biosynthesis 
, pathNav) 
401.2655 2AG or monoQlvcerides 8MWT r 
506.4211 Mono~rides SMWT s 
3S4.2256 Eicosapentaenovi Ethanolamide 8MWT t 
Table 3.4: Lipid metabolites and associated m/z values displaying significant variation 
between wildtype CNT) and APPswe/PS1~E9 mice (n=10) at 6 and 8 months based on the 
output of Principal Component Analysis. 
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Figure 3.4 a-g: Scatter plot for m/z values found to be significantly different in the striatum 
of wildtype (WT) and APPswe/PS1 t.E9 mice at 6 or 8 months n=9-10 per group). Unpaired 
t-test: *p<O.05 "p<O.01 "·p<O.001 
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Figure 3.4 h-p: Scatter plot for m/z values found to be significantly different in the striatum 
of wildtype (WT) and APPswe/PS ME9 mice at 6 or 8 months (n=9-10 per group). 
Unpaired t-test: ·p<0.05 ··p<0.01 ***p<O.001 
130 
q) mlz 475 .41 53 .. r ) mlz 401.2655 .. 
45000 600 
40000 •• 
... 
>- ?1i= • _ Z. 400 C; !: 35000 to .- I c: ., C ., co C • :t Q C •• - .. - .. '" £ 30000 • "'- '. £200 •• +. • 25000 
•• • 
20000 0 
~J:' q'l. ~J:' q'l. 
'0 ~~ 
'Ii ~~ 
'Il 
Grou p Gr oup 
s) mlz 506.4211 .. t ) mlz 384.2256 · ' 
80000 70000 
• 
70000 
• 
'" 
>- 60000 • 1ii "ii~ I ::t= C .. .~ ~ 60000 QI: u;~ •• "'J; . , .. .E 50000 •• •••• • 
* 
50000 
••••• 
•• 
40000 40000 
~"" q'l. ~J:' q'l. ~~ '0 .. ~~ 'Il '0 Gro up 
Group 
Figure 3.4 q-t: Scatter plot for m/z values found to be significantly different in the striatum 
of wildtype (WT) and APPswe/PSM E9 mice at 6 or 8 months (n=9-10 per group) . 
Unpaired t-test: ·p<O.05 ··p<O.01 ···p<O.001 
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3.4.3 Cannabinoid receptor-effector coupling: 
G protein coupling efficiency of cannabinoid receptors in the frontal cortex, 
hippocampus and striatum was assessed using the [35S]GTPyS binding 
assay (figure 3.4). 
In the frontal cortex APPswe/PS 1 L1E9 mice displayed significantly greater 
receptor activation than wildtype animals [F(1.51) = 4.40; p<0.05] independent 
of age. No significant differences in receptor activation were observed as a 
function of age or genotype in the hippocampus. In the striatum a significant 
effect of age [F(2.52) = 8.81; p<0.001] and genotype [F(1.52) =11.26; p=0.002] 
was observed in addition to a significant genotype x age interaction [F(2.52) = 
6.94; p=0.002]. Post hoc analysis indicated this to be due to 
APPswe/PS1L1E9 mice displaying significantly greater receptor activation 
compared to their wildtype littermates at 8 months of age. 
3.4.4 Correlation analysis 
No correlations were observed between the concentration of 2AG and 
cannabinoid receptor effector coupling efficiency in the striatum of wildtype 
and APPswe/PS 1 L1E9 animals at 4 (~=0.017 p=0.733 wildtype; r2=0.013 
p=0.309 APPswe/PS1L1E9), 6 (~=0.023 p=0.700 wildtype; ~=0.027 p=0.650 
APPswe/PS1L1E9) and 8 (~=0.020 p=0.700 wildtype; ~=0.058 p=0.531 
APPswe/PS1 L1E9) months. 
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Figure 3.4: HU210 induced [35S] GTPyS binding (mean ± SEM). Percentage of activity above basal elicited by the binding of the cannabinoid receptor 
agonist HU210 to receptors in (a) frontal cortex (b) hippocampus and (c) striatum of 4, 6 and 8 months (n=9-10) wildtype and APPswe/PS16E9 mice. (a) 
APPswe/PS16E9 show significantly enhanced receptor-effector coupling activity (p<O.05) compared to wildtype animals. (b) No significant differences 
were observed in the hippocampus between wildtype and APPswe/PS16E9. (c) APPswe/PS16E9 display significantly enhanced receptor-effector 
coupling activity compared to wildtype (pSO.001) with age (p<O.001). Pairwise comparisons*p=O.002. 
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3.5 Discussion 
The aim of this experiment was to determine the levels of endocannabinoids 
and cannabinoid receptor-effector coupling efficiency in the frontal cortex, 
hippocampus and striatum of wild type and APPswe/PS1AE9 at 4, 6 and 8 
months of age. Lipodomic profiles were also obtained for all three brain 
areas. 
Alterations in endocannabinoid levels 
The results showed an age-related increase in the concentration of AEA, 
OEA and PEA in the hippocampus and frontal cortex of both wildtype and 
APPswe/PS1AE9 animals in a similar pattern (Table 3.3) to that observed in 
the TASTPM mouse model of AD (Pardon et al. 2009). However, the size of 
the increase is much larger in Pardon et al. 2009, most likely due to the 
differences in behavioural regimens undergone by 5.5 month animals 
compared to 4 months. Furthermore, the levels of endocannabinoids 
measured by Pardon et al. 2009 were much higher then those observed in 
this study, possibly due to differences in mouse strain used and behavioural 
regimens. Of particular import is that Pardon et al. 2009 were testing the 
effects of stress which is known to promote the release of endocannabinoids 
(Hohmann et al. 2005). However, support for the validity of the 
endocannabinoid concentrations measured in this study is provided by Di 
Marzo et al. 2000 whose measurements were broadly in line with ours. 
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4M WT (1) 4M TASTPM (1) 4MWT 4MAPP 5.5M WT (1) 5.5M TASTPM (1) 6MWT 6MAPP 8MWT 8MAPP 204M WT (2) I 
Frontal Cortex 
AEA (pmol/g) 63.00 75.00 7.31 7.63 875.00 1416.00 10.16 9.90 15.98 14.59 U 
OEA (pmol/g) 680.00 554.00 10.15 10.06 7070.00 19649.00 15.82 13.69 20.37 17.39 U 
PEA (nmol/g) 15.37 11.92 0.07 0.07 19.65 23.98 0.14 0.10 0.15 0.14 U 
2AG (nmol/g) 69.93 72.00 3.40 3.47 418.29 537.82 5.77 3.98 4.34 5.38 U 
., 
Hippocampus : 
AEA (pmol/g) 146.00 153.00 25.37 27.75 144.00 146.00 24.20 25.46 29.58 31.56 26.00 
OEA (pmol/g) 991.00 955.00 22.40 24.28 756.00 738.00 22.25 22.61 26.42 27.72 U 
PEA (nmol/g) 17.97 17.77 0.12 0.12 13.29 12.79 0.14 0.14 0.18 0.18 U 
2AG (nmol/g) 63.93 56.12 2.53 2.96 225.01 221.65 2.57 2.56 2.70 2.96 5.00 
, 
~ 
-
• ~v " ,. p ... ~ , .~ •• 
- . -;"'. ._ ~A' n. ,. '" ~~_ 'u ._._. . .. 
Striatum ; 
AEA (pmol/g) U U 31.44 34.16 U U 38.21 31.19 39.18 42.10 28.00 
~G(nmol/g) U ~ ~~l! ~.58 I~LI U J U 6.27 5.20 8.60 5.53 6.00 _._-
Table 3.3: Comparison of regional endocannabinoid levels in wildtype (WT). APPswe/PS1LlE9 (APP) and TASTPM mice measured using LC·MS/MS. 
(1) Figures from Pardon et al. 2009. (2) Figures from Di Marzo et al. 2000. U = unavailable. 
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In contrast to 5.5 month old TASTPM animals, AEA, OEA and 2AG levels 
were not significantly higher in the frontal cortex of APPswe/PS1.1E9 
compared to wildtype at any age, although hippocampal AEA levels 
appeared to be higher in APPswe/PS1.1E9 animals than in wildtype. No 
differences were observed in 2AG levels in the frontal cortex or hippocampus 
as a function of age or genotype in APPswe/PS1.1E9, in contrast to TASTPM 
animals in which age and genotype related increases were observed in the 
frontal cortex, along with an age-related increase in the hippocampus 
(Pardon et al. 2009). In addition to the strong influence of behavioural 
regimes stated previously, these discrepancies could also be due to strain 
differences (C57b1l6J versus C57) or the PS1 mutations expressed by the 
TASTPM (A246E) and APPswe/PS1.1E9 (PS1.1E9). Support for this 
observation is provided by the existence of phenotypic differences between 
the two genotypes with APPswe/PS 1.1E9 consistently displaying 
hyperactivity in contrast to TASTPM animals at similar ages (Scullion et al. 
2011). Alternatively, they may be due to differences in extraction techniques 
as this study used an extraction method optimised for the small tissue 
samples associated with mice whereas that of Pardon et al. (2009) was 
undertaken using the procedure of Richardson et al. 2007 which was 
optimised for rat. Additionally, the sensitivity of the HPLC-MS/MS systems 
used differed between the two studies as the Q-Trap used in this study is 
considered to be a more sensitive instrument than the Quattro Ultima. 
AEA and OEA levels also increased with age in the striatum of both wildtype 
and APPswe/PS 1.1E9 animals whilst PEA levels increased as a 
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consequence of interplay between genotype and age. However, at 6 months 
of age, levels of AEA, OEA and PEA were significantly higher in wildtype 
animals than APPswe/PS1LlE9. In contrast to the hippocampus and frontal 
cortex, 2AG levels were found to be lower in APPswe/PS1LlE9 animals 
compared to wild type animals, this difference was most apparent at 8 
months of age. 
The involvement of N-acylethanolamines in neuroprotection has previously 
been established in multiple experiments including the demonstration of the 
ability of AEA to confer neuroprotection in a rat model of excitotoxicity 
(Veldhuis et al. 2003), OEA has been shown to reduce infarct volume 
following middle cerebral artery occlusion in mice (Sun et al. 2007) and PEA 
was able to protect against oxidative stress in a neuronal cell line (Duncan et 
al. 2009). Based on this, the age-related increases in AEA, OEA and PEA 
may represent a response by the eNS to protect against oxidative stress and 
neuroinflammation, both of which are known to increase in normal (Park et al. 
2009; Lee et al. 2000) and pathological ageing (Du et al. 2008; Cameron et 
al. 2010). In support of this proposal, Hamilton et al. (2012) demonstrated an 
increased expression of 8-oxoguanine (a marker of oxidative stress), in the 
hippocampus of both wildtype and APPswe/PS1LlE9 animals with age 
independent of genotype. Hamilton et al. detected the presence of 8-
oxoguanine as early as 3 months in both wildtype and APPswe/PS1~E9 
animals. Similarly, Zhang et al. 2012 have reported the presence of GFAP+ 
astrocytes in both wildtype and APPswe/PS1~E9 animals at 3 months of age. 
Both oxidative stress and neuroinflammation increase with age in these 
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animals (Hamilton et a1.2012; Zhang et al. 2012), an observation which is 
paralleled by the rise in the levels of N-acylethanolamines in the present 
study. Additionally, the presence of markers of oxidative stress such as 8-
hydroxyguanine in 6 month and glutathione conjugates and leukotriene 
oxidation products in 8 month old APPswe/PS1~E9, in addition to high levels 
of prostaglandins in both groups, provides further support for the presence of 
oxidative stress and neuroinflammation in this model of AD. Furthermore, 
these results provide support for the proposed involvement of the ECS in 
certain aspects of ageing, as suggested by the observation that CB1 null 
mutants display accelerated cognitive decline and skin histology associated 
with ageing compared to wildtype age-matched controls (Bilkei-Gorzo et al. 
2012). 
Although both wildtype and APPswe/PS1~E9 animals display indicators of 
oxidative stress and neuroinflammation, the rate at which they proceed is 
higher in APPswe/PS1~E9 animals (Zhang et al. 2012). Based on this, the 
Significantly higher levels of AEA observed in the hippocampus of 
APPswe/PS1~E9 mice may represent an attempt by the CNS to combat the 
higher levels of neuronal stress they may be experiencing. This is in contrast 
to a study that examined post-mortem tissue from human AD patients which 
found lower levels of AEA in the temporal cortex (Jung et al. 2011). This 
may be due to several reasons. Firstly, it could be due to species 
differences, as mouse and humans are known to possess different amounts 
of white matter (40% humans, 1 O%mouse). It has recently been suggested 
that microglia in white matter are more responsive to inflammatory stimuli 
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than those in grey matter (Hart et al. 2012). Hence, as humans possess 
more white matter than mice, they are likely to experience a more aggressive 
pathology. This difference in white matter content may be partially 
responsible for one of the significant caveats of using animal models of AD 
which is their failure to recapitulate the extensive neurodegeneration seen in 
human AD patients. Alternatively, the discrepancy between the 2 studies 
may be due to differences in the brain regions studied (hippocampus versus 
the whole of the temporal cortex), the extraction protocol (ethyl 
acetate:hexane (9:1 v/v) versus chloroform:water (2:1 v/v) , the mobile 
phases used for elution (acetonitrile versus methanol) and the instruments 
used for detection (MS/MS versus MS). 
No interactions between genotype and age were observed in relation to AEA, 
OEA and PEA levels in the frontal cortex and hippocampus but an interaction 
was observed in the striatum. This observation was due to APPswe/PS1AE9 
animals exhibiting significantly lower levels of AEA. OEA and PEA at 6 
months of age compared to wildtype animals and higher levels at 4 and 8 
months. In contrast, wildtype animals appear to have higher levels of AEA, 
OEA and PEA at 6 months than at 4 months, with levels remaining 
consistent between 6 and 8 months. At 6 months, APPswe/PS1AE9 animals 
have been shown to have prominent AJ3 pathology and deposits were 
frequently found in close proximity to tyrosine hydroxylase immuno-reactive 
fibres (Perez et al. 2005). It is possible that the eNS immune response is 
initially able to overcome the initial AJ3 insult which may result in N-
acylethanolamine levels decreasing by 6 months. However, as AJ3 
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deposition increases exponentially with age (Perez et al. 2005) the bulk CNS 
immune response changes from an anti-inflammatory to a pro-inflammatory 
phenotype As a result, there is a requirement for the anti-inflammatory 
actions of N-acylethanolamine causing levels to rise again by 8 months. 
Alternatively, N-acylethanolamines are able to signal through intracellular 
peroxisome proliferator-activated receptors (PPARs) which are able to sense 
alterations in lipid dynamics. The lipidomic analysis indicates the presence 
of high levels of fatty acids and cholesterol in APPswe/PS1,1E9 animals at 6 
months. These changes may be sensed by PPARs and result in altered 
gene transcription which may ultimately impact upon reduced N-
acylethanolamine production. Finally, as stated earlier, the number of A~ 
plaques increases exponentially between 4 and 6 months which may result 
in a subsequent reduction in the levels of soluble A~ oligomers and ADDLs. 
If, as some have suggested, these soluble oligomers and ADDLs are the 
primary cause of neuroinflammation then their recruitment into A~ plaques 
will reduce the unbound concentration of these ligands and thereby may 
result in reduced inflammation and therefore a subsequent decrease in the 
release of anti-inflammatory mediators. 
In line with previous work conducted by Pardon et al. (2009) no differences 
were found in hippocampal 2AG levels between wildtype and 
APPswe/PS1,1E9 animals at any age. There were also no differences in 
frontal cortical 2AG levels observed between wildtype and APPswe/PS1,1E9 
animals. Studies examining the CSF of human AD patients also found no 
differences in 2AG levels between control and AD patients (Koppel et al. 
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2009). This is in contrast to other studies which have observed an elevation 
in 2AG levels in rats injected with A~1-42 fragments in the frontal cortex (van 
der Stelt et al. 2006). However, protein profiling studies conducted by 
Mulder et al. (2011) found no difference in DAGL and MAGL levels in 
APPswe/PS1~E9 mice. Alternatively, the differences between this study and 
that of van der Stelt et al. (2006) may be methodological, as the acute 
exposure to A~ used by van der Stelt et al. (2006) is likely to have a different 
pathological profile compared to the gradual build up of A~ in the 
APPswe/PS1~E9 model used in this study. It has also been suggested that 
pathological stimulation of neurons results in a substantial rise in 2AG levels 
with only modest effects on AEA (Walter et al. 2003). Thus, it is possible that 
neuronal distress at the ages studied has not reached a level which triggers 
a rise in 2AG synthesis. Based on this speculation it would be interesting to 
determine whether AEA and 2AG have differing actions in response to 
different distress signals. For example does inflammation initially trigger the 
release of AEA and related acyl ethanolamines which are able to interact 
with TRPV1 and PPAR receptors in addition to CB1 and thus recruit their 
anti-inflammatory effects too, whilst neuronal distress signals generated from 
more severe cellular stress such as excitotoxicity results in 2AG 
accumulation? 
In contrast to the frontal cortex and hippocampus, APPswe/PS1~E9 animals 
showed lower 2AG levels in the striatum at 8 months compared to their 
wildtype counterparts. This would result in reduced neuroprotection as well 
as reduced inhibitory control of GABA neurons resulting in excessive 
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glutamate release and may contribute to the neurodegeneration observed in 
the striatum of these animals at 12 months (Richner et al. 2009). 
Lipid metabolism 
peA of the lipodomic profiles for the frontal cortex and hippocampus showed 
no distinct separation of lipids between wildtype and APPswe/PS1~E9 
animals at 4.6 or 8 months. However. a clear separation was observed for a 
number of lipid classes in the striatum of 6 and 8 month old animals. In 
particular. peA which is an unsupervised clustering method requiring no 
prior knowledge. provided support for the targeted endocannabinoid analysis 
by indicating that AEA. OEA and PEA levels are higher in the striatum of 
wildtype animals at 6 months than APPswe/PS1i1E9. Similarly, in the 8 
month age group, peA indicated that 2AG was higher in wildtype animals 
than APPswe/PS1~E9. 
The lipidomics analysiS indicates that there are global disturbances in lipid 
metabolism present in the striatum of APPswe/PS 1 i1E9 animals at 6 and 8 
months. Due to time constraints these differences could not be fully 
investigated. The presence of high levels of cholesterol and fatty acids in 6 
month old APPswe/PS1i1E9 and 8 month old wildtype animals suggests both 
aging and Alzheimer's disease impact upon these factors. As these 
comprise components of cell membranes and lipid rafts their altered levels 
suggest disturbance in membrane fluidity and protein activation (Niemala et 
al. 2009) as a function of age (Yechiel et al. 1985) and AD-related pathology 
(Qiu et al. 2011). Indeed. Qiu at al. (2011) suggested that the presence of 
142 
cholesterol results in a more ordered lipid domain which protects against Aj3-
induced membrane disruption and formation of a j3-sheet structure which 
they hypothesise acts as a seeding platform for toxic Aj3 oligomers. This is in 
contrast to other studies which suggest that high cholesterol levels are a risk 
factor for developing AD (Papolla et al. 2003). 
Wildtype animals appear to show high levels of N-acylethanolamines 
products which are therefore, by default, lower in APPswe/PS1,1E9, 
suggesting impairments in synthesis or degradation of these lipid mediators 
in AD. 
High levels of glycerophospholipids and cholesterol present in 6 month 
APPswe/PS1~E9 animals may cause alterations in membrane fluidity and 
lipid rafts. Modification of the cholesterol content of lipid rafts has previously 
been shown to control CB 1 receptor function in the striatum (De Chiara et al. 
2010) although whether this has any influence on N-acylethanolamines 
synthesis is currently unknown. 
All groups showed high levels of glycerides although the composition and 
chain length varies between them. This observation provides further support 
for disturbed lipid metabolism being a feature of age and AD pathology as 
well as emphasising the need for accurate analytical techniques for 
measuring lipids. 
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Influence of post-mortem delay interval 
The post-mortem delay interval has been shown to have a substantial impact 
on levels of endocannabinoids and other fatty acids in a number of different 
animals (Schmidt et al. 1995). Studies examining the influence of post-
mortem delay on levels of AEA in rat brain samples have found levels begin 
to rise steadily after a 3 hour interval but found very little effects prior to this 
time point (Kempe et al. 1996). Further studies modelling post-mortem delay 
intervals ranging from 0 to 80 hours at room temperature and 4·C using 
human brain extracts to measure fatty acid composition, demonstrated no 
change up to 72 hours (Fraser et al. 2008). Specifically, studies using 
human tissue and measuring AEA and 2AG content found a steady increase 
in AEA at 1-6 hours post-mortem and a converse decrease in 2AG content 
(Palkovits et al. 2008). Similar studies in C57bll6J mice have found AEA to 
increase significantly 5 hours after decapitation but not before, whilst 2AG 
levels were found to decrease for the first few hours although not significantly 
(Patel et al. 2005). However, Palkovits et al. 2008 observed that once frozen 
at -80·C, sample endocannabinoid content was stable up to 13 years 
following collection. 
The post-mortem interval between decapitation and freezing in liquid 
nitrogen for this study was approximately 5 minutes. Additionally, all regional 
brain dissections were undertaken by the same researcher to reduce 
variability due to individual differences in collection strategy and duration. 
Thus, whilst some changes may have been inevitable based on the literature 
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cited above, as all the samples were collected in very similar time intervals 
by the same researcher, any post-mortem changes will apply equally to all of 
them. Based on this, any differences observed in regional endocannabinoid 
levels are due to experimental effects rather than an influence of post-
mortem delay although this caveat cannot be wholly discounted. 
Cannabinoid receptor coupling 
No differences in CBR coupling were observed between wildtype and 
APPswe/PS1~E9 animals in the hippocampus. As AEA levels were raised in 
APPswe/PS1 ~E9 in this brain area compared to wildtype animals, the lack of 
alteration in CBR activation would provide support for the idea that AEA may 
be acting through non-CBR pathways such as TRPV1 (Veldhuis et al. 2003). 
The lack of change in hippocampal CBRs is supported by a recent study in 
human AD patients where no changes in CB 1 expression were detected 
(Mulder et a!. 2011). 
In contrast to the hippocampus, APPswe/PS1~E9 had higher receptor-
effector coupling activity compared to wildtype animals in the frontal cortex 
and striatum. The increased CBR activity in the striatum was most apparent 
at 8 months of age corresponding with the observed reduction in 2AG levels 
in APPswe/PS1~E9 compared to their wildtype counterparts at 8 months. 
The enhanced receptor activation may represent an attempt to compensate 
for reduced 2AG levels although a correlation analysis does not support this 
as no correlations was observed between concentrations of 2AG and 
receptor-effector coupling at any age in the striatum. These observations 
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contrast with those of Ramirez et al. (2005) and Westlake et al. (1994) in 
human AD patients where they observed reduced coupling in the cortex, 
hippocampus and striatum. However, Westlake et al. (1994) suggested the 
reduction in CBR activation was due to advancing age and other non-AD 
related pathology. These differences are possibly due to this study 
examining CBR coupling in a mouse model of AD which recapitulates some, 
but not all, aspects of AD pathology whereas the human AD sufferers will 
express the full pathological cohort. Additionally, the CBR agonists used in 
each study varied. For this study HU210 was used, whilst Ramirez et al. 
2005 used WIN55, 212-2 and Westlake et al. ['H]CP-55,940. WIN55, 212-2 
has also been shown to interact with PPARa (Downer et al. 2012) implying 
that non-CB receptors may potentially have influenced the results of Ramirez 
et al. (2005). 
3.6 Conclusion 
The results presented in this chapter provide support for the involvement of 
endocannabinoid system in the ageing process. Some tentative support for 
the involvement of endocannabinoids in Alzheimer's disease is also provided, 
although a more thorough examination of the system involving biochemical 
studies examining the sub-cellular distribution and activity of major synthetic 
and degradation enzymes is required. Lipidomics analysis reveals that 
disturbed lipid metabolism is a feature of both ageing and pathology; hence it 
is crucial to ensure differentiation between the two when investigating 
diseases such as AD. Additionally, it highlights the usefulness of lipidomics 
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as a tool for unbiased research with no prior expectations, thereby potentially 
revealing the influence of factors previously not associated with a given 
condition. 
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Chapter 4 
Drug Intervention Study 
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4.1 Introduction 
It has long been established that CB 1 receptor blockade alleviates memory 
impairments (Wolff et al. 2003; Thiemann et al. 2007; Lichtman, 2000; Wise 
et al. 2009). As a result, it was thought that it might be beneficial in 
Alzheimer's disease (AD) which is defined by impairments in learning and 
memory. In support of this hypothesis, Mazzola et al. 2003 demonstrated 
that the selective CB1 receptor antagonist SR141716A (rimonabant) 
prevents memory impairments in a step-through passive avoidance test in 
mice which had received intracerbroventricular injections of Aj3 peptide 
fragments. 
In contrast to CB1 blockade, CB2 receptor stimulation is also thought to be 
potentially beneficial in AD. Ramirez et al. (2005) demonstrated that the CB2 
selective agonist JWH133 prevented toxicity mediated by microglia following 
treatment with Aj3 peptide. Furthermore, Aso et al. (2012) recently reported 
improvements in memory following 5 weeks of JWH133 treatment (0.2 mg/kg) 
in 6 month old APP/PS1.1E9 mice. They attributed their observations to 
reductions in the pro-inflammatory cytokines IL-6 and interferon V as well as 
to reductions in microglial reactivity. 
As can be observed from the preceding information pharmacological 
manipulation of an animals' CNS is frequently used to test hypotheses about 
the influence of a given exogenous or endogenous compound on behaviour. 
Two procedures commonly used for administering drugs to mice are by 
means of injection into the peritoneal cavity (Lp) or subcutaneously (s.c) 
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(Leenaars et al. 1998). However, both these procedures are unsuitable for 
long-term dosing regimens, particularly with regard to i.p injections which can 
cause peritonitis and carry the risk of intestinal puncture (Diehl et al. 2001). 
Injection stress is also a potential confounder. Additionally, neither of these 
methods enable plasma levels of the compound to be maintained at a steady 
concentration. 
Osmotic minipumps are a viable alternative to the above procedures. 
Osmotic minipumps can be implanted subcutaneously (Paria et al. 1998) or 
intraperitoneally (Murikinati et al. 2010). Among the benefits of using 
osmotic minipumps is a reduced requirement for animal handling and, hence, 
reduced levels of stress related to handling and injection discomfort 
(Balcombe et al. 2004). Additionally, they enable substances to be 
continuously infused, thereby ensuring stable plasma levels of the compound 
are maintained (Alzet.com). Furthermore, osmotic minipumps reduce 
experimental variability. Due to these benefits, osmotic minipumps are 
increasingly popular as research tools in pharmacological intervention 
studies. 
A number of techniques can be used to assess the effects of drug 
intervention upon brain physiology including behavioural paradigms and 
immunohistochemistry (IHC). IHC is a well established (first reported in 1941 
by Coons et al.) commonly used technique based upon the amalgamation of 
immunology, histology and chemistry (Ramos-Vara, 2005). The principles of 
IHC are centred on the binding of a specific antibody to its cognate brain 
150 
antigen. The antibody-antigen complex can subsequently be visualised in a 
number of ways, most frequently involving the use of a fluorescent tag or 
enzyme-chromogen complex. Behavioural testing regimens are crucial in 
determining the functional consequences of central manipulation. A number 
of memory tests have been used in the studies mentioned above including 
object recognition and passive avoidance learning. The present study 
utilised similar testing protocols to those described in Chapter 2 and the 
reader is referred to section 2.1 for a reminder. 
This study administered vehicle, SR141716A or JWH133 via subcutaneous 
implantation of osmotic minipumps to female wildtype and APPswe/PS1~E9 
mice for 28 days preceded and followed by behavioural testing. 
Representative brain slices from APPswe/PS1~E9 mice from the vehicle and 
SR141716A treated groups also underwent IHe for Aj3 to confirm its 
presence in the APPswe/PS1~E9 mice. In addition, a separate, smaller 
study examining the effects of acute administration of JWH133 on the 
behaviour of female wildtype and APPswe/PS1L\E9 mice, also at 7 months, 
was undertaken. 
4.2 Aims 
An underlying hypothesis in this thesis is that endocannabinoids have 
potentially opposing actions in Alzheimer's disease, with CB 1 receptors 
mediating acute detrimental effects on memory, whilst CB2 receptors 
mediate positive effects on disease progression via control of 
neuroinflammatory processes. 
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The aims of this chapter were, therefore, to observe the effects of chronic 
administration of the CB1 receptor antagonist SR141716A or the CB2 
receptor agonist JWH133 via subcutaneously implanted osmotic minipumps, 
on cognitive deficits in 7 month old female wildtype and APPswe/PS1~E9 
mice. Brain slices from some of the APPswe/PS1 ~E9 animals were used to 
confirm the presence of Af3. The remainder of the brain slices were intended 
for IHC experiments examining various components of the endocannabinoid 
system. Due to time constraints the IHC is still an on-going process as a 
consequence of which the results of this part of the study will not be 
presented in this chapter. 
4.3 Materials and Methods 
4.3.1 Study Design 
Animals underwent behavioural testing at 4 and 6 months in a two day test 
battery comprising the locomotor activity (LMA) task, spontaneous 
alternation in the Y maze and novel object recognition paradigm. Two days 
after the behavioural testing at 6 months of age, animals underwent surgery 
for SUbcutaneous (s.c) osmotic minipump implantation. Prior to surgery the 
osmotic minipumps were filled with either vehicle, SR141716A or JWH133, 
and remained in place for 28 days following which they were surgically 
removed. Two days after pump removal surgery, animals underwent 
behavioural testing in the locomotor (to enable recovery from surgery and 
drug washout) activity task, spontaneous alternation in the Y maze, novel 
object recognition and contextual fear conditioning (CFC). Following CFC 
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animals were placed back in their home cages for 2 days followed by 
terminal anaesthesia whilst undergoing cardiac perfusion. The brains were 
removed and placed in 4% paraformaldehyde followed by placement in 30% 
sucrose (Figure 4.1). 
6 months 7 months 
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Figure 4.1: Timeline for study. LMA = locomotor activity; 
In addition, a separate smaller study was conducted pbserving the effects of 
acute administration of JWH133 on the behaviour of wildtype (n=5) and 
APPswe/PS1~E9 (n=8) female mice between 6 and 7 months of age. 
Animals were injected with either vehicle or JWH133 intraperitoneally (Lp) 
followed by behavioural testing of spontaneous alternation in the Y maze 30 
minutes later. 25 minutes after completing the spontaneous alternation in 
the Y maze, animals undertook the LMA task. Three days after the test 
session, the process was repeated with animals which had been 
administered JWH133 in the first testing session receiving . vehicle in the 
second testing session and vice versa. 
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4.3.2 Animals 
The animals used in this study were of the same background and genotypes 
(wildtype and APPswe/PS1~E9) as those detailed in chapter 2.3.1. However, 
whilst the previous studies used male animals, this study used female 
animals. All animals were housed in the same room on a 12h light:dark 
cycle with room temperature, humidity and air exchange all being 
automatically regulated. Animals were group-housed (3 per cage) in cages 
supplied with nesting material and a play tube, with ad-libitum access to food 
and water. Animals were randomly allocated to 6 independent groups (n=10 
per group based on power analysis of data from study 2 using an a error 
probability value of 0.05, effect size of 0.25 and power of 0.99) which were 
tested at 4, 6 and 7 months in a battery of behavioural tasks. The existence 
of sexual dimorphisms in AD means that females tend to show a more rapid 
decline than males (Finch et al. 1999; Clinton et al. 2007) as a result of which 
this study used female animals only. 
4.3.3 Drugs 
SR141716A (kindly donated by the National Institute of Mental Health 
Chemical Synthesis and Drug Supply Program (North Carolina, USA», was 
dissolved in 100% dimethyl sulfoxide (DMSO) (Sigma Aldrich, UK) at a 
concentration sufficient for final delivery of a dose of 3 mg/kg which has been 
found to be sufficient for CB1 blockade and alleviating memory impairments 
(Lichtman, 2000; Robinson et al. 2008). For use in osmotic minipumps 
(Alzet® model 2004, mean pumping rate 0.25 jJllhour, reservoir volume of 
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200 f.ll) JWH133 (Tocris Bioscience, Bristol, UK) was prepared in 20% 
DMSO and 5mg/ml bovine serum albumin (BSA) (Sigma Aldrich, UK). For 
use in acute intraperitoneal (i.p) injections, JWH133 (Tocris Bioscience, 
Bristol, UK) was prepared in a solution of ethanol (Sigma Aldrich, UK):tween 
80 (Sigma Aldrich):saline (1:1:18 v/v). In both cases JWH133 was made up 
to a concentration calculated to deliver a dose of 1.2 mg/kg (Goncalves et al. 
2008). Vehicle was either 100% DMSO or 20% DMSO added to 5mg/ml 
BSA in the chronic study using osmotic minipumps and ethanol:tween 
80:saline (1:1 :18 v/v) in the acute study. A stock solution of 50 mg/ml 
Rimadyl (Pfizer, Kent, UK) was diluted 1:100 in saline. 
For the acute study, drugs were freshly prepared on the day of use. For the 
chronic studies, drugs were prepared on the day on which the minipumps 
were to be implanted. 
4.3.4 Surgery 
Animals were anaesthetised using isofluorane (3.5% for induction; 1.5- 2% 
for maintenance) in 100% oxygen. Once an animal was fully anaesthetised 
rimadyl (analgesic) was administered (s.c), a small area in the upper back 
where the surgical incision was to be made was shaved, wiped with 
chlorohexidine (Ecolab Ltd, Leeds, UK) and a topical analgesic (lidocaine 25 
mg/g; Astra Zeneca, Luton, UK) applied. The animal was subsequently 
transferred to the sterile surgical area located over a heated mat. A small 
incision was made in the skin on the upper back, a sterile osmotic mini pump 
(Alzet® 2004, supplied by Charles River, UK) containing vehicle, 
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SR141716A or JWH133 was inserted into the area underneath the incision. 
The outlet for the osmotic minipump was placed so it was facing away from 
the incision site. Absorbable sutures (Ethicon, UK) were used to close the 
incision and the animal was placed into a pre-heated new cage and 
monitored until it had recovered from anaesthesia. Animals were weighed 
daily and monitored post-surgically for a minimum of 5 days. 
4.3.5 Spontaneous Alternation in the Y Maze 
Spontaneous alternation in the Y maze is very similar to that in the T maze 
detailed earlier (section 2.8.2) and operates on similar principles in that it is 
based on the innate tendency of mice to explore a novel maze arm over a 
familiar arm which they have just vacated, and thus to alternate between 
arms (Hughes, 2004). As with the T maze, it is used as an indicator of 
spatial working memory performance. 
The Y maze was constructed from transparent Perspex and comprised 3 
identical arms measuring 7.5cm in width, 46 cm in length and 25 cm in height. 
Animals were placed in the centre of the Y maze and permitted to explore for 
5 minutes following which they were placed back in their home cage. The 
number of alternations and arm entries the animals made during the 5-
minute period were recorded and subsequently used for statistical analysis. 
The same protocol was used for both the chronic and acute studies. 
4.3.5 Locomotor Activity 
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The LMA task for the chronic study was identical to that detailed in section 
2.3.3. In the case of the JWH133 acute study, the procedure was identical 
with the exception of the time in the arena being 15 minutes rather than 30 
minutes. 
4.3.6 Novel Object Recognition 
The principles of the novel object recognition (NOR) paradigm are explained 
in section 2.8.2. The protocol used was as described in Scullion et al. (2009) 
with modifications in the form of automated scoring replacing manual scoring 
and object exploration defined as a distance of s2cm rather than sO.5cm. 
The NOR paradigm was conducted in the same arena in which the animals 
had undergone LMA testing the previous day, thus habituating them to the 
arena. Animals were placed in an arena containing one object (wooden 
circular or triangular block) and permitted to explore freely for 10 minutes 
after which they were returned to their home cage. After 4 hours, the 
animals were placed back in the arena which now contained a novel object in 
addition to the object that was present in the first trial. As previously, animals 
were permitted to explore freely for 10 minutes before being placed back in 
their home cage (figure 4.2). All of the trials were recorded by a camera 
positioned directly above the arena and later used to determine the amount 
of time spent exploring each object using a validated protocol for Ethovision 
XT automatic tracking software (Noldus, Wagenigen, Netherlands). 
Exploration was defined as the amount of time spent by an animal with its 
nose pointing towards the object at a distance of ~ 2 cm. The distance 
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moved, total exploration time and exploration time for each object were 
recorded for each trial. To determine an animals' preference for the novel 
object, the amount of time spent exploring the novel object was divided by 
the total exploration time and multiplied by 100% to obtain a preference 
index value. 
Ll A · Ll A 
4 hours 
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Trial 1 10 minutes Trial 2 10 minutes 
Figure 4.2: Novel Object Recognition Paradigm. Animals are placed in the arena (A) in 
trial 1 and permitted to explore freely. For 10 minutes after which they are removed. After 4 
hours animals are placed back into the same arena which they occupied earlier (8) which now 
has a novel object in it. Animals are again permitted to explore freely for 10 minutes prior to 
removal. 
4.3.7 Contextual Fear Conditioning 
The contextual fear conditioning paradigm was identical to the one described 
in section 2.3.4. 
4.3.8 Statistical Analysis 
Due to the dual nature of this study, statistical analysis was conducted in 2 
parts. Animals from the 4 and 6 month groups were compare9 to assess the 
effects of age on behavioural outcomes, whilst animals from the 7 month 
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group undergoing drug treatments were assessed separately to analyse the 
effects of pharmacological manipulation of the ECS. 
Ymaze 
4-6 months: Alternation rates and arm entries were analysed using repeated 
measures ANOVA with age and genotype as between-group factors. 
7 months: Alternation rates and arm entries were analysed using two way 
ANOVA with genotype and drug treatment as between-group factors. 
One sample t-tests were used to determine if alternation rates were 
significantly different from chance levels (50%) for all groups. 
LMA 
4-6 months: The total distance travelled and the ratio of time spent in the 
centre of the arena to the periphery were analysed using repeated measures 
ANOVA with age and genotype as between-group factors. 
7 months: Total distance travelled and the ratio of time spent in the centre of 
the arena to the periphery were analysed using two way ANOVA with 
genotype and drug treatment as between-group factors. 
Novel Object Recognition 
4-6 months: Repeated measures ANOVA with age and genotype as 
between-group factors were used to analyse the total distance moved, object 
exploration times, total exploration times and preference index. 
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7 months: Repeated measures ANOVA was used to analyse total distance 
moved, object exploration times and total exploration times. Two way 
ANOVA was used to analyse preference index measures. Genotype and 
drug treatment were used as between-group factors. 
One sample t-tests were used to determine if preference index was 
significantly different from chance levels (50%) for all groups. 
Contextual Fear Conditioning 
7 month: Acquisition of contextual fear was analysed using two-way repeated 
measures ANOVA with genotype and drug treatment as between-group 
factors and time (1 shock per minute, 10 modalities) as the within-subjects 
factor. 
Retention, extinction and extinction index were analysed using two way 
ANOVA with genotype and drug treatment as between-group factors. A two 
way repeated measures ANOVA comparing immobility in the retention trial to 
that in the extinction was also conducted, with genotype and drug treatment 
as between group factors and trial (2 modalities) as the within-subjects factor. 
A one-sample t-test was used to determine whether the extinction index was 
significantly different from 0 which would indicate that no extinction had taken 
place. 
Post-hoc testing: 
Planned comparisons were conducted post-hoc when appropriate using the 
least significant difference (LSD) test. The main focus of this study was to 
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identify differences between wildtype and APPswe/PS1t.E9 animals between 
4 and 6 months, and the effect of drug treatment at 7 months. Hence, 
planned comparisons identified to be of interest prior to the start of the 
experiment were those between wildtype and APPswe/PS1t.E9 at 4 and 6 
months, and between vehicle, SR141716-treated and JWH-treated wildtype 
and APPswe/PS 1 t.E9 animals at 7 months. 
4.3.9 Cardiac Perfusion 
Animals were anesthetised using isofluorane (3.5% for induction; 1.5-2% for 
maintenance) in 100% oxygen. Once fully anaesthetised, an incision was 
made in the chest area to expose the ribcage. The ribcage was cut away to 
expose the heart. A needle attached to a hydraulic pump was placed in the 
left ventricle, a small incision was made in the right atrium, and the pump 
turned on. The systemic circulation was initially perfused with 0.1 M 
phosphate-buffered saline (PBS) to clear the system of all blood. This was 
followed by perfusion with 4% paraformaldehyde (Sigma Aldrich, UK) until 
the liver became pale in colour and the limbs of the animal became rigid. 
Following perfusion, the brain was removed and placed in 4% 
paraformaldehyde for 7 days at 4·C after which it was placed in 30% sucrose 
solution (30% sucrose in 0.1 M PBS (Oxoid Ltd, Hampshire, UK) 
supplemented with sodium azide) and stored at 4·C until sectioned. 
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4.3.10 Amyloid P immunohistochemistry 
All A~ immunohistochemistry-related sectioning, staining and imaging was 
undertaken by the laboratory of Professor James Lowe, Department of 
Histopathology, Queen's Medical Centre, University of Nottingham. 
Following storage in 30% sucrose, APPswe/PS1.1E9 mouse brains for the 
vehicle and SR141716A treated groups (n=3) were placed back in 4% 
paraformaldehyde for 48 hours prior to paraffin wax infusion using a LEICA 
TP 1050 tissue processor, (Leica Microsystems, Milton Keynes, UK). 
Following processing, brains were embedded in paraffin wax using a LEICA 
EG 1160 paraffin embedding station and 5 IJm sections cut using a LEICA 
RM 2135 rotary microtome. Slices were obtained 10 IJm apart from the 
frontal cortex, striatum and hippocampus for each animal. 
Sections were stained using the Leica Bond Polymer Refine Detection Kit as 
follows. Sections were dewaxed in xylene (2 x 5 minutes) followed by 
rehydrating in industrial methylated spirit (IMS) and rinsed with tap water. 
Sections were subsequently placed in concentrated formic acid for 2 minutes 
followed by washing in tap water for 10 minutes and rinsed in Bond wash 
buffer prior to loading onto the Dako Techmate 500 Plus immunostainer (Ely, 
Cambridgeshire, UK). Antigen retrieval was conducted using ER2 (Leica 
Microsystems, Milton Keynes. UK) followed by washing in Dako REAL wash 
buffer 1. Sections were stained automatically using a standard protocol 
designed by the Department of Histopathology. The protocol is outlined 
below; each step listed was followed by washing in Dako REAL wash buffer 
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1. Sections were peroxide blocked for 5 minutes, followed by washing, 
incubated in Af3 primary antibody (Leica Vision Biosystems) diluted 1 :25 for 
15 minutes, washed, incubated with a dual link secondary antibody for 8 
minutes (Dako REAL link biotinylated secondary antibody, anti mouse and 
anti rabbit), washed, exposed to horseradish peroxide (HRP) (DAKO REAL 
streptavidin peroxidase) for a further 8 minutes and washed. The HRP was 
subsequently stained with the chromogen diaminobenzadine exposure (DAB) 
for 10 minutes, washed, exposed to a DAB enhancer for 5 minutes, washed 
and counterstained with haematoxylin for 5 minutes prior to alcohol 
dehydration and xylene cleaning followed by mounting in DPX glue. 
Sections were subsequently scanned using the Nanozoomer Digital 
Pathology slide scanner at x20 magnification to confirm the presence of Af3. 
IHe was only conducted on sections from APPswe/PS1.1E9 animals' brains 
as wildtype mice do not naturally possess the APP gene and hence to not 
produce Af3. 
4.4 Results 
4.4.1 Y Maze 
Spatial memory was assessed using spontaneous alternation in the Y maze. 
There were no statistically significant differences between wildtype and 
APPswe/PS 1.1E9 animals as a function of age or genotype alone between 4 
and 6 months of age. However, a significant age x genotype interaction was 
observed [F(1.60)=4.51; p=0.038] indicating that alternation performance 
decreased with age in wildtype animals whilst increasing with age in 
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APPswe/PS1 ~E9 mice (figure 4.3a). Post-hoc analysis indicated a 
significant difference between wildtype and APPswe/PS1~E9 animals at 4 
months (p=0.042). In contrast, no significant differences in alternation rate 
were observed as a function of drug treatment or genotype in the 7 month 
old animals (figure 4.3a). All groups alternated significantly above chance 
levels (50%). 
APPswe/PS 1 ~E9 animals showed a significantly greater number of arm 
entries [F(1.60)=11.66; p=0.001] compared to wildtype animals (figure 4.3b) as 
a function of age [F(1,60)=7.07; p=0.01]. Post-hoc analysis revealed a 
significantly reduced number of arm entries in wildtype compared to 
APPswe/PS1~E9 at both 4 (p=0.001) and 6 months (p=0.025). No effects of 
drug treatment were observed on the number of arm entries made, but, in 
line with the observations made in 4 and 6 month old animals, 
APPswe/PS1~E9 also made a significantly greater number of arm entries 
[F(1,56)=5.91; p=0.018] than wildtype animals at 7 months (figure 4.3b). Post-
hoc analysis indicated this to be due primarily to differences between 
wildtype and APPswe/PS1~E9 animals in the vehicle-treated condition 
(p=0.01) since both treatments significantly reduced the number of arms 
visited in the 5 min period. 
4.4.2 Locomotor Activity 
APPswe/PS1~E9 animals were significantly hyperactive compared to their 
wildtype counterparts at 4, 6 [F(1,59)=62.65; p<0.001] and 7 months 
[F(1,55)=31.99; p<0.001]. Overall activity levels decreased significantly with 
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Figure 4.3 (data presented as mean ± sem): Spontaneous alternation and number of arm entries in the Y Maze. (a) Percentage alternation in the 
Y maze at 4 (n=35 WT;39 APP) , 6 (n=33 WT; 38APP) and 7 (n=10) months of age for wildtype (WT) and APPswe/PS1 ,1.E9 (APP) animals. Pairwise 
comparisons *p=0.042. All animals alternated significantly above chance :j: p<0.05. (b) Number of arm entries at 4 (n=35 WT;39 APP) , 6 (n=33 WT; 
38APP) and 7 (n=10) months of age for wildtype (WT) and APPswe/PS1 ,1.E9 (APP) animals. Pairwise comparisons *p= 0.001 (4 months) ; 0.025 (6 
months) and 0.01 (7months vehicle). 
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Figure 4.4 (data presented as mean ± sem): Locomotor activity and ratio of activity in the centre:activity in the periphery. (a) Total 
distance travelled in 30 minutes by wildtype 0JVT) and APPswe/PS1.1E9 (APP) animals at 4 (n=35 WT;39 APP), 6 (n=33 WT; 38APP) and 
following treatment with either vehicle , SR141716A (SR) or JWH133 (JWH) at 7 (n=10) months of age. Pairwise comparisons: **p<0.001 ; 
*p<0.01 . (b) Ratio of activity levels in the centre of the arena to those in the periphery during the 30 minute testing session for wildtype 0JVT) and 
APPswe/PS1.1E9 (APP) animals at 4 (n=35 WT;39 APP) , 6 (n=33 WT; 38APP) and following treatment with either vehicle, SR141716A (SR) or 
JWH133 (JWH) at 7 (n=10) months of age. Pairwise comparisons: *p<0.05. 
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age [F(1.59)=83.34; p<O.001] but, at all ages, APPswe/PS1~E9 were 
hyperactive compared to their age-matched wildtype littermates (figure 4.4a) 
as indicated by post-hoc analysis: p<O.001 (4 months, 6 months, 7 months 
vehicle); p=O.002 (7 months SR141716); p=0.008 (7 months JWH). No 
effect on LMA was observed as a function of drug treatment. 
A comparison of the ratio of activity in the centre of the arena to the 
periphery (figure 4.4b) revealed that APPswe/PS1~E9 animals spent a 
greater proportion of time moving in the centre compared to wild type animals 
[F(1.59)=12.95; p<0.001] at 4,6 and following treatment with either vehicle, SR 
or JWH at 7 [F(1.55)=24.86; p<O.001] months. Post hoc analysis yielded the 
following p values for each age and treatment condition (vs WT mice): 
p=O.042 (4 months); p<O.001 (6 months); p=0.004 (7 months vehicle); 
p=O.001 (7 months SR) and p=0.031 (7 months JWH). 
LMA was also analysed during the novel object recognition trials (table 4.1 ). 
Significant main effects were observed for genotype [F(1.138)=49.21; p<O.001], 
age [F(1.138)=9.73; p=O.002] and trial [F(1,136)=67.86; p<O.001] between 4 and 
6 months indicating APPswe/PS1L\E9 animals are significantly hyperactive 
compared to wildtype animals although activity levels decline as a function of 
age and increasing trial number as indicated by significant genotype x trial 
[F(1.136)=15.51; p<O.001] and age x trial [F(1.136)=1 0.61; p=O.001]interactions. 
No significant effects on LMA during NOR were observed as a function of 
drug treatment in the 7 month group although in line with the above, 
significant main effects were observed for genotype [F(1,54)=1 0.11; p=0.002]. 
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with APPswe/PS1~E9 mice being hyperactive and trial [F(1.54)=4.60; p=O.036] 
with locomotor activity increasing in the novel object trial compared to the 
acquisition. In addition a significant genotype x trial interaction [F(1.54)=5.33; 
p<O.025] was also observed indicating the increase in locomotor activity 
between trials was greater for wild type animals compared to 
APPswe/PS 1 ~E9 (table 4.1). 
4.4.3 Novel Object Recognition 
All animals spent significantly more time exploring the novel object than the 
familiar at 4,6 [F(1,137)=17.79; p<O.001] and 7 months [F(1.55)=20.37; p<O.001]. 
A significant main effect of age [F(1.137)=7.13; p=O.009] on object exploration 
times was also observed between 4 and 6 months reflecting the reduction in 
exploration times with age (table 4.1). No effects of drug treatment on 
exploration times were observed in the 7 month group but a just significant 
main effect of genotype [F(1,55)=4.19; p=O.046] was observed which reflected 
the higher object exploration times displayed by APPswe/PS 1 ~E9 compared 
to wildtype animals. 
Total exploration times (table 4.1) were significantly higher in the novel object 
test trial compared to the acquisition trial at 4,6 [F(1,140)=43.35; p<O.001] and 
7 [F(1,54)=14.39; p<O.001] months. Exploration times decreased significantly 
with age between 4 and 6 months [F(1,140)=13.10; p<O.001]. A significant 
genotype x trial interaction [F(1,54)=4.35; p=O.042] was observed at 7 months 
but not between 4 and 6 months. No significant effects of drug treatment on 
total exploration times were observed. 
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Vehicle SR141716A JWH133 
DIstance Moved 1m) 4MWT I 4MAPP 6MWT I 6MAPP 7MWT I 7MAPP 7MWT I 7MAPP 7MWT I 7MAPP 
AcqJisition 2469:1.08-' 32.19=0.96 2110:0.80 -' 2803J:1.09 2166:1:2.37 I 2710:1:2.32 19.91::1.37 I 24.93:1:1.08 21.67:1:0.99 I 25.96::1.95 
Pairwise CO"1l8risons P<OO01 P<0.001 P=O.02 P=O.02 NS 
Novel Object 22.00:0.91.1 26.41:1:0.80 20.70:0.61.1 2603J:1.43 23.41:1:1.88 [ 28.32:1:3.92 22.30::1.14 J 25.86:1:1.10 23.66:1:1.10 1 27.09=1.78 
Pairwise !;O"1l8risons P<O.001 P=O.002 NS NS NS 
Object exploration TIme (s) 
AcqJisition 28.93::3.12 37.35:1:3.35 19.01 :1:2.26 2583J:2.79 13.66:1:4.65 13.10:1:3.24 18.10::4.24 17.93::1.95 11.58:3.09 13.43::3.26 
Novel Object 26.90:1:3.03 23.77:1:2.02 18.53:1:2.59 18.72::1.68 11.47::3.58 14.94:1:4.29 11.12::1.56 15.65::1.88 10.48:2.17 1508:1:1.81 
Total Exploration llme (sl 
AcqJisition 28.93:1:3.12 37.35:1:3.35 19.01:1:2.26 25.83::2.79 13.66:1:4.65 13.10:1:3.24 18.10:1:4.24 17.93:1:1.95 11.58:3.09 13.43:1:3.26 
Novel Obtect 43.15:1:3.96 43.70:1:3.31 32.76:1:3.11 34.27:1:2.95 16.82:1:4.00 25.47:1:8.05 17.98:1:2.96 26.31:1:337 18.94:1:3.12 2520:1:3.21 
Preference Index (%l TIme 
Novel Object 60.60:1:3.06 56.43:1:2.68 54.78:1:4.45 54.98:1:2.72 63.75:1:6.99 63.15:1:3.87 65. n:l:4. 52 59.58:1:4.43 62.48:5.34 61. 54:1:2.88 
One safT'l)le t-test (vs 50%) P=O.001 P=0.02.2 NS (P=O.291) NS (P=0.076) NS (P=O.085) P=O.007 P=0.OO6 NS (P=O.056) 0.044 P=O.004 
Pairwise COlTClllrisons NS NS NS NS NS 
Table 4.1 (data presented as mean ± sem): Performance in the Novel Object Recognition test for drug naive 4 (n=35 WT;39 
APP) and 6 (n=33 WT; 38APP) month animals, and for 7 month old animals (n=10) following treatment with either vehicle, 
SR141716A (SR) or JWH133 (JWH). Distance moved in 10 minutes per trial. Object exploration times in the acquisition and test trials . 
Total exploration times during each 10 minute trial. Preference index calculated as a percentage using the following formula: novel 
object exploration time I total exploration time x100%. One sample t-test was used to compare preference index values to those 
achievable by chance (50%). 
No significant differences in preference index were observed at 4, 6 or 7 
months (table 4.1). Preference index was significantly above chance for 4 
month, 7 month vehicle and JWH treated APPswe/PS1~E9 and 7 month 
JWH133 and SR141716 treated wildtype animals. 
4.4.5 Contextual Fear Conditioning 
All animals were able to learn the contextual fear (CF) as indicated by 
immobility increasing significantly [F(9.504)=181.93; p<O.001] with time (figure 
4.5 a-c). APPswe/PS1~E9 mice appeared to learn the task at a significantly 
slower rate than wildtype animals [F(1.56)=17.99; p<O.001] as indicated by a 
significant genotype x time interaction [F(9.504)=2.30; p=O.015]. Post-hoc 
analysis indicated that this was due to the APPswe/PS1~E9 mice in the 
vehicle-treated (p=O.003; figure 4.5a) and JWH133-treated conditions 
(p=O.007; figure 4.5c) learning CF at a slower rate. 
No significant differences between wildtype and APPswe/PS1~E9 animals 
were observed in the retention of contextual fear memory (figure 4.5d). 
However, a significant main effect of drug was observed [F(2.55)=3.33; 
p=O.043] which post-hoc analysis indicated was due to JWH133-treated 
APPswe/PS1~E9 animals displaying significantly higher immobility levels 
than those treated with vehicle (p=O.014). 
A significant main effect of drug was observed in the extinction trial 
[F(2.55)=7.45; p=O.001] independent of genotype. Post-hoc analysis indicated 
this also to be due to immobility differences between vehicle-treated and 
JWH133-treated APPswe/PS1~E9 mice (p=O.004). 
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Figure 4.5 (data presented as mean ± SEMi: Contextual Fear Memory. Immobility levels displayed by wildtype and APPswe/PS1 .1E9 animals 
(n=9-11) treated with vehicle, SR141716A (SR) or JWH133 (JWH) in the contextual fear memory task. (a-c) Wildtype and APPswe/PS1 t1E9 
animals acquired contextual fear although vehicle (a) and JWH (c) treated APPswe/PS1 .1E9 animals learned at a slower rate than SR treated (b) 
JWH treated APPsweIPS1 .1E9 displayed significantly higher immobility levels than vehcile treated in the CF retent ion (d) and extinction trials (e) . 
Post hoc *p$ 0.01 . Vehicle and SR treated animals displayed significantly lower immobility levels in the extinction trial (e) than the retention (d) . (e) 
vehicle and SR treated wildtype and APPswe/PS1 t1E9 animals displayed successful extinction . One sample t-test ·p<0.05 compared to 0 (no 
extinct ion). 172 
A comparison of immobility levels in the retention trial to those in the 
extinction trial revealed a significant main effect of trial [F(1.55)=35.21; p<O.001] 
indicating lower immobility levels in the extinction trial than the retention 
(figure 4.5 c-d). A significant main effect of drug [F(2.55)=6.03; p=O.004] and a 
trial x drug interaction [F(2.55)=3.66; p=O.032] indicated the higher immobility 
levels in JWH treated APPswe/PS 1 ~E9 animals compared to vehicle treated 
APPswe/PS1~E9 in both retention (p=O.02) and extinction trials (p=O.002). 
A significant main effect of drug [F(2.56)=3.67; p=O.032] was also observed in 
the extinction index values obtained for each group. One sample t-testing 
indicated successful extinction in vehicle-treated and SR141716-treated 
wildtype and APPswe/PS1~E9 animals only. 
4.4.6 Amyloid JJ immunohistochemistry 
Immunohistochemistry (IHC) was conducted to determine the presence of Af3 
in a representative sample of APPswe/PS1~E9 mice from the vehicle-treated 
and SR141716-treated conditions (n=3). Numbers were not sufficient to 
conduct Af3 IHC in the JWH133-treated mice. Figure 4.6 demonstrates the 
presence of Af3 in the frontal cortex, hippocampus and cortex of 7 month old 
APPswe/PS1~E9 animals in the vehicle-treated condition. However, almost 
no A13 depOSits appear to be present in the striatum. No qualitative 
differences were observed in A13 staining between vehicle and SR141716 
treated animals as a result of which images are only shown for vehicle 
treated animals. 
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Figure 4.6: Representative samples of amyloid 13 staining in the frontal cortex, 
hippocampus and striatum of vehicle treated APPswe/PS1 E9 mice at 7 months 
of age. Areas selected in low power images indicate region of high power image. 
4.4.7 Acute JWH 133 Treatment 
In order to ensure that the absence of a drug effect in the LMA and 
spontaneous alternation in the Y maze was not due to the development of 
tolerance in JWH treated animals a small study examining the effects of 
acute administration of JWH133 in these animals was conducted. 
4.4.7.1 Locomotor Activity 
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APPswe/PS1 LlE9 animals between 6 and 7 months of age were significantly 
hyperactive [F(1.11)=5.32; p=O.041] compared to their wildtype counterparts 
(figure 4.7a). No significant differences were observed between wildtype and 
APPswe/PS1LlE9 animals in the ratio of activity in the centre of the arena to 
that in the periphery (mean ± standard error, vehicle: wildtype = O.23±0.02. 
APPswe/PS1LlE9 = O.27±O.02; JWH133: wildtype = 0.24±0.02. 
APPswe/PS1LlE9 = 0.25±0.03). No significant effects of drug were observed 
on either of these behaviours. 
4.4.7.2 Y Maze 
No significant main effects of drug or genotype were observed for 
spontaneous alternation in the Y maze. However, a significant drug x 
genotype interaction was observed [F(1.10)=5.80; p=0.037] indicating that 
APPswe/PS1LlE9 animals exhibited greater spontaneous alternation 
following JWH133 treatment whilst wildtype animals display reduced levels 
(figure 4.7b). Post-hoc analysis yielded an almost significant (p=0.052) 
difference between vehicle and JWH133-treated APPswe/PS1LlE9 animals. 
All animals displayed alternation rates significantly above chance (50%) 
levels (p<0.05 wildtype vehicle; p<0.01 APPswe/PS1LlE9 vehicle and JWH; 
wildtype JWH). 
No significant differences were observed in number of arm entries made by 
either wildtype or APPswe/PS 1 i\E9 animals as a function of vehicle or 
JWH133 treatment (mean ± standard error vehicle: wild type = 19±3.92. 
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APPswe/PS1~E9 = 23±2.96; JWH133: wildtype = 20.S0±1.48, 
APPswe/PS1~E9 = 21.S0±3.0S). 
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Figure 4.7 (data presented as mean ± sem): Locomotor activity and spontaneous alternation in the Y Maze following acute administration of 
JWH133 (JWH). (a) Total distance travelled in 30 minutes by wildtype 0NT; n=5) and APPswe/PS1.1E9 (APP; n=8) animals aged 6-7 months. (b) 
Percentage alternation in the Y maze for WT and APP animals. All animals alternated significantly above chance • p<0.05 . 
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4.5 Discussion 
The main aim of this chapter was to assess the effects of modifying 
components of the endocannabinoid system on the behaviour of wildtype 
and APPswe/PS1~E9 animals at 7 months of age. An additional aim was to 
observe the behaviour of these animals between 4 and 6 months of age 
when levels of amyloid beta are known to increase (Garcia-Alloza et al. 
2006). 
Female APPswe/PS1~E9 mice were hyperactive compared to their wildtype 
counterparts at all ages. Hyperactivity is not related to an anxiogenic trait as 
APPswe/PS1~E9 animals spent significantly more time in the centre (i.e do 
not display thigmotaxis) of the arena than wildtype animals. Interestingly. no 
differences were observed in the ratio of activity in the centre:activity in the 
periphery between wildtype and APPswe/PS 1 ~E9 animals following acute 
JWH133 treatment. This is due to the wildtype animals displaying higher 
ratios in the acute trial compared to the chronic whilst APPswe/PS 1 AE9 
show equivalent ratios in both treatment regimes. This may be due to the 
fact that LMA trials were only conducted for 15 minutes in the acute study in 
contrast to the 30 minutes used for the chronic study. The natural tendency 
of animals to explore any new environment they are placed in would result in 
both genotypes spending time in the centre of the arena as part of this 
exploratory process. However, once they have become habituated to the 
arena it is reasonable for animals to return to the periphery which is usually 
considered a 'safer' location due to its reduced exposure. This process is 
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more likely to be observed in longer trial durations which allow time for 
animals to become habituated in opposition to shorter trials which may not. 
Using a trial duration of 15 minutes would suggest that wildtype animals have 
not become habituated to the arena and thus there is no difference in the 
ratios between wildtype and APPswe/PS1~E9 animals. However, with a 
longer trial time as in the chronic study the wildtype animals may have 
become habituated and thus lose the exploratory drive to remain the more 
exposed central area. However, as the APPswe/PS 1 ~E9 display elements 
of behavioural disinhibition, they do not follow the expected pattern and thus 
the difference between the genotype is revealed. 
In line with their hyperactive behaviour, APPswe/PS 1 ~E9 animals also 
showed higher object exploration times in the novel object recognition 
paradigm as well as a greater number of arm entries in the Y maze 
spontaneous alternation task. Pharmacological intervention of the 
endocannabinoid system by means of CB1 receptor blockade using the CB1 
selective antagonist SR 141716 or stimulation of CB2 receptors using 
JWH133 had no influence on activity levels or exploration times. These 
results would indicate that activity levels are not influenced by CB 1 activity 
which is somewhat in contrast to previous studies conducted in this group 
which demonstrated that chronic SR141716 administration increased 
locomotor activity in rats (EIBatsh at al. 2012). This may be due to species 
differences between rats and mice or may be related to differences in dose, 
as the study by EIBatsh et al. (2012) used a dose of Smg/kg whereas the 
present study used 3mg/kg. Alternatively, it may be related to the method of 
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administration, as EIBatsh et al. used intraperitoneal injections which would 
have resulted in fluctuating plasma levels of SR141716 in contrast to the 
consistent levels presumably maintained by steady state infusion by osmotic 
minipump (although no plasma or brain levels were measured). Additionally, 
the use of i.p injections in long term studies is likely to result in animals 
experiencing chronic stress which could potentially influence the results 
obtained. Similarly, chronic and acute JWH133 administration had no 
influence on locomotor activity levels, in contrast to work by Xi et al. (2011) 
which demonstrated that JWH133 reduced hyperactivity induced by cocaine 
in wildtype and CB1 knockout animals. However, the dose of JWH133 used 
by Xi et al. to obtain these effects was very high (20mg/kg) compared to the 
relatively low dose of 1.2mg/kg used in this study. 
In contrast to previous work by Bonardi et al. (2011) in these animals, 
APPswe/PS 1 ~E9 showed significantly lower altemation rates compared to 
wildtype animals at 4 months whilst no differences in altemation rate were 
observed at 6 and 7 months. All animals altemated above chance (50%) 
levels indicating that spatial memory is intact in these animals. Curiously, a 
significant genotype x age interaction indicated that spontaneous altemation 
increased with age in APPswe/PS 1 ~E9 mice whilst simultaneously 
decreasing with age in wildtype animals between 4 and 6 months. This may 
be due to the chronic nature of the study and may indicate impaired recall in 
APPswe/PS1~E9 animals. As both wildtype and APPswe/PS1AE9 animals 
undertook the spontaneous altemation task at 4 months, it is possible that, 
when exposed to it again at 6 months, wildtype animals habituated to the 
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apparatus quickly due to having been exposed to it previously, whilst 
APPswe/PS1.::\E9 animals may not have habituated as quickly despite 
previous exposure. This may manifest in spontaneous alternation being 
reduced in wildtype animals whilst increasing in APPswe/PS1.::\E9. 
Chronic administration of SR141716A or JWH133 had no effect on 
spontaneous alternation rates, although there appeared to be a trend 
towards JWH133 administration increasing altemation rates relative to the 
vehicle treated condition. This might reach significance with greater 
experimental numbers. Support for this concept was provided by the 
observed increase in spontaneous alternation in APPswe/PS 1.::\E9 animals 
following acute administration of JWH133 (1.2mglkg i.p). In contrast to the 
trend observed in the chronic study, wildtype animals did not show increased 
rates of alternation following acute JWH133 administration. However, as 
wildtype animal numbers were low (n=5) in the acute study, it is possible that 
a larger sample size could reveal an increase in alternation. 
No differences were observed in the object preference index between 
wildtype and APPswe/PS1.::\E9 animals at any age, indicating that both 
genotypes were able to discriminate between the novel and familiar objects 
to an equal extent. However, in contrast to 4 month old animals, 6 month old 
animals from both genotypes did not display a preference index significantly 
different from chance, thus suggesting that they may not be able to 
distinguish between the novel and familiar objects. However, as no 
differences were detected in preference index by means of a two way 
181 
ANOVA it is more likely that the lack of a significant difference from chance 
levels is due to large variations in the performance of individual animals in 
the wildtype and APPswe/PS1~E9 groups at 6 months of age. 
Chronic administration of vehicle, SR141716 or JWH133 had no influence on 
the novel object preference index at 7 months, although vehicle-treated 
wildtype and SR141716-treated APPswe/PS1~E9 animals did not show a 
preference index Significantly different from chance. However, in both cases 
p values obtained were almost significant and, therefore, the lack of 
statistical significance is most likely due to a high individual variation in 
preference index values of animals in those groups. 
Total exploration times were significantly higher in the novel object test trial 
compared to the acquisition trial suggesting animals had greater motivation 
to explore in a trial with 2 objects than 1. As with other aspects of the novel 
object paradigm, no drug effects on behaviour were observed. 
The results discussed above lead to three possible conclusions. First. 
spatial memory and object recognition memory are not impaired in 
APPswe/PS 1 ~E9 animals between 4 and 7 months. Support for this concept 
is provided by a number of studies. Bonardi et al. (2011) observed no 
deficits in recognition memory indices in 
APPswe/PS1~E9 mice compared to wildtype. 
4 month old female 
Savonenko et al. (2005) 
demonstrated intact spatial memory in APPswe/PS 1 AE9 at 6 months using 
the Morris water maze. Lalonde et al. (2004) and Park et al. (2010) also 
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found no deficits in spontaneous alternation behaviour in APPswe/PS1.1E9 
animals at 7 and 8 months respectively. 
Second, no drug effects could be identified in the chronic treatment condition 
due to wildtype and APPswe/PS1.1E9 animals performing at equivalent 
levels, thereby precluding the presence of a deficit. Drug effects are unlikely 
to manifest in the absence of memory impairment as demonstrated by 
Mazzalo et al. (2003) who reported that administration of SR141716 alone 
had no effect on the memory performance of mice. However, a drug and 
genotype interaction was observed for the performance of JWH133 treated 
animals in the spontaneous alternation task, indicating further refinements of 
tests and increasing experimental numbers might reveal a more distinct 
effect. Based on this, it is possible that the constant infusion of drugs for 28 
days in the chronic study results in desensitisation, thus masking any 
beneficial effects. However, as this suggestion does not account for the 
main conclusion of these tests, which is the absence of an impairment for the 
drugs to act upon, desensitisation is unlikely to explain the observations 
made. 
Third, spontaneous alternation and novel object recognition paradigms are 
not sensitive enough to detect the presence of subtle cognitive impairments 
which mayor may not be present in these animals at the ages tested. 
Additionally, although novel object recognition is thought to be a 
hippocampal-dependant task, some studies have shown that, when the 
learning and test contexts are the same, as in this case, object recognition 
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memory is unaffected by hippocampal inactivation (Oliveira et al. 2010; 
O'Brien et al. 2006). Furthermore, with respect to the spontaneous 
alternation task, Gerlai, (1998) indicated the behaviour of an animal in this 
task is influenced by its strain, with some mouse strains, such as the 
C57BLl6 performing better than others. Additionally, it is thought animals 
bred on a mixed background show more impairments than those on a pure 
background (Marie C Pardon, personal communication). Hence as 
APPswe/PS1~E9 animals used in this study are bred on a pure C57 
background this observation may explain why these animals display no 
impairment in this task. Based on these considerations, the lack of a 
prominent drug effect does not indicate that the treatment is not effective, but 
rather that the tests may not be sensitive enough to distinguish any effects. 
In contrast to the above tests, significant drug effects were observed in the 
CFC paradigm. As stated in Chapter 1, endocannabinoid signalling is a 
prerequisite for the successful extinction of aversive memories (Marsciano et 
al. 2002). In addition, an early impairment in contextual fear extinction has 
previously been reported in these mice (Bonardi et al. 2011) and is thought 
to represent a neural correlate of the deficits in cognitive flexibility associated 
with the preliminary stages of human AD (Alberts, 1996). These two factors 
indicate that the CFC paradigm may provide the necessary sensitivity to 
discern any beneficial effects of drug treatment which may be present. With 
respect to this assertion, 7 month old vehicle controls and JWH133-treated 
APPswe/PS1~E9 animals were able to learn the contextual fear (CF) 
responses, albeit at a slower rate than their wildtype counterparts. However, 
184 
this learning impairment was not observed in SR141716-treated 
APPswe/PS 1 .::1E9 animals which learned at an equivalent rate to their 
wildtype littermates, thus indicating that CB1 antagonism is able to reverse or 
counteract this effect, possibly by blocking CB 1 mediated inhibition of 
neurotransmitter (e.g ACh) release in the prefrontal cortex. This is in line 
with previous studies which demonstrated that SR141716 is able to 
counteract the negative effects of central AI3 administration (Mazzola et al. 
2003) and .::19 tetrahydrocannabinol (Wise et al. 2009). In contrast, other 
studies have demonstrated the beneficial effects of enhancing central 
endocannabinoid transmission in AD (van der Stelt et al. 2006). 
All animals were able to recall CF indicating the absence of memory 
impairments. Indeed, JWH133-treated APPswe/PS1.::1E9 animals displayed 
significantly better recall than those administered vehicle. Similarly, in the 
extinction trial, JWH133 administration resulted in significantly higher 
immobility levels in APPswe/PS1.::1E9 mice compared to vehicle treatment, 
despite the reduced learning. The main effect of drug was due to JWH133-
treated animals being unable to extinguish CF memory. The effect was 
independent of genotype as illustrated by it being present in both wild type 
and APPswe/PS1L\E9 animals. This is surprising as JWH133 is a highly 
selective CB2 receptor agonist and CB2 has not previously been associated 
with the extinction of aversive memories. Indeed, the existence of CB2 
receptors on neurons is contentious (Lanciego et al. 2011) although support 
for the presence of the receptors in the CNS is increasing (den Boon et al. 
2012; Lanciego et al. 2011; Gong et al. 2006; Onaivi, 2006). In relation to 
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neurodegeneration. many of the reported beneficial effects of JWH133 are 
related to its anti-inflammatory actions through the stimulation of CB2 on 
microglia (Ramirez et al. 2005; 2012; Aso et al. 2012). It is unlikely that the 
deficit in CF extinction observed in this study originates from an anti-
inflammatory mechanism as it was also evident in wildtype animals which are 
unlikely to exhibit neuroinflammation at the same levels as APPswe/PS 1 AE9 
mice. One possibility could be that JWH133 results in a robust memory trace 
which is resistant to the modification necessary to promote extinction over 
short time intervals such as 24 hours. This could be tested by increasing the 
amount of time over which extinction lakes place from 24 hours to 48/72. 
Should it be the case that the memory is particularly robust, it is possible 
JWH133 treated animals require multiple extinction sessions prior to being 
able to successfully extinguish CF. Further work is necessary to elucidate 
the signalling mechanisms responsible for the observed effects, but these 
results provide further tentative support for the existence of functional CB2 
receptors on CNS neurons. 
Alternatively. the JWH133 effects may be due to indirect effects on neurons 
as a result of triggering CB2 receptors in microglia and astrocytes and 
thereby triggering a rise in intracellular Ca2+. This in turn may result in the 
release of glutamate subsequently able to activate neuronal NMDA receptors 
and thereby potentially initiating the process of L TP. Furthermore. it has 
recently been demonstrated that L TP can be inhibited by preventing the 
release of the NMDA receptor co-agonist D-Serine from astrocytes 
(Henneberger et al. 2010). Hence. JWH133 mediated astrocytlc CB2 
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activation may promote the release of D-Serine thereby increasing the 
likelihood of L TP initiation and possibly forming a more durable memory 
trace. 
In contrast to JWH133, both wildtype and APPswe/PS1.1E9 animals treated 
with SR141716 were able to successfully extinguish CF memory. This is 
also surprising, as previous reports in the literature indicate that 
administration of the antagonist results in impairments in CF extinction 
(Marsciano et al. 2002; Pamplona et al. 2008; Niyuhire et al. 2007). 
However, the protocols used in these latter studies differed from that used in 
the present study. Marsciano et al. (2002) used auditory fear conditioning; 
Pamplona et al. 2008 used contextual fear conditioning but did not 
administer SR141716 until 24 hours after CF acquisition, and subsequently 
tested for extinction 7 days later; Niyuhire et al. (2007) also administered 
SR141716 24 hours after CF acquisition and the animals were subsequently 
assessed for extinction 30 minutes later. However, in the present study. CF 
extinction was assessed 7 days after the removal of the osmotic minipumps 
(figure 4.1) by which time it is possible that the effects of chronic CB 1 
antagonist infusion would have begun to dissipate as a consequence of 
which animals were able to display normal extinction behaviour. 
Both vehicle-treated wildtype and APPswe/PS1.1E9 animals were able to 
successfully extinguish contextual fear as indicated by an extinction index 
Significantly different from O. This is in contrast to what would be expected 
for APPswe/PS1.1E9 mice based on previous observations (Bonardi et al. 
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2011) in that they might be expected to be unable to successfully extinguish 
CF. The successful extinction observed in these animals may be related to a 
number of factors. It is possible that the repeated exposure to the 
behavioural experiments may act as a mild form of environmental enrichment. 
Environmental enrichment in the form of enriched cages has previously been 
shown to alleviate cognitive impairments in APPswe/PS16E9 mice 
(Jankowsky et al. 2005). Alternatively, it is possible that the vehicle itself 
may have had some beneficial effect on the performance of 
APPswe/PS 1 LlE9 in the CFC paradigm. However. this is unlikely as the 
beneficial effects of vehicle would be expected in wild type animals also 
which would be expected to manifest as a more negative extinction index 
value compared to that shown by the APPswe/PS1LlE9 mice which was not 
the case. Interestingly, a deficit in extinction observed in T ASTPM animals 
(Pardon et al. 2009) has been rescued when animals receive injections 
(Marie C Pardon, personal communication). Based on this, it is possible the 
act of surgery itself is having a beneficial effect on the behavioural 
performance of animals. Immunohistochemical analysis confirmed the 
presence of A~ in these animals, thereby supporting their validity as a model 
of AD. However, very little A~ deposition was observed in the striatum of 
vehicle-treated APPswe/PS1LlE9 animals in this study, although substantial 
amounts were found in cortical and hippocampal regions. It is possible that 
SUbstantial A~ deposits do not form in the striatum, in which earlier studies 
have detected lowered 2AG levels and is therefore an area of particular 
interest in this study, until later in the course of the disease. This is 
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supported by Perez et al. (2005) and Richner et al. (2009) who also reported 
very little AJ3 deposition in the striatum at 6 months but substantial levels at 
12 months. Additionally, it should be noted that the lack of AJ3 deposition in 
the striatum at 7 months does not indicate a lack of pathological processes in 
this region. As can be seen, extensive AJ3 deposition is observed in the 
frontal cortex of APPswe/PS 1 ~E9 which is connected to the striatum via the 
frontostriatal loop thought to be involved in cognitive flexibility (Clarke et al. 
2008; Devan et al. 2011). 
4.6 Conclusion 
The results presented in this chapter demonstrate, for the first time in a 
transgenic mouse model of AD, that chronic administration of a cannabinoid 
CB1 antagonist via osmotic minipump is able to alleviate impainnents in 
learning as predicted. It has also been demonstrated, for the first time, that 
JWH133 a CB2 receptor agonist prevented the extinction of CF memories in 
wildtype and APPswe/PS1~E9 animals, implying for the first time, a role for 
the CB2 receptor in this process, and providing support for its presence on 
neurons. 
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Chapter 5 
General Discussion 
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5.1 General Discussion 
The main aim of this project was to determine the role of the 
endocannabinoid system (ECS) in an Alzheimer's disease (AD) model. A 
number of in vitro and in vivo studies over the years have indicated that 
modification of the ECS may prove beneficial in a number of 
neurodegenerative diseases including AD. However, at the point in time at 
which this project was initiated, none of these studies had investigated ECS 
function in a transgenic model of AD. 
Prior to the commencement of a full scale study, the performance of wildtype 
and APPswe/PS 1 ~E9 animals in a locomotor activity task and contextual 
fear paradigm was observed at 4 and 5.5 months to establish their suitability 
for studying AD-related memory impairments. The results obtained from this 
initial analysis confirmed that APPswe/PS1.1E9 animals represented a valid 
model for studying AD-like deficits and that 4 months was a suitable starting 
point for future studies. 
Once suitability had been determined, the first full scale study examined the 
behaviour of pharmacologically naive male 4, 6 or 8 month old wildtype and 
APPswe/PS1.1E9 animals in a battery of behavioural tests followed by post-
mortem measurement of regional concentrations of endocannabinoids and 
cannabinoid receptor coupling. The results of this study revealed that 
APPswe/PS 1.1E9 were hyperactive compared to their wildtype counterparts 
and displayed deficits in behavioural flexibility. The results also indicated 
that spatial memory was intact in these animals whilst indicating possible 
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perturbations in recognition memory. AEA, OEA and PEA levels In the 
hippocampus and frontal cortex increased with age in all animals whilst no 
changes were observed in 2AG levels. AEA and OEA levels also increased 
with age in the striatum whilst 2AG was lower in APPswe/PS 1 ~E9 animals 
compared to wildtype. Cannabinoid receptor-effector coupling was higher In 
the frontal cortex and striatum of APPswe/PS1~E9 animals compared to 
wildtype whilst no differences were observed in the hippocampus. 
Additionally, lipid markers of inflammation and oxidative stress were raised In 
the striatum of both wild type and APPswe/PS1~E9 with age. 
Based on these observations, it was reasonable to conclude that alterations 
in the ECS were playing a role in the AD-like cognitive impairments. 
Following on from these observations, another study was conducted in 4. 6, 
and 7 month old female wildtype and APPswe/PS1~E9 animals. The aims of 
this study were twofold: to observe changes in the behavioural performance 
of animals between 4 and 6 months and to observe the influence of 28 days 
administration of the CB1 antagonist SR141716A or CB2 agonist JWH133 
on behaviour. The results of this study demonstrated that. in common with 
their male counterparts used in the previous study. APPswelPS1 !lEg 
females were also hyperactive and displayed greater exploratory activity. 
Additionally, spatial and recognition memory appeared to be intact in these 
animals between 4 and 7 months of age. Prominent ~ deposition was 
observed in the frontal cortex and hippocampus, but not in the striatum. of 
the APPswe/PS 1 ~E9 animals showing that the model did display the prime 
marker of AD-like pathology. The administration of neither SR141716A nor 
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JWH133 had any effect on any of the above parameters. In contrast. vehicle 
and JWH133 treated APPswe/PS1~E9 animals learned the contextual fear 
(CF) conditioning paradigm at a slower rate than their wildtype counterparts. 
This impairment in learning was absent in SR141716A treated animals. All 
animals were able to recall CF but JWH133 treated animals showed greater 
recall than vehicle or SR141716A treated mice. Whilst vehicle and 
SR141716A treated animals were able to extinguish CF, JWH133 treated 
animals were not. 
Taken together, these studies indicate that levels of ECs and related 
molecules increase with age. Alterations in the ECS do take place In the 
presence of AD-like pathology and altering signalling by means of CB 1 
receptor blockade can reverse some of the impairments in learning and may. 
therefore, be of potential clinical beneficial in AD. Additionally, promoting 
signalling through the CB2 pathway can result either in enhanced recall or 
impaired cognitive flexibility. Distinguishing which of these two processes 
are occurring will provide a clearer answer in relation to whether CB2 
stimulation has potential as a treatment for AD-related memory impairments. 
5.2 Future Directions and Points to Consider 
In order to fully appreCiate the results of the drug intervention study it will be 
necessary to assess levels of neuroinflammatlon in wild type and 
APPswe/PS1~E9 animals treated with cannabinoid receptor ligands. This is 
particularly important in relation to the effects of stimulating the CB2 receptor 
which is known to playa central role in anti-inflammatory processes. This 
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will be achieved using immunohistochemistry (IHC) with an antibody directed 
against the ionized calcium binding adaptor molecule 1 (IBA 1) located on 
microglia, the major central cell type expressing CB2 receptors. IHC will also 
be employed in determining CB1 expression levels in wildtype and 
APPswe/PS1~E9 treated with cannabinoids to determine whether drug 
intervention resulted in changes in CB receptor levels in response to chronic 
deactivation (CB1) and stimulation (CB2). These studies are still ongoing 
and complete data sets were not available for inclusion in the thesis. 
Further work which is not within the scope of the present project but would 
be beneficial includes determining the impact of drug interventions on 
neurogenesis in these animals. This could be done by administering a 
marker of proliferation such as bromodeoxyuridine (BrdU) to a subset of 
animals prior to schedule 1 killing followed by IHC using an anti-8rdU 
antibody. 
It would also be beneficial to assess, immunohistochemically, the levels of 
enzymes involved in the synthesis and degradation of ECs, to determine 
whether AD pathology or drug intervention results in an alteration in their 
levels. 
As stated in Chapter 1, in addition to stimulating CB1 and CB2, ECs are also 
able to act on PPAR and TRPV1 receptors. Thus, to fully determine which 
receptors are responsible for the behavioural effects observed, it will be 
necessary to attain an accurate indication of PPAR and TRPV1 expression 
before and after drug treatment. Alternatively, a separate study could be 
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undertaken whereby animals are administered vehicle, SR141716A or 
JWH133 but are also simultaneously administered either a PPAR or TRPV1 
antagonist. Furthermore, as both CB1 and CB2 receptors are capable of 
forming hetrodimers it would be beneficial to determine whether this is 
occurring in the wildtype and APPswe/PS1~E9 animals used in these studies 
and, if so, what impact these associations have on the cognitive status of 
these animals. 
As stated in Chapter 3, the hyperactivity observed in APPswe/PS 1.1E9 mice 
may be as a consequence of the reduced 2AG levels in the striatum of these 
animals. To further elucidate whether this is the case, preventing 2AG 
catabolism using a MAGL inhibitor such as JZL 184 may prove instructive. 
The behavioural outcome of this intervention would be of particular interest 
as the lack of AJ3 pathology observed in the striatum of APPswe/PS1t\E9 
animals suggests that hyperactivity is not related to AJ3 deposition. However, 
the absence of hyperactivity in the wildtype littermates indicates that whilst it 
may not be directly due to the presence of Af3, the hyperactive behaviour IS 
connected to the expression of the APP/PS1 genes and probably with A~ 
deposition in related brain regions. Thus, elucidating the pathway 
responsible may provide some insights into mechanisms not previously 
associated with AD. 
The benefits of lipidomic analysis were discussed in Chapter 3 and future 
work employing this strategy is likely to yield dividends. This can be 
observed using the example of the raised levels of inflammatory markers and 
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disturbances in lipid metabolism highlighted by this study which correspond 
well with the findings of recent genetic studies attributing over 50% of the risk 
for developing AD to genes related to lipid transport and inflammation. 
Because lipidomic analysis requires no prior knowledge of disease 
mechanism it is not constrained by pre-conceived ideas relating to which 
factors might have a greater impact in a given disease process. As an 
example, it has been contended by many that fixation on the amyloid 
cascade hypotheSiS has prevented alternative mechanisms being explored 
and, thus, is partially responsible for the lack of progress in the search for a 
cure. The use of lipidomics may reveal pathways and mechanisms not 
previously associated with AD and, as a consequence, suggest alternative 
therapeutic courses, thereby possibly accelerating the process of generating 
effective treatments for AD. An extension of this analytical approach would 
be to employ MALO I mass spectrometry imaging (MSI) to study the lipid 
expression pattern in different brain regions (Gagnon et aI., 2012). Hence, 
future studies employing MS techniques to further elaborate the results 
obtained in this study are highly recommended. 
Finally, one factor outside the scope of this project but of importance is the 
effect of stress. Stress has been shown to increase the risk of developing 
AD as well as exacerbating AJ3 pathology, and has also been linked to 
impairments in cognition during normal ageing (Pardon et al. 2008; 1I et al. 
2010). Stress results in the activation of the hypothalamic-pituitary-adrenal 
axis (HPA) leading to the release of glucocorticoid hormones which self-
regulate through negative feedback shown to be mediated in part by 2AG 
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(Evanson et al. 2010). Additionally, chronic glucocorticoid treatment results 
in a decrease in CB1 receptor density whilst acute exposure has been shown 
to reduce AEA levels in the hippocampus (Hill et al. 2008). Studies have 
also shown that acute stress results in decreased AEA levels which are 
thought to be involved in activation of the HPA axis, whilst concurrently 
increasing 2AG mobilisation to terminate the stress response (Hill et al. 
2010). 
It is likely that the procedures used in the course of this project prompted 
some level of stress response in the animals and possible activation of the 
HPA axis. As all animals underwent all procedures, they were all exposed 
equally to stressors, and it is thus unlikely that this factor would have had too 
great an influence on the data. However, given the influence of stress on EC 
levels it would be beneficial in future studies to obtain an indication of the 
baseline levels of stress experienced by animals at different ages and in 
response to different behavioural experiments. The results obtained should 
then be cross-referenced with EC levels in these animals in order to 
determine whether any caveats are likely to exist in other studies employing 
these animals. 
5.3 Conclusion 
This study demonstrates that, as predicted, CB1 receptor blockade may be 
beneficial in alleviating some aspects of AD-related memory impairments. 
However, whilst CB1 receptor blockade may be beneficial acutely in AD. it 
could not be considered to be an effective treatment alone. Due to the 
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complex multidimensional aetiology of AD, any effective treatment approach 
is likely to involve a combination of agents acting on different systems. one of 
which may be the ECS. 
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15 ! Isolithocholic acid 
15' Isoaliolithocholic acid. 
15 iAllolithocholic: acid 
15 ,7a-Hydroxy-5b:clx>lanlc !lcld 
15 ! 12b-Hydroxy-5b-cholanolc acid 
46 :OG(24:0/16:0/0:0) 
46 i0G(22:Q/18:0/0:0) 
46 10G(20:0120:0/0:0) 
46 10G(18:0122:0/0:0) 
46 '0G(16:0124:0/0:0) 
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AMId.., toe,.." "IM. 
"""IIMI 
m.2'r' .. 'PII~ 
m.2""'pW~ 
3222r, .. , PII~ 
m .n*, plO .;.o:~1 
322:/r*,PlG1«):~1 
322:/'*, PIG 1«):"1 
m 27*' (lIO 1«):)011 
m ,,*' PIG 1«):)011 
m 27*' pot .NO.7.M) 
m .2'*' pot }401~1 
32U'*,Pl' '**1 
S4l.2lnel (n4 : TIl' &1 
)6821ntl PH J'tiICIIMf 
)68 1.703 1*1'UIIIIOt 
,..2el703 poe ~
~703pJO~ 
,..211703 pJO.HaIO! 
,..2.70' PJO 1MMOI 
"'~703P" .. ~ 
)68211703 P'" 1L~ 
S60302M P1' " ''''1 
S60302MP1' )""'1 
S60.-.mpoa1".''1 
S60 306»1 1»11" &I &l 
350 3OWtptl~ 
3113'''' PlllO..~ 
311318104 P11 ~
3113'''' pU 30.. .... ""81 
17'.31"'P'1~ 
311l201e4ps4 ,." POl 
311320114 PM Jt." POl 
111l201e4 PM Jt', POt 
371 320114 pta" ''''1 3M)3'.U rna J9' reot 3M.)3'Snp",.,,,,,, 
3M.33'.,) PPI ,.,,.,. 
3M )3,." p.,. ""NOI 
3M )3"'" P"""NOI 
3M )3'6" p" :t'NOI 
691e6& 71 0 IMO ""-'1 
"_J101MO~'.'1 
"-f'OINO~''''1 
I4IU""O INO 6.t '-'1 
691-"01NO""'-'1 
High In. month APP ..... , ... 
PCA Rank Common Name 
24 1 0.11-dihydro-2~hydroxy:lltlJ<otrtene .8.4 
. 24. 1 0, 11-dihydro-20:1!ihydro~IJ<()lrter1lt. ~ _ 
Capsianoside ,_ 
25 S-(PGA 1 )-ghJalhil?f'18 
25 S-(9-/¥1roxy-PGA 1)-g'~Iti()ne 
25 S-(11-h~roxy-9-d~xy-deIta12-PG02}guathione 
6 OG(22:5(7Z,10Z,13Z, 16Z, 19zy20:0IO:O) 
6 DG(22:S( 4Z, 7Z, 1 OZ, 13Z,16zy20:01O:0) 
6 DG(22:4(7Z,10Z,13Z, 16zylO:1(11Z)1O:O) 
6 DG(22:2(13Z,16Z)/20:3(8Z.11Z,14Z)1O:O) 
6 DG(22 :2( 13Z, 16Z)120:3(sz,8Z. 11 Z)IO:O) 
6 DG(22:1(13Z)120:4(sz, 11Z,14Z,17Z)1O:O) 
6 DG(22:1(13Z)/20:4(5z'8Z.11Z,14Z)1O:O) 
6 DG(22:0f20:5(5Z,8Z.11 Z,14Z,17Z)1O:0) 
6 DG(20:5(SZ,8Z. 11 Z,14Z,17zy22:01O:O) 
6 DG(20:4(sz, 11 Z.14Z, 17Z)(22:1 (13Z)1O:O) 
6 DG(20:4(5Z.sz, 11z'14Z)/22:1(13Z)1O:0) 
6 DG(20:3(8Z, 11Z,14Z)(22:2(13Z, 16Z)1O:0) 
6 DG(20:3(SZ,sz, 11zy22:2(13Z, 16Z)1O:0) 
6 DG(20:1(11Z)/22:4(7Z,10Z,13Z, 16Z)1O:0) 
6 DG(20:0f22:5(7Z,10Z,13Z.16Z.19Z)1O:0) 
6 DG(20:0f22:5( 4Z, 7Z, 1 OZ, 132, 16Z)1O:O) 
6 DG(18:4(6Z,9z'12z'15Z)(24:1(15Z)'O:O) 
6 DG(24:1(15ZY18:4(6Z,9Z,12Z, 15Z)'O:O) 
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ee, lUll' Il1O ue.JI 
eet ~,. ... ) "*Jj 
ee, ~"""')l''''JI 
ee, ~""1Ml "*"1 
13' ~ "" MoIIOOI 
13'~""~ 
13' 6410)6 "" "...,.,. 
13' ~ "" NI800I 
13 7 &410)6 "" &6etOOI 
137 MIOl6 11M MoMOOf 
137 WIOl6 11M *I0OI 
73., 6410)& ,.. &6ItOCIt 
137M1Ol611M~ 
13764O)&IIM~ 
1316410)6 11M ~ 
')7~"'~ 
"17~"'~ 
131 ~,...,...,.,. 
137~""~ 
737~"'~ 
'37640)$", ~ 
737 ~ ....... G'It 
High In. month wlldtype 
PCARank CommonNamt 
.. 
11, Eico.sap-Et~~!pyll:~!p~m.ld~ .. 
23 2-Arachi(jorl)'lglyceR?1 
23 . M<3(20:4(8?11Z.14?17Z)1O:0~:O) 
23 M(3(20:4{5?8?11Z • .14Z)1O:O~:O) 
23 MG(O:OflO:4(8?11Z,~4Z.17Z)1O:0) 
23 Canreno.~. ._ ........... . 
1 0 4alpha-form~5alp~-clV)k:tsta-8-en-3betJH)1 
10 . (22Alpha}-hydroxy-campest-4-en-3-1 
8 MG(24:01O:01O:0). 
8 .. ' MG(O:OI?~:OIO:O) , ..... _ 
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